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Summary 
Autophagy is a well-studied catabolic process through which cytoplasmic components are 
targeted for lysosomal degradation by autophagosomes. A key step in this process is the 
recruitment, processing and lipidation of LC3 to autophagosomes. Recently it has become 
increasingly apparent that, through the unconventional use of some autophagy related proteins, 
LC3 can also become lipidated to distinct non-autophagosomal membranes of the endolysosomal 
system. This process is termed non-canonical autophagy and occurs independently of 
conventional autophagy initiation signals. Non-canonical autophagy usually occurs after macro-
endocytic engulfment events such as macropinocytosis, entosis and LC3 associated phagocytosis 
(LAP). Certain ionophores and lysosomotropic drugs, such as monensin, can also activate this 
process and promote LC3 lipidation to lysosomes. This project focuses on Atg16L1, an essential 
autophagy protein that directs the membrane site where LC3 is lipidated. Atg16L1 is relatively 
well characterised in autophagy but little is known about the mechanisms underlying its role in 
non-canonical autophagy. This project used a structure/function approach to assess the 
importance of different domains of Atg16L1 in the context of autophagy versus non-canonical 
autophagy. I have demonstrated for the first time, that the Atg16L1 C-terminal WD40 domain 
(CTD) is dispensable for its role in autophagy but essential for LC3 lipidation during non-canonical 
autophagy. Furthermore, single point mutants were uncovered in the CTD of Atg16L1 that 
likewise are dispensable for autophagy but fundamental to LC3 lipidation in non-canonical 
autophagy. These data provide a novel strategy for dissecting canonical and non-canonical 
autophagy pathways at a molecular level. This project used an existing  mouse model with an 
Atg16L1 truncation (lacking the CTD and nearby residues) and implicated the lack of non-
canonical autophagy to a defect in MHCII antigen presentation. Furthermore this project has 
generated new refined Atg16L1 mutant models ablating non-canonical autophagy without 
affecting canonical autopahgy. In parallel,  proteomic analysis was done to provide mechanistic 
insights into Atg16L1 binding partners in the context of non-canonical autophagy.  
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1 Introduction  
1.1 Autophagy  
 
Autophagy is a fundamental catabolic process with important physiological and 
pathophysiological roles. Autophagy mediates the recycling of cellular material in times of 
starvation or stress, allowing nutrients to be recovered through lysosomal degradation and 
retrieval mechanisms. Various related processes facilitate the degradation of other cellular 
components, such as mitophagy, aggrephagy, lysophagy and xenophagy. 
Importantly, some key molecular players from the autophagy pathway also play an important role 
in degradation of material engulfed from outside the cell. This parallel, non-canonical autophagy 
pathway plays a range of important functions, particularly in the context of immunity and 
inflammation, and forms the focus of this thesis. 
1.1.1 Molecular mechanisms of autophagy. 
 
Autophagy is a cellular recycling process by which cytoplasmic material is sequestered into de 
novo formed, double membrane structures (autophagosomes) to be degraded by the lysosome, 
where amino acids and other nutrients can be recycled back into the cytoplasm of the cell [1-3]. 
Autophagy is required by the cell to overcome various stresses such as nutrient depletion, 
oxidative stress and damage to organelles. Autophagy has complex associations with 
neurodegeneration, ageing and cancer [4-6].  
There are multiple forms of autophagy, including macro-autophagy, micro-autophagy and 
chaperone mediated autophagy (CMA). Macro-autophagy sequesters cargo for degradation, 
either in a selective or non-selective manner. Non-selective macro-autophagy will be termed 
canonical autophagy from this point onwards. Micro-autophagy is where the lysosome directly 
invaginates and takes in cytoplasmic content to degrade [7], and CMA involves the transport of 
unfolded or misfolded proteins from the cytosol into the lysosome [8]. 
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Autophagy is a conserved process and was first characterised in yeast, however this project 
focuses on mammalian autophagy pathways. A series of autophagy related proteins (Atgs) act in a 
tightly regulated manner to mediate initiation, maturation and degradation of the 
autophagosome. The overall process of autophagy initiation is summarised in (FIGURE 1.2). 
Initiation of autophagy depends on the pre-initiation complex made up of a serine threonine 
kinase ULK1 (Unc-51 like autophagy activating kinase 1), FIP200 (FAK-family interacting protein of 
200 kDa), Atg13 and Atg101. All of these components localise to the early autophagosome 
structure termed the phagophore and are essential for mammalian autophagy [9-12]. How this 
activated complex is recruited to these membranes has not yet been fully elucidated, however 
there is evidence that Atg13 may interact with certain lipids found on the autophagy initiation 
membrane [13].  
The ULK1 complex is regulated by the nutrient and energy status of the cell through the action of 
mammalian target of rapamycin complex 1 (mTORC1), which is a nutrient, energy and stress 
sensor important in the regulation of growth and many cellular processes [14]. mTORC1 is 
carefully modulated through the action of the Ragulator complex and, in amino acid rich 
conditions, mTORC1 is in an active state and interacts with Rheb at the lysosome. In basal, fed 
conditions mTORC1 hyper phosphorylates Atg13 inhibiting its interaction with ULK1 [15]. But 
when the cell is starved of amino acids mTORC1 disassociates from the lysosomal membrane and 
this allows activation of the ULK1 complex [16]. Upon starvation induced mammalian autophagy, 
or under pharmacological inhibition by Rapamycin, mTORC1 inactivation leads to de-
phosphorylation of ULK1 and Atg13[15], as shown in (FIGURE 1.2). In addition, AMPK (5' 
adenosine monophosphate-activated protein kinase) is another energy sensing kinase and upon 
energy depletion phosphorylates ULK1 to aid activation of the pre-initiation complex [17]. This 
allows for the complex to assemble and concentrate at sites of growing autophagosome 
formation, permitting self-phosphorylation and further activation of ULK1 complex assembly. 
Furthermore, the activated ULK1 complex can phosphorylate other substrates, including beclin 
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that makes up part of the Vps34 complex outlined below. This ULK1 dependent activation of the 
PI3K complex furthers the initiation of autophagy [18].  
The phosphoinositide 3 kinase (PI3K) complex consists of the class III PI3K Vps34, the only 
mammalian class III PI3K that catalyses the phosphorylation of phosphatidylinositol (PI) to 
phosphatidylinositol 3-phosphate (PI3P). In canonical autophagy, this acts in conjunction with 
UVRAG, Beclin1 and Atg14. The activity of the PI3K complex enriches initiation membranes with 
PI3P, forming an omegasome cradle to act as a platform for the expansion of the double 
membrane autophagosome, and allowing the recruitment of various PI3P effectors such as 
WIPI2b [19].  
The source of the initiation membrane, also termed the phagophore, has been widely debated.  
There is now strong evidence to suggest it is the ER, specifically the ER mitochondrial exit sites, 
that provide the site for nucleation of the phagophore. This is evidenced by mitochondrial 
markers found on the autophagosome [20, 21] and visualised through live cell imaging of ER 
mitochondrial exit sites alongside autophagy initiation proteins [13]. However, other membrane 
sources such as the mitochondria, Golgi and endosomes have also been implicated in forming 
autophagosomes [22]. 
The next step involves a small cytosolic protein, LC3 (microtubule-associated protein light chain 
3), being recruited and lipidated to the autophagosome to form LC3-phosphatidylethanolamine 
(LC3-II, LC3-PE) [23]. LC3 is a member of the Atg8 family of proteins and other Atg8 members are 
lipidated to autophagosomes [24, 25]. This process was first characterised in yeast where Apg8 
was shown to relocalise to autophagosomes upon starvation, and Apg8 null yeast had impaired 
autophagosome formation [26]. There are multiple orthologs of Atg8 in mammals: LC3 [23], 
GABARAP (γ-aminobutyric acid receptor-associated protein)[27] and GABARAPL (γ-aminobutyric 
acid receptor-associated protein like) subgroups [28], for the sake of this report LC3 will be the 
focus and is the most widely studied. The Atg8 proteins will be discussed further in a later section.  
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The translated LC3 protein is referred to as pro-LC3. In the cytosol most of this pro-LC3 is cleaved 
by Atg4, a protease, to expose the C-terminal glycine residue, this form of the protein is termed 
LC3-I.  
LC3-I is recruited and lipidated onto the autophagosome via two ubiquitin-like conjugation 
systems, these are summarised in (FIGURE 1.1). LC3-I can directly bind Atg3 in an intermediate 
state, assisted by the E1-like activity of Atg7, and is subsequently conjugated to the head group 
amine of phosphatidylethanolamine (PE) to form LC3-II [29]. This conjugation is reversible as Atg4 
can act here to cleave PE from LC3-II [29].  
Furthermore, in another ubiquitin-like conjugation reaction, Atg12 covalently attaches to a lysine 
residue of Atg5, via an isopeptide bond; this reaction is activated by Atg7, and Atg12 forms an 
intermediate complex with Atg10 before it is then transferred to Atg5. Atg5 and Atg12 then 
complex with Atg16L1, existing as a homo-oligomer, forming a ~800 kDa complex in eukaryotes 
[25]. Atg5-12-16L1 complex acts as an E3-like ligase for the transfer of Atg8 from Atg3 onto PE 
[30], FIGURE 1.1.  
It is the Atg16L1 complex that drives the specification of the site for LC3 lipidation [31]. The Atg5-
12-16 protein complex is recruited to sites of autophagosome formation via the binding of 
Atg16L1 to FIP200 [32] and/or WIPI2b [33]. The Atg16L1 complex is recruited to the target 
membrane and the LC3 Atg3 intermediate binds Atg12, where LC3 is transferred from Atg3 to PE 
[31]. Atg16L1 itself will be discussed in more detail in a subsequent chapter.   
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Figure 1.1 Role of Autophagy related proteins in LC3 conjugation. 
This shows the two ubiquitin-like conjugation systems that are required for autophagy. LC3 after 
translation is referred to as pro-LC3 but most LC3 in the cytosol is cleaved by Atg4 a protease that 
exposes a C-terminal glycine to form LC3-I. This can then be targeted by Atg7 that has an E1 like active 
site that allows LC3-I to bind Atg3 as an intermediate before it is then conjugated to the phospholipid PE 
on the autophagosome membrane forming LC3-II.  In a similar system, Atg12 is activated by Atg7 and 
transferred to Atg10 as an intermediate before forming an isopeptide bond with Atg5. This complex of 
Atg5-12 can then complex with Atg16L1, essential to transfer LC3-I from the Atg3 intermediate onto PE 
to form LC3-II. 
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Detection of lipidated LC3 (LC3-II) levels is a common way to experimentally estimate the level of 
autophagic activity, due to the lipidated LC3 staying attached to the autophagosomal membrane 
after completion (see section 1.1.2). LC3 also acts itself as an autophagic substrate providing a 
way to measure autophagic flux [34]. The functional role of LC3 is an area of increasing interest 
that will be discussed will be discussed separately (section 1.1.3).  
Autophagosomes elongate and close before finally fusing with the lysosome, where their 
contents are degraded and released back into the cytoplasm of the cell for nutrient recovery to 
reactivate the status of m-TOR [3]. This fusion process is dependent on the soluble N-
ethylmaleimide-sensitive factor attachment protein receptor (SNARE), syntaxin 17 (Stx17). The 
structure of Stx17 allows for the specificity of this SNARE to recruit to complete autophagosomes. 
Stx17 on the autophagosome surface interact with SNARES on the lysosome surface such as 
VAMP8 [35].  
Rab7 [36] and the homotypic fusion and protein-sorting complex (HOPS) [37] have also been 
implicated in fusion events in autophagy. It has been found that the pleckstrin homology domain 
containing protein family member 1 (PLEKHM1) interacts with Rab7, HOPs, Stx17 and LC3, 
assisting autophagosomes fusion with lysosomes [38]. Therefore, there are multiple factors that 
mediate fusion of autophagosomes to lysosomes and absence of these components can lead to 
accumulation of autophagosomes, which is then implicated in neurodegeneration and lysosomal 
storage disease [38].  
A major research interest in the Florey lab, and this project, is understanding the processes and 
molecular mechanisms that are involved in non-canonical autophagy, where Atgs act in a distinct 
and unconventional manner to recruit and lipidate LC3 to single membranes of the 
endolysosomal system.  This is discussed further in section 1.2 onwards. 
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Figure 1.2: Molecular mechanisms of autophagy 
When the cell is starved, mTOR is inactive, this can also be achieved by the drug rapamycin, and the 
phosphorylation status of the ULK1 complex (ULK1, FIP200, Atg13 and Atg101) changes to an active 
state. This active ULK1 complex can then auto-phosphorylate components and leads to the recruitment of 
the PI3K complex (Vps34, Beclin1, Vps14 and Vps15).This initiates the growth of a double membrane 
autophagosome around cytoplasmic substrates. The enzymatic reactions lead to an enrichment of PI3P 
on the double membrane that then facilitates the action of various autophagy related proteins (Atgs) 
that allow the LC3-I to become conjugated to PE a lipid on the double membrane structure. The double 
membrane with the sequestered contents finally seals and fuses to the lysosome where the contents are 
degraded.  
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1.1.2 Common methods to study autophagy  
 
The tightly controlled process of autophagy, like many signalling pathways, has multiple steps 
that can be regulated. Therefore, it can be manipulated and studied in various ways to look at the 
initiation or the flux through the pathway. The flux of the pathway refers to the whole process, 
from initiation of autophagy through to the degradation and turnover of autophagosomes and 
their contents. Relevant and common methods are introduced below, for a more comprehensive 
review of autophagy methods see the following reference [39].  
One method to look at autophagosome number is to use GFP-LC3 as a reporter to observe 
localisation through fluorescence microscopy. When GFP-LC3 is unlipidated (LC3I), it has a diffuse 
signal in the cytosol. Upon autophagy induction, it gets recruited and lipidated to 
autophagosomes, forming puncta that correspond to the number of autophagosomes [23]. The 
isoform of LC3 that is commonly GFP tagged on its N-terminal is LC3B. Other autophagy proteins 
can be fluorescently tagged to similarly look at their localisation, for instance DFCP1 is an 
omegasome marker, a very early marker of autophagy initiation [19]. ULK1 and WIPI2b also offer 
markers for autophagy initiation.  
Autophagic function can be monitored by analysing p62, an autophagy cargo protein. p62 is 
degraded by autophagy and can be studied, via imaging or western blot, to assess the levels of 
autophagy within a cell. If there is an increase in p62, this is suggestive of defective autophagy 
and conversely a loss of protein is an indicator of activation of the pathway.  
Fixing cells and counting the changes in puncta of various autophagy markers offers a way to 
quantify the number of autophagosomes at a given time and how this changes depending on 
different treatments to the cells. This is a powerful way to set up high throughput screens for 
novel regulators of the autophagy pathway, with automated algorithms to count the puncta per 
cell. Transmission electron microscopy is another way of looking at the membrane structures 
forming in a specific layer of the cell at a specific time; this is useful as it can identify 
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autophagosomes from lysosomes and even autolysosomes. Alternatively, fluorescent reporters 
can be followed via live cell imaging to look at the dynamics of the signalling pathway. This gives 
more information than just looking at the number of autophagosomes at a given time, for 
instance, if the puncta count has increased, this does not give information on whether this is due 
to increased initiation of autophagy or inhibition of autophagosome degradation.  
Western blots are a useful way to look at endogenous proteins involved in the autophagy 
pathway. The most common approach involves comparing the amounts of unlipidated and 
lipidated LC3 in cell populations. LC3-I and LC3-II migrate differently on an SDS-PAGE gel, allowing 
the visualisation of the two forms, where LC3 II migrates faster due to its hydrophobicity. LC3 
western blots can be quantified in different ways, either looking at changes in the lipidated LC3 
band, or the ratio of LC3II/I (as used in our lab). LC3 blots are sensitive to handling of the cells and 
therefore the pattern of the change is usually more reproducible than the exact ratios. Other 
western blot assays for this signalling pathway involve looking at phosphorylation statuses of the 
upstream initiation components to unravel what parts of the pathway are being regulated. This 
gives a better idea of what is happening throughout the signalling process.  
Additional methods to assess flux through the pathway include the use of a tandem fluorescence 
tagged LC3. This is an mRFP-GFP-LC3 where only the GFP signal is quenched by the acidic 
lysosome [40]. Therefore, newly formed autophagosomes can be visualised in yellow, as both 
tags fluoresce, while the autolysosomes can also be visualised in red, because the mRFP 
fluorescence is more stable than the GFP [40]. This allows the opportunity, in fixed and live cell 
imaging, to appreciate if the forming autophagosomes are going onto fuse with the acidic 
lysosomes.  
In addition, lysosomal inhibitors are used to assess flux. Common methods to inhibit lysosomal 
degradation of autophagosomes exploit drugs, such as bafilomycin A1 and concanomycin, that 
raise the lysosomal pH. Previously monensin and chloroquine were used for similar functions to 
block the flux of the pathway, but recent work shows they additionally activate LC3 lipidation to 
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non-autophagosomal membranes of the endolysosomal system. This will be introduced in more 
detail later in the chapter, section 1.2.3, and raises caveats in their use in studying autophagic flux 
[41]. Other inhibitors can be used to look at flux, such as leupeptin and pepstatin that inhibit the 
lysosomal proteases. Using these drugs, when autophagy is initiated, blocks the flux, resulting in 
an increase in autophagosome number. This can be assessed as mentioned previously by imaging 
or western blot.  
Other methods to study autophagy include flow cytometry to look at unlipidated and lipidated 
LC3, a sensitive and reproducible way to quantify changes in LC3 lipidation. This assay uses 
detergent, to permeabilise the cell and therefore release cytoplasmic components including 
unlipidated LC3, while membrane bound constituents remain, such as LC3-II; this is a way to show 
how much lipidated LC3 there is in cells [42]. This method has been used to look at autophagy 
levels in B cell activation [43] and the Florey lab also use this as a method to look at Atg8 
lipidation. This has potential for screening opportunities [44].  
 
Autophagy is often initiated by modulating mTOR activity where the most common approach is to 
starve the cells. When starvation is referred to in this project, the method involves amino acid 
and serum starvation. This, as already described, inhibits mTOR and initiates autophagy. Another 
way to achieve this is to inhibit mTOR pharmacologically, using rapamycin or PP242. This provides 
a way to look at autophagy initiation and, if the turnover of the pathway is functioning, then this 
initiation should result in increased LC3II levels in puncta form or by western blot. The opposite 
can be done and autophagy initiation can be inhibited, through the use of ULK1 inhibitors or PI3K 
inhibitors. This would result in decreased LC3 puncta and LC3II by western blot. Common pan 
PI3K inhibitors used are wortmannin, 3-MA and LY294002 [45]. A potent and specific inhibitor of 
VPS34 is SAR405 [46]. These pan inhibitors are useful to an extent but they also stop other 
signalling processes within the cell and therefore, inhibiting ULK1 more specifically using 
MRT67307 and MRT68931 provides a better way to study this process [47].  
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Finally, further to pharmacological stimulation, a powerful tool to unpick the autophagy pathway 
in vitro and in vivo is to genetically manipulate the pathway by CRISPR knocking out of specific Atg 
genes.  
1.1.3 Role of Atg8 family proteins in autophagy.  
 
Atg8 exists as a single protein in yeast but has six different isoforms in mammalian cells, which 
may help explain why the function of this family has become so complex. These proteins are said 
to be ubiquitin-like, due to their structural similarity [48]. The Atg8s in mammalian cells fall into 
two families: LC3 (LC3A, B, C) and the GABARAPS (GABARAP, GABARAPL1 and L2). Overall, their 
expression is tissue wide, although GABARAP L1 and L2 are predominantly found in the brain [49] 
and LC3C is at its highest in lung tissue [50]. They are all synthesised as cytosolic proteins and 
then through the autophagy conjugation machinery they are recruited and lipidated to 
membranes. It has been shown that in autophagy, this conjugation is to PE [51] and it has only 
been shown in vitro that the Atg8s can also conjugate phosphatidylserine (PS) [52]. There is a 
study to suggest that LC3 conjugated to PS is not supported at physiological pH and that adding 
acidic phospholipids to liposomes favours LC3-PE conjugates [53]. This relationship between pH 
and LC3 lipid conjugation could be interesting when thinking about LC3 lipidation in the context of 
non-canonical autophagy.  
Atg8 proteins in mammalian autophagy have a role as cargo receptors in selective autophagy. 
Selective autophagy is the degradation of specific cargo, where autophagy receptors link the 
cargo to the autophagy machinery for degradation. A range of proteins bear an LC3 interacting 
region (LIR) or Atg8 interacting motif (AIM) that lead to anchorage of selective cargo to 
autophagosomes.  
The first selective autophagy receptor to be identified was p62/SQSTM1 (sequestosome-1), this 
interacts with Atg8 proteins and also binds ubiquitinylated protein aggregates, targeting these for 
degradation via autophagy [54, 55]. As previously mentioned, p62 provides a way to study 
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autophagic flux, when the pathway is inhibited there is an accumulation of p62 and protein 
aggregates [55]. Other LIR containing proteins have since been identified, sometimes known as 
sequestosome like receptors (SLRs), and this includes, but is by no means limited to, selective 
cargo receptors such as NBR1 (Neighbour of BRCA1 gene1)[56], NDP52 (Nuclear dot protein 52 
kDa) [57, 58] and optineurin [59]. These are important in selective autophagy processes that will 
be further covered in the next section.  
As well as playing a role in cargo recruitment, Atg8s also control the recruitment of autophagy 
initiation proteins. For instance, ULK1 has a LIR domain that can interact with Atg8 and this is 
thought to be a way to concentrate these proteins on the autophagosome membrane [60]. 
Another process that links into this idea is precision autophagy. This has been termed after 
discovering more about the role of TRIM proteins in autophagy. These proteins act as cargo 
receptors and as regulators; there are a large number of TRIMs that have specificity for various 
cargo. They directly interact with their cargo, without the need for tags such as ubiquitin or 
galectin, although in some situations TRIM proteins can bind galectins [61]. TRIMs have LIR 
domains and therefore interact with Atg8s, where there seems to be a preference for GABARAPs 
and LC3A [62]. As well as these interactions, they act as a platform for autophagy proteins, such 
as ULK1, beclin1 and Atg16L1, to form complexes that in some settings activate autophagy and in 
others, like in the case of TRIM17, negatively regulate autophagy [63]. TRIM 20 directly interacts 
with Atg16L1 to mediate inflammasome signalling [62].  
It was long assumed that the Atg8s were essential for autophagy. However, more recent papers 
suggest that its role is more nuanced. In a paper where they generated CRISPR knockouts of each 
individual Atg8 family member, they found that when all the Atg8s had been knocked out, 
initiation and nucleation of autophagosome formation could still occur, although at a slower rate 
and with smaller autophagosomes [64]. This is supported in another study where knocking out 
Atg5 and Atg3, other key members of the conjugation machinery, slows down but does not 
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prevent the elongation and closure of autophagosomes [65]. The knockout of the GABARAP 
family had a much more profound affect than the knockout of the LC3 family [64]. This may 
suggest that the Atg8s are required for efficient autophagosome formation while the GABRAPs 
play an important role in the final stages of autophagosome fusion with the lysosome [64]. There 
is further evidence that Atg8s are involved in membrane fusion, from in vitro studies that showed 
lipidated Atg8 led to tethering and fusion of liposomes [66]. Another assay similarly done in a cell 
free system showed that permanently lipidated LC3B and GABARAPL2/GATE-16 promoted 
liposome fusion and tethering and the N-terminal part of these Atg8s were also relevant to this 
function [67].  
In this project, we have used LC3 as a reporter. However, it is important to acknowledge that the 
lipidation of GABARAPs, and other LC3 isoforms, may also be important and we and the field 
should consider this too.  The roles of Atg8 proteins in non-canonical autophagy will be discussed 
later (see section 1.3.4).  
1.1.4  Other types of autophagy  
 
As well as mediating bulk degradation, autophagy also has a role as a selective degradation 
pathway. Selectivity of cargo, to be degraded by the autophagosomes, is achieved through the 
action of receptors that bridge the cargo with the autophagy machinery. The cargo receptors 
often have LC3 interacting motifs (LIR) that can bind members of the Atg8 family. Another 
common feature is that the targeted cargo is often ubiquitinylated.  
Mitophagy is a process through which the autophagy machinery selectively degrades old, 
damaged or dysfunctional mitochondria; further information can be found in the referenced 
reviews [68, 69]. This project does not analyse mitophagy, but in brief, it is paramount to cellular 
homeostasis. Dysfunctional and depolarised mitochondria result in the production of ROS and 
cause stress responses and damage that ultimately lead to apoptosis. Mitochondria have been 
shown to be targeted to the lysosomes since 1962 [70]. The molecular mechanisms are still being 
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unravelled, but the process is dependent on the autophagy machinery that is bridged through the 
action of LIR proteins such as p62, NBR1 and optineurin. The best studied aspect of the process is 
PINK1/PARKIN dependent ubiquitinylation of depolarised mitochondria, that are then targeted 
for degradation through selective autophagy [69]. When this process is not functional, there are 
implications in neurodegeneration and tumorigenesis [69]. There are similar roles and 
consequences when the process of aggrephagy, to target aggregated proteins, is dysregulated 
[71]. These are interesting from an ageing perspective and the onset of age related conditions.  
Another selective autophagy process is lysophagy, through which damaged lysosomes are 
targeted for degradation by autophagy. Lysosomes are acidic membrane bound organelles that 
function themselves in autophagy. When lysosomes are damaged, the contents can be released 
into the cell, including proteolytic enzymes, calcium and protons, that have cellular implications 
including the induction of apoptosis [72]. The leftover damaged organelles need to be targeted 
for degradation to stop abhorrent signalling especially inflammation, this is done via lysophagy 
[73]. The damaged lysosomal membrane is targeted by the galectin family of proteins, and the 
released lysosomal proteins are ubiquitinylated, to be targeted via receptors to be degraded by 
autophagy. Lysosomal damage is thought to increase with age, in neurodegeneration and can be 
further caused by oxidative stress or by bacterial toxins. It has now been shown that the 
autophagy receptor and regulator TRIM-16 acts in a ULK-1 dependent fashion to interact with 
Galectin 3 after membrane damage [61]. TRIM-16 directly regulates beclin1 and Atg16L1 to allow 
for clearance of damaged membranes, such as after LLOME treatment or Mycobacterium 
Tuberculosis infection[61]. 
 
The selective autophagy process most relevant to this project is xenophagy, which is involved in 
intracellular pathogen clearance [74]. Some bacteria break out of their bacterial containing 
vacuoles to invade the cytosol, leaving behind damaged membrane compartments. The broken 
membrane exposes glycans and other signalling molecules to the cytosol that would not normally 
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be exposed and this acts to initiate autophagy to eliminate the bacteria. Such signals include the 
galectin molecules, that act as danger receptors, binding to β-galactosidase containing 
carbohydrates. For instance, galectin 8 usually monitors the integrity of membrane 
compartments such as endosomes and lysosomes [57]. In the case of Salmonella enterica serovar 
Typhimurium this bacteria is restricted by galectin 8 which recruits NDP52, a cargo receptor [57], 
that also preferentially interacts with LC3C [57, 75]. Furthermore, the bacteria gets 
ubiquitinylated and this is just as important as galectin 8 for the action of NDP52, without this 
mechanism the bacteria proliferate [57, 58]. NDP52, p62 and optineurin all restrict Salmonella 
enterica serovar Typhimurium [57, 58, 76]. The kinase TBK1 has also been shown to play a role in 
autophagy dependent bacterial clearance, through its recruitment to escaped cytosolic bacteria 
through multiple signals [58], to enhance autophagy receptor affinity [59]. It is also important as 
it recruits WIPI2b, linking the downstream autophagy machinery [77 ]. This process of bacterial 
clearance is distinct from LC3 associated phagocytosis (LAP) where LC3 is becoming lipidated 
directly to the intact phagosome membranes, this process will be outlined in later sections (see 
sections 1.3 and 1.4).  
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1.1.5 Non-autophagic roles of autophagy proteins.  
 
As more work is done on autophagy related proteins (Atgs), it is increasingly apparent that their 
roles are not limited to the canonical autophagy system. There are other distinct roles of Atgs 
[78]. Therefore, careful characterisation is required when studying Atgs, to ensure autophagy is 
not being wrongly attributed in unconventional settings. As an example, autophagy related 
proteins control extracellular secretion, completely separate from the lysosomal degradation role 
of canonical autophagy and bypassing the usual process of ER to Golgi trafficking for secretion 
[78]. Atgs have also been implicated in IL-β secretion, where inhibiting Atg5 leads to accumulation 
of IL-β inside the cell [79]. The cytokine was found to sit in between the two autophagosome 
membranes and somehow is delivered to the plasma membrane for secretion [79]. 
In addition, Atgs have been shown to control metabolic signalling in response to metabolic stress. 
Under glucose starvation, LC3 on autophagosomes binds to the Rab GAP TBC1D5, that can also 
bind components of the retromer complex in an inhibitory fashion [80]. The binding of LC3 
releases the retromer complex from TBC1D5, allowing for endosomal transport of the glucose 
transporter 1 (GLUT1 receptor) through the trans Golgi network to the plasma membrane for 
increased glucose uptake [80]. This links Atgs to endosomal trafficking in a manner that is distinct 
from their canonical role in lysosomal degradation.   
The reason that these autophagosomes do not go on to fuse with the lysosome in secretory 
autophagy is thought to be due to the differential functions of SNAREs. For instance, there is 
evidence that in secretory autophagy the autophagosomes lack SNTX17, required for lysosomal 
fusion, and therefore these autophagosomes avoid lysosomal degradation [81]. Instead, they 
have been shown to have the SNARE SEC22b that aids plasma membrane fusion [81]. TRIM16 
regulates this process, where it is an essential cargo receptor with binding affinity for LC3, but 
also Sec22 to mediate the fusion of secretory LC3 positive vesicles with the plasma membrane 
SNAREs [81].  
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There is also evidence that Atg proteins promote the secretion of lysosomes in osteoclasts. 
Osteoclasts release proteolytic enzymes into the extracellular space in order to degrade bone, 
essential for bone resorption [82]. LC3 has been shown to play a role in this and when Atg5 is 
inhibited there is much less bone resorption. No autophagosome structures are observed near 
the ruffled border, therefore, how LC3 controls this is yet to be elucidated [82].  
Host defence by autophagy is something that has already been touched upon. Bacterial infection 
can be cleared by xenophagy, as previously mentioned, but also by LC3 associated phagocytosis 
(LAP). LAP is a process that uses Atgs in an unconventional way, and will be one of the focuses of 
this project; it is covered in more detail in later sections 1.3 and 1.4. There is also evidence for 
other processes that involve Atgs in bacterial tolerance by the cell. For instance, in the case of 
Toxoplasma Gondii (T. gondii), an intracellular pathogen that attempts to escape immune 
detection in pathogen containing vacuoles (PCVs) is targeted by the immune system through the 
action of some of the autophagy machinery. Specifically the PCVs are decorated with GABARAPL2, 
that recruits interferon (IFN) inducible GTPases to disrupt the membrane and replication of T. 
gondii (Sasai 2017). However, in other examples, certain Atgs can favour bacterial replication. For 
instance, in the case of Brucella abortis, the early autophagy machinery, but not the lipidation 
machinery, is needed to form bacterial containing vacuoles [83].  
1.1.6 The role of autophagy proteins in viral infection particularly Influenza infection. 
 
Non-autophagic roles of Atgs have also been uncovered in the context of virology. Autophagy 
related proteins are often involved in viral infection, depending on the context they can 
contribute to promotion or inhibition of the viral lifecycle. For instance, viruses can hijack the 
autophagy machinery and this is common in positive strand RNA viruses such as poliovirus. In this 
instance, the virus activates autophagy to utilise the forming membranes as scaffolds for viral 
replication [84].  Depleting autophagy proteins in this case decreases viral yield [84]. Other 
viruses such as the herpes simplex virus type 1 (HSV-1) inhibit autophagosome initiation, in this 
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instance achieved via a viral protein binding to beclin1, a key autophagy protein [85].  This 
inhibition of autophagy is essential for the virulence of HSV-1 [85].  
HIV-1 infection also appears to activate an unconventional autophagy pathway. It has been 
shown that the small transmembrane HIV protein Vpu helps to overcome host restriction factors 
through interactions with LC3C that, in a manner distinct from autophagy, removes the host 
restriction factor, BST2, from viral budding sites [86]. These data suggest there maybe a role for a 
pathway distinct from autophagy that plays a role in virology.   
The interplay of viruses and autophagy related proteins is complex and the virus that is most 
relevant to this project is Influenza A (IAV), which activates LC3 lipidation to membranes. Upon 
infection, the virion is taken up by endocytosis into host cells. The viral protein M2 (matrix protein 
2), an ion channel protein, inserts into the infected cell membrane and through the action of its 
LIR motif recruits and lipidates LC3 to the plasma membrane [87]. There is also evidence of 
accumulated LC3 lipidated membranes [88]. This LC3 lipidation is reliant on the Atg16L1-12-5 
complex but, interestingly, is independent of FIP200 [87], an autophagy initiation protein, 
suggesting that these may not be accumulated autophagosomes. Instead, there may be a non-
autophagic role of some of the autophagy proteins. The role for LC3 lipidation in this context is 
thought to contribute to virion budding and stability [87], which is similar to HIV-1 infection 
where the viral gag protein interacts with LC3 to help promote budding and assembly [89]. 
Studying IAV infection in more detail may help uncover if non-canonical autophagy, as defined as 
part of this project, plays a role in this pathology.  
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1.2 Non-canonical autophagy  
 
1.2.1 Definition and discovery.  
 
For a long time in the autophagy field, levels of cytosolic LC3 and lipidated LC3 were measured 
solely as a readout for canonical autophagy. However, it has now been accepted that LC3 can also 
be lipidated in the context of non-autophagosome single membranes through processes known 
as “non-canonical autophagy” [90, 91].  
The term non-canonical autophagy used in this project refers to the promotion of LC3 lipidation 
to single-membrane endolysosomal compartments occurring through the unconventional use of 
some autophagy proteins [92]. Although this is not a bonafide autophagic process, many groups 
have used the term non-canonical autophagy to refer to LC3 lipidation to single non-
autophagosomal membranes, for instance in the case of LAP [41, 93-96]. Due to high profile 
publications using the term non-canonical autophagy, we felt it was important to keep this name 
for consistency. Other processes have been referred to as non-canonical autophagy, including  
Atg5 and beclin independent autophagy [97], but these are distinct processes from the 
classification discussed in this project. In the future, an alternative term for the pathway may be 
derived to improve clarity. 
Non-canonical autophagy, as described here, involves a cell engulfment event such as 
phagocytosis, entosis or macropinocytosis, where LC3 is recruited and lipidated to phagosomes, 
entotic vacuoles or macropinosomes respectively, all single membrane compartments of the 
endolysosomal system. The molecular mechanisms underlying this unconventional LC3 lipidation 
event are yet to be fully determined and details seem to be context specific, each of these 
engulfment events will be described in turn later. 
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1.2.2 How is non-canonical autophagy distinct from autophagy? 
 
Autophagy, as outlined above, is involved in the clearance and turnover of intracellular 
cytoplasmic material, while non-canonical autophagy is associated with the engulfment and 
degradation of extracellular material.  
Canonical autophagy involves a de novo double membrane forming inside the cell, whereas in an 
engulfment event, the cytoskeleton is re-modelled to enwrap the cargo in the plasma membrane. 
This membrane has been shown by electron microscopy (EM) to be a single membrane distinct 
from double membrane autophagosomes [91]. 
Evidence suggests that endolysosomal LC3 lipidation shares the common lipidation complex with 
autophagy. For instance, knocking down Atg5 and Atg7 abolishes LC3 lipidation in both pathways 
[91]. However, the nature of the LC3 lipidation is somewhat different. While autophagosomes are 
decorated with lipidated LC3 on both the inner and outer surfaces of the double membranes 
during their formation, in non-canonical autophagy the vacuole formed following an engulfment 
event will only be decorated with LC3 on the outer surface of its membrane. 
It is the upstream initiation signals that most clearly separate the two LC3 lipidation pathways. 
For instance, LC3 can become lipidated to non-autophagosome membranes independently of the 
ULK1 complex (ULK1, FIP200, Atg13) whereas in autophagy this complex is essential for LC3 
lipidation to autophagosomes [91]. Knockdown of FIP200, ULK1, Atg13 all confirm that non-
canonical autophagy still occurs despite the inhibition of autophagy [41, 91]. The differences in 
the upstream signaling to LC3 recruitment and lipidation suggest the lipidation machinery could 
be recruited in a different way to non-autophagosomal membranes. 
It is more complex when looking at the involvement of the PI3K complex and the production of 
PI3P in non-canonical autophagy. The PI3K complex in autophagy is made up of Vps34, UVRAG, 
Beclin and Atg14 whereas in non-canonical autophagy Rubicon takes the place of Atg14, this will 
be further described when introducing LAP. In certain cellular processes, Vps34 is required for 
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endolysosomal LC3 lipidation associated with non-canonical autophagy [91]. However, in 
experiments involving pharmacological induction of the pathway, such as monensin or 
chloroquine, LC3 lipidation is insensitive to PI3K inhibitors such as wortmannin and LY29004 [98]. 
Therefore, it is hypothesized that the production of PI3P is necessary for non-canonical autophagy 
in the context of vesicle maturation, but it is not required directly for recruitment of the LC3 
conjugation machinery to endolysosomal membranes [98].  
Finally, non-canonical autophagy acts in a manner distinct from autophagy because p62 and 
NDP52, common autophagy cargo receptors, are not present at endolysosomal membranes [98]. 
Also, the membranes targetted by non-canonical autophagy are not damaged, as galectin 3 and 8 
are absent [41, 98], therefore making this process distinct from selective autophagy processes 
such as xenophagy or lysophagy. 
1.2.3 Pharmacological modulators 
 
Many high throughput drug screens have been carried out to find modulators of autophagy. The 
readout depends on where the drug is acting in the autophagy pathway. If the drug is inhibiting 
early stages of autophagy initiation, the number of autophagosomes decreases, as do lipidated 
levels of LC3. However, if the drug is blocking the lysosomal degradation of autophagosomes and 
their contents, flux of the pathway is being inhibited and autophagosome number increases, as 
do lipidated levels of LC3.  
 In this study we have used Bafilomycin A1, a potent and specific inhibitor of vacuolar ATPases (V-
ATPase) [99], which causes an increase in lysosomal pH, thereby blocking the final degradation 
step of autophagosomes. This affects autophagic flux and leads to a build-up of autophagosomes 
[34]. Other drugs such as: monensin, chloroquine, nigericin, hydroxychloroquine, betahistine, 
procanimide (see publication for further names [41]), have been previously used to look at 
autophagic flux as they too block the final steps in the signaling pathway. However, the Florey lab 
discovered that, unlike bafilomycin, these drugs also promote LC3 lipidation to membranes of the 
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endolysosomal system [41]. This LC3 lipidation is distinct and independent of autophagy but is 
dependent on V-ATPase activity, which is why bafilomycin does not promote LC3 lipidation to 
single membranes of the endolysosome [41, 98]. Some of these afore mentioned drugs are 
shown in (FIGURE 1.3) to summarise their role in LC3 lipidation to endolysosomal compartments 
dependent on V-ATPase and the Atg16 conjugation machinery. Therefore, these drugs should be 
used with caution when looking at autophagic flux [98].  
AMDE-1 (Autophagy Modulator with Dual Effect-1) is another drug previously identified to 
increase GFP-LC3 puncta formation through its action on AMPK to then inhibit mTORC1 [100]. It 
was also shown to block autophagic flux by affecting the lysosomal enzymes [100]. AMDE-1 has 
now been shown to activate a form of unconventional autophagy that is independent of ULK1, 
WIPI2b and Beclin, inducing LC3 lipidation to the Golgi [101]. This lipidation of LC3 occurs in a V-
ATPase dependent manner, shown using V-ATPase inhibitors such as bafilomycin [101]. This is 
further evidence that pharmacological modulators assigned to autophagy need to be used with 
caution.  
In this study monensin, an ionophore, was used as shown in (FIGURE 1.3). Monensin exchanges 
protons with sodium ions, raising the lysosomal pH, which causes water influx to lysosomal 
compartments [102], and activates endolysosomal LC3 lipidation. Chloroquine was also used, 
which is a lysosmotropic drug, a basic lipophilic compound that gets protonated and trapped in 
acidic compartments [103], again raising the lysosomal pH, causing osmotic imbalance and so 
leading to the influx of water and inducing endolysosomal LC3 lipidation [98]. 
The induction of endolysosomal LC3 lipidation by these lysosomotropic or ionphores is V-ATPase 
dependent. For instance, if cells are pretreated with bafilomycin (inhibiting V-ATPase), and then 
stimulated with monensin, endolysosomal LC3 lipidation is prevented [98]. Indeed, even merely 
using hypertonic medium is enough to induce endolysosomal LC3 lipidation, which can then be 
reduced using aquaporin inhibitors (blocking the osmotic change of endolysosomal 
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compartments) or bafilomycin [98]. How the influx of water activates LC3 recruitment and 
lipidation at these membranes is yet to be determined.  
Monensin and chloroquine thus provide a signal for endolysosomal LC3 lipidation based on 
osmotic changes to compartments in a V-ATPase dependent manner [41, 98]. These drugs 
outlined, will be essential tools for examining LC3 lipidation in both canonical and non-canonical 
autophagy.  
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Figure 1.3: Drugs that activate non-canonical autophagy with a detailed mode of action for 
monensin 
List of drugs that cause water influx into endolysosomal compartments, in a V-ATPase dependent 
manner. This results in LC3 recruitment and lipidation dependent on the Atg5-12-16L1 complex. 
Monensin carries out this activity by acting as an ionophore, exchanging hydrogen H+ ions for sodium 
ions Na+. This is V-ATPase dependent and results in LC3 lipidation by the Atg5-12-16L1 complex.  
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1.2.4 Toxins  
 
The drugs outlined above all have properties that cause water influx into endolysosomal 
compartments, resulting in the activation of the autophagy lipidation machinery in an 
unconventional manner, leading to the recruitment and lipidation of LC3 to these single 
membranes. Interestingly, there is evidence that in bacterial pathogenesis certain toxins can 
insert into membranes and similarly affect the osmotic balance of intracellular compartments.  
An example for this is Heliobacter pylori (H. pylori) a bacteria that can infect the digestive tract. 
This bacteria, following its endocytosis into the cell, has a virulence factor which is a secreted 
toxin, vacuolating toxin A, VacA [104, 105]. This toxin complexes and inserts into the endosomal 
membrane to form a selective calcium channel resulting in an influx of calcium ions into the 
lumenal space [106]. In order to overcome this, the V-ATPase found on the same membrane 
increases its activity to pump more protons into the lumen [107]. This results in the accumulation 
of protonated weak bases accumulating in the endosomal lumen, such as ammonium chloride , 
which in turn creates an osmotic gradient that results in water influx and vacuolation of 
endolysosomal compartments [108]. As previously mentioned, vacuolation and swelling of 
endolysosomal compartments after pharmacological stimulation activates LC3 lipidation. Similarly 
in in MEFs treated with VacA toxin, the cells vacuolate and, in an Atg5 and V-ATPase dependent 
manner, lipidate LC3 to the single membrane endolysosomes [98]. This was shown to be 
independent of the canonical autophagy proteins such as Atg13 [98]. This toxin will be used to 
study LC3 lipidation in the context of non-canonical autophagy.  
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1.3 Macro-endocytic engulfment events associated with non-canonical 
autophagy. 
1.3.1 LC3 associated phagocytosis (LAP) 
 
The best studied non-canonical autophagy pathway where LC3 is recruited and lipidated to non-
autophagosomal membranes is LAP. Phagocytosis is defined by engulfment of particles more than 
0.5 µm in size. Like autophagy, phagocytosis has a role in maintaining the homeostasis of an 
organism, through the clearance of both self and foreign particles, and similarly finishes with 
lysosomal degradation of said particles. Phagocytosis occurs in professional phagocytes in the 
blood, such as macrophages, neutrophils and dendritic cells, and other specialised cells in the 
nervous system and liver. Non-professional phagocytes such as epithelial cells can also perform 
phagocytosis and it is these that play an essential role in clearing debris.  
LC3 associated phagocytosis (LAP) occurs when pathogenic material or apoptotic debris are 
phagocytosed and LC3 is recruited and lipidated directly onto the phagosomal membrane. The 
phagosomes then mature and fuse with the lysosome for the acidification and degradation of the 
contents [109].   
LAP is not to be confused with xenophagy, a mechanism that targets pathogens and other foreign 
materials for autophagic processing. Xenophagy has been extensively described and the process 
relies on LC3 adaptor proteins and membrane damage markers, which are left as evidence when 
a pathogen tries to escape from an endosome. LAP is distinct, it does not require membrane 
damage to initiate the process of LC3 lipidation and is arguably a more direct and swift way to 
clear pathogens or apoptotic debris from the cell [110]. 
The upstream signals that initiate phagocytosis or LAP involve cell surface receptors recognising 
and internalising extracellular material, for instance, Toll like Receptors (TLRs) and FcγR found on 
macrophages, dendritic cells and neutrophils. TLRs recognise surface markers on the pathogen 
and they signal to the machinery for LC3 lipidation [109]. It has also been shown that cellular 
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corpses are targeted for degradation by LAP via the action of the phosphatidylserine receptor 
TIM4 [111]. There is also a role of Dectin-1, recognising fungal antigens [112-114].   
Before going onto describe the molecular mechanisms of LAP, it is important to understand the 
process of phagocytosis. As mentioned above, it is a process mediated by cellular receptors, 
where often the signalling is activated upon clustering of said receptors. The phagosome cup 
forms and engulfs particles, reliant on actin cytoskeleton re-arrangements and tightly regulated 
phosphoinositide signalling. This eventually leads to scission and formation of a nascent 
phagosome in the cytosol. This nascent phagosome undergoes a series of maturation steps, 
similar to the steps in endosome maturation. Fusion of early endosomes to the nascent 
phagosomes results in the accumulation of Rab5, essential to the maturation of the phagosome 
[115]. Rab5 then has a role in recruiting the Vps34 complex, a PI3K complex, which allows the 
phagsosomal membrane to become enriched with PI3P [115-117]. This in turn allows PI3P 
effector proteins to be recruited, such as the NADPH oxidase complex. When the phagosome is 
matured, Rab5 is no longer present at these membranes and Rab7 increases at the phagosome, 
again this is essential to the maturation of the phagosome [115]. Furthermore, the membrane 
proteins LAMP1 and LAMP2 ,found at late phagosomes, endosomes and lysosomes, are thought 
to be needed to recruit Rab7 [118, 119]. This mature phagosome can then fuse with the 
lysosome; V-ATPase allows for acidification and the NADPH complex has a role in reactive oxygen 
species (ROS) production.  
Further to the characterisation of phagocytosis, the molecular mechanisms of LAP have begun to 
be unraveled, a particularly important paper is by Martinez et al [120] and the findings are 
summarised in (FIGURE 1.4). They show through SILAC (stable isotope labelling of amino acids in 
cell culture) studies that rubicon is present at the LC3 associated phagosomal membrane, which 
they term the laposome [120]. Rubicon is a negative regulator of autophagy, when it is knocked 
down there is more autophagosome formation under autophagy inducing conditions, due to 
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rubicon inhibiting Vps34 [121]. In non-canonical autophagy, rubicon is essential for LAP, acting in 
complex with UVRAG, Beclin1 and Vps34 to form a distinct and specific PI3K complex [121], as 
shown in (FIGURE 1.4), and rubicon is needed for Vps34 activity in this context. The PI3K complex 
is recruited upon stimulation of cell surface receptors to the laposome and sustains PI3P 
production at these membranes. Without the engagement of these receptors, for instance if 
uncoated beads are phagocytosed, no LAP is observed [109, 110, 120]. As noted above, LC3 
lipidation is also dependent on V-ATPase activity and inhibiting V-ATPase blocks LC3 lipidation but 
has no effect on PI3P generation at phagosome membranes, therefore it must act downstream of 
the PI3K complex and upstream of the lipidation machinery [98].  
Rubicon also stabilises the NOX2 complex, which is an NADPH oxidase 2 expressed in phagocytes, 
which are able to transport electrons across a membrane to produce superoxide and other ROS 
[122]. NOX2 has previously been shown to activate ROS production in response to cell surface 
receptor stimulation and results in LC3 lipidation to the phagosome [110]. NOX2, along with 
p22PHOX, sits at the intracellular side of membranes and in order for it to be able to produce ROS 
it has to complex with cytosolic p47PHOX, p40PHOX, p67PHOX and Rac1 [122]. Rubicon directly 
interacts with p22PHOX and stabilises this NOX2 complex [123]. PI3P production acts upstream of 
NOX2 and both signals are dependent on rubicon and essential for LAP [120]. The PI3P and ROS 
production leads somehow to the recruitment of the conjugation machinery to lipidate LC3 on 
the phagosomal membrane to then fuse with the lysososome [110, 120], as shown in (FIGURE 
1.4).  
 
Martinez et al. [120] produced a knockout rubicon mouse and analysed bone marrow derived 
dendritic cells (BMDCs) from these animals, compared with WT cells [120]. The amount of 
phagocytosis was equal, but in the rubicon knockout cells there was no LC3 lipidated to 
phagosomes, additionally increased LC3 puncta were observed, due to rubicon no longer having a 
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negative effect on canonical autophagy [120] .The signals for LAP were independent of WIPI2b 
and FIP200 [120].  
In NOX2 knockout cells, the PI3K complex was recruited to LAPosomes, however, LC3 was not 
recruited and lipidated to these membranes [120]. Therefore, LAP involves cell surface receptor 
signaling to activate a distinct PI3K complex where rubicon is essential to also stabilise NOX2 for 
the production of ROS [120]. This results in the recruitment of the Atg16-5-12 conjugation 
machinery and LC3 lipidation to the phagosome membrane, how this lipidation machinery is 
recruited is unclear [120]. Florey et al [98] hypothesise that ROS production has the potential to 
alter the ionic balance of the phagosome and may therefore introduce osmotic imbalances, that 
can drive non-canonical LC3 lipidation [124]. Furthermore, solutes are released from degrading 
cargo in the phagosome lumen that may also cause an osmotic imbalance [125]. An overview of 
the signals involved in non-canonical autophagy are summarised in (FIGURE 1.5). 
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Figure 1.4: Molecular mechanisms of LAP 
The pathogen or in this case the zymozan particle engages the cell surface receptor to be internalised, 
NOX2 and the P22 PHOX subunits are present at the membrane. 1. The PI3K complex (Beclin1, Vps34, 
UVRAG and rubicon) is recruited to the phagosome. 2. The PI3K activity enriches the phagosome with 
PI3P. 3. PI3P production recruits the cytosolic NOX2 components to the membrane to form a stable NOX2 
complex, rubicon stabilises this complex. 4. NOX2 on the phagosome membrane produces ROS. 5. By an 
unknown mechanism the Atg16L1 conjugation complex is recruited and LC3 is lipidated to the 
phagosomal membrane. 6. The phagosome then fuses with the lysosome for degradation of the contents. 
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1.3.2 LAP in fungal infection.  
 
Aspergillus fumigatus is an airborne fungus that can lead to invasive aspergilliosis. This is common 
and extremely dangerous in immuno-compromised patients and chronic granulomatous disease 
(CGD) patients [126]. A. fumigatus can be targeted by the immune system and cleared through 
the action of LAP. This is dependent on the removal of melanin, a component of the fungal cell 
wall [127], and exposure of β-glucan, to activate Dectin-1 receptor and Syk dependent ROS 
production, resulting in LC3 lipidation to phagosomes [128].  
LAP is inhibited in CGD, an X-linked heritable disease, where the phox subunits of NOX2 are 
mutated or deleted, resulting in inhibited ROS production in immune cells [129]. CGD murine and 
human immune cells were used to look at LAP in response to A.fumigatus and showed that there 
was defective LC3 lipidation to phagosomes and increased fungal load, resulting in increased IL-
1β, an inflammatory cytokine, in patient cells compared to healthy cells [130]. This was further 
confirmed by Martinez et al. taking genetically modified animals deficient for LAP and infecting 
them with A.fumigatus resulted in invasive fungal infection and a plethora of inflammatory 
cytokines [120]. Similarly, patients treated with corticosteroids that inhibit ROS production and 
therefore LAP see a similar pathogenesis [128]. Therefore, non-canonical autophagy, specifically 
LAP, is important in the clearance of airborne fungal spores and when LAP is inhibited, because of 
disease or other factors, the consequences can be fatal.  
Interestingly, LAP can be reactivated in certain circumstances. For instance, IFNγ treatment has 
been used to treat invasive fungal infections [131] and Oikonomou et al. looked at this in the 
context of LAP after A.fumigatus infection [132]. IFNγ activates the expression of death-
associated protein kinase 1 (DAPK1), a protein involved in programmed cell death that also plays 
a role in inflammation [133]. DAPK1 co-localises at the phagosomes with proteins including LC3 
and Rubicon following A.fumigatus infection [132]. In cells from CGD patients, there was 
defective IFNγ and DAPK1 expression, furthermore when DAPK1 was silenced in healthy cells LAP 
was inhibited [132]. Treating the CGD cells with IFNγ resulted in DAPK1 expression and rescued 
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fungal clearance decreasing inflammation [132]. Interestingly, this mode of action is independent 
of NOX2 activity, because CGD patients do not have functional NOX2, suggesting DAPK1 may 
activate an alternate ROS pathway [134]. Therefore, IFNγ treatment offers a therapeutic way to 
target fungal pathogenesis potentially through LAP.  
1.3.3 Calcium signaling in LAP 
 
Recent work implicates calcium signaling, upstream of the rubicon containing PI3K complex, in 
the regulation of LAP. Calcium is a secondary messenger that underpins many signaling and 
trafficking processes, including autophagy and phagocytosis. Free  cytosolic calcium is an inducer 
of autophagy [135], while intracellular calcium is linked to the regulation of membrane fusion in 
phagocytosis, and ROS formation after zymozan engulfment, but this is a largely unstudied area 
[136, 137].  
As mentioned above, melanin protects A.fumigatus from LAP through blocking the assembly of 
the NOX2 complex [127, 138]. Recent work shows that calmodulin, a protein that binds and is 
activated by calcium, transiently recruits to phagosomes containing melanin deficient 
A.fumigatus conida [139]. Furthermore, global calcium depletion inhibits this calmodulin 
recruitment to phagosomes and inhibits NOX2 components, ROS production and therefore LAP 
[139]. This was shown to be specific to intracellular and ER calcium store depletion. Calcium was 
shown to be released from phagosomes activating calmodulin signalling regulating LAP [139]. 
Fungal melanin blocks this calcium signalling, by sequestering calcium in the phagosomal lumen 
to inhibit the recruitment of the key signalling molecules to allow LAP to clear the fungal infection 
[139]. Interestingly this study went on to link this to human pathogenesis, where a SNP in the 
calmodulin I gene that decreases calmodulin expression increases risk of invasive fungal infection 
[139].  
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1.3.4 Assays to study phagocytosis and xenophagy.  
 
In order to study pathogen clearance in the context of autophagy or non-canonical autophagy, 
bead experiments in phagocytic and non-phagocytic cells are used in the literature. To model 
pathogen clearance via autophagy, beads coated with transfection reagent are often used [140]; 
this mimics the damage the pathogens cause to the endosome/ phagosomes via virulence factors 
such as toxins, causing the initiation of the autophagy machinery [140]. Non-canonical autophagy 
has also been investigated using beads. Uncoated beads are internalised into the cell but alone 
will not activate LC3 lipidation to bead containing phagosomes [98, 110, 140]. However, if the 
beads are ligand-coated, or combined with a drug treatment, they can be used to activate non-
canonical autophagy [98]. Using IgG (ligand of FcƳR) or lipopolysaccharide (LPS; ligand of TLR4) 
coated beads, LC3 recruitment and lipidation onto phagosomes is observed [110], in a manner 
dependent on NADPH and the production of ROS [110].  
1.3.5 Macropinocytosis  
   
In addition to LAP, non-canonical autophagy is also implicated in other engulfment events, 
including macropinocytosis and entosis (see below). Pinocytosis was originally observed by Lewis 
in 1931 [141] where extracellular medium was being “drunk” into the cells. It is a form of 
endocytosis and occurs in a non-selective manner where extracellular macromolecules are taken 
into the cell via membrane ruffling, dependent on cytoskeletal rearrangements and 
phosphoinositol signalling [142]. The uncoated vesicles are usually 0.5-10 µm in size but 
characteristically irregular and it has been reported that they can mature and fuse with lysosomes 
similar to endosomal and phagososmal maturation [143].  
Macropinocytosis has been observed in response to growth factor signaling [144] and implicated 
in receptor trafficking and antigen presentation [145]. Macropinocytosis is also implicated in 
pathogenesis due to certain bacteria [146], protozoa [147] and viruses [148, 149] using it as a 
method of cellular entry. Furthermore, macropinocytosis plays a role in Ras-driven tumours 
because oncogenic Ras activates macropinocytosis, allowing increased growth factor signalling 
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[150] and amino acid delivery to aid tumour proliferation [151]. Therefore, inhibiting 
macropinocytosis offers a potential therapeutic target [151].  
LC3 is often lipidated onto macropinosomes in a manner distinct from autophagy initiation signals 
and in line with non-canonical autophagy, the summary diagram 1.5, shows that macropinosomes 
is one of the examples where non-canonical autophgay occurs [91]. The mechanism and function 
of non-canonical autophagy in this context is unclear. Macropinocytosis will be used in this 
project to study non-canonical LC3 lipidation in a physiological setting.  
1.3.6 Entosis 
 
Entosis is a process where one live epithelial cell pushes into another epithelial cell to form a so-
called ‘cell in cell’ structure [152]. This process occurs in epithelial cells following matrix 
deadhesion, aberrant mitosis [153], or glucose deprivation [154], often in tumours. The 
internalisation of neighbouring cells depends on the relative deformability of cells, where the 
stiffer cell pushes into a softer neighbour, in a manner dependent on the formation of an 
epithelial junction and the force provided by Rho-dependent actin signalling [155, 156]. 
The internalised entotic cell is housed inside a single membrane vacuole. The internalised cell 
may occasionally escape back into the cytosol but it is usually killed by lysosomal degradation 
[152]. Non-canonical autophagy plays a role in entosis as a rapid and transient recruitment and 
lipidation of LC3 from host cells onto entotic vacuole membranes is apparent, in a manner 
separate from autophagosomal LC3 lipidation [91].  The LC3 lipidation seems to influence the 
maturation of the entotic vacuole and subsequent death of the housed cell [91]  
Entosis is a “double-edged sword” in the context of cancer. On one hand it has a tumor 
suppressive role because it eliminates cells that have become detached or undergone aberrant 
division: in vitro assays suggest inhibiting entosis promotes tumor proliferation [152]. On the 
other hand, entosis promotes ploidy changes, by physically disrupting host cell cytokinesis; this 
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genetic instability is associated with tumour promotion, encouraging more aggressive cancers and 
poor patient outcome [157]. 
The entotic vacuole is targeted for LC3 lipidation via non-canonical autophagy and is a form of 
engulfment event associated with non-canonical autophagy, therefore it is included in the 
summary diagram 1.5. Entosis will be used in this project as a system to study non-canonical LC3 
lipidation.  
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Figure 1.5: Molecular mechanisms of non-canonical autophagy. 
Multiple engulfment events activate a non-canonical autophagy process dependent on the PI3K complex 
(Beclin1, Vps34, Vps15, Rubicon) and V-ATPase activity. In LAP NADPH oxidase is needed to produce ROS 
and the internalised cell surface receptors such as TLRs could be involved in further signalling. These 
signals all act upstream of the LC3 conjugation machinery, this machinery is common to canonical 
autophagy. This results in LC3-I becoming lipidated to single endolysosomal membranes LC3-II. These 
membranes then fuse with the lysosome for the contents to be degraded.  
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1.4 Importance of non-canonical autophagy.  
 
Although the role for non-canonical autophagy is yet to be elucidated in entosis and 
macropinocytosis, a number of studies show that LAP is critical in health and disease. LAP is a vital 
cellular process with important functional consequences, particularly with regards to its role in 
the immune system. As previously outlined, non-canonical autophagy regulates the degradation 
of material following macro-endocytic engulfment. LAP is involved in pathogen clearance, 
including fungal pathogens, impacting on immune responses including antigen presentation. LAP 
has also been shown to be essential for cellular homeostasis through apoptotic cell clearance, 
controlling immune responses but also playing a role in maintenance and control of signalling 
pathways and processes, such as the visual cycle and in cell division.  
1.4.1 LAP maintains homeostasis through clearance of apoptotic debris.   
 
The body is challenged not only by foreign invaders but also with the millions of cells that die 
every second. It is essential that this does not activate an inappropriate innate immune response 
and this is achieved through engulfment and degradation of apoptotic cells and general cellular 
debris by phagocytes [158]. The persistence of apoptotic corpses not only causes aberrant 
inflammation but also could impair parts of phagocytosis itself, for instance it has been seen in 
Drosophila that persistence of corpses could impair phagocyte motility [159].  
Dead cells are recognised by phagocytes through “eat me” signals, this is in the form of 
phosphatidyl serine (PtdSer) which is usually present on the inner leaflet of the plasma 
membrane but upon apoptosis become exposed [160]. TIM-4 is a receptor on macrophages and 
dendritic cells that recognise PtdSer and if this receptor is blocked these cells can no longer engulf 
dead cells [161, 162]. A knockout TIM-4 mouse model was engineered to show that in vivo there 
is inefficient engulfment and consequent clearance of dead cells, resulting in hyperactivity of 
immune cells and signs of systemic autoimmunity [163]. LAP was shown to be involved in this 
engulfment event as rapid LC3 lipidation to apoptotic cell containing phagosomes was seen, 
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peaking at 120-150 min post engulfment, and electron microcopy confirmed it was a single 
membrane surrounding the apoptotic cell [111].  
In macrophages that do not support LAP, for instance Atg7 knockout macrophages, LC3 lipidation 
to engulfed apoptotic cells was absent and led to decreased acidification and clearance of these 
compartments [111]. The result of this was the production of inflammatory cytokines IL-1β and IL-
6, compared to a dampening anti-inflammatory response evidenced by IL-10 levels in WT cells 
[111]. This supports what was seen when the autophagy protein, Atg16L1, important for both 
canonical and non-canonical autophagy, was knocked out, resulting in IL-1β production in mouse 
macrophages [164].  
Mouse models deficient in LAP were also used, both in vitro and in vivo, to look at their response 
after challenge with apoptotic cells [96]. Mice that supported LAP were able to clear apoptotic 
cells, independent of FIP200 expression [96]. When LAP was impaired, for instance in knockout 
rubicon or NOX2 mice, animals were smaller, and after repeated challenge with apoptotic cells 
had an inflammatory cytokine profile and autoantigens were produced [96]. The mice also 
suffered kidney damage, all consistent with an autoimmune systematic lupus erythenatasus (SLE) 
like phenotype [96].  
Taken together, this highlights the importance for non-canonical autophagy in homeostasis and 
the ability to mount an appropriate immune response.  
1.4.2 Role of LAP in maintaining the visual cycle. 
 
LAP also plays an important role in maintenance of the visual cycle. In order to maintain the 
health of the retina and support vision, photoreceptor outer segments (POS) are shed and 
phagocytosed by the neighbouring retinal pigment epithelial cells (RPE). The mechanism for this 
phagocytosis is reliant on “eat me” signals on the POS being recognised by receptors and integrins 
on the RPE surface.  
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A paper by Kim and colleagues looked at how the autophagy machinery is involved in this 
maintenance event [94]. They knocked out Atg5 in RPE cells and showed that LC3 was no longer 
lipidated to phagosomes and there was an accumulation of enlarged phagosomes containing POS 
leading to a visual defect in mice [94]. They showed further evidence that this was due to a defect 
in LAP, and not linked to canonical autophagy, by knocking out components such as ULK1, FIP200 
and Atg13 and showing no defect in the phagocytosis and clearance of POS by RPE cells [94]. This 
could be explained by their observations that in the knock out Atg5 RPE cells had decreased 
lysosomal activity [94]. Transmission electron microscopy showed the membranes surrounding 
the POS were also single membranes [94]. This paper provides a link for non-canonical autophagy 
with RPE phagocytosis implicating the process in the visual cycle. This is interesting from an 
ageing point of view as the age related decline in vision could be linked to the decline in 
phagocytosis and LAP [94].  
1.4.3 Signalling linked to cell division in c. elgans is controlled by LAP.  
 
LAP has also been implicated in controlling signaling linked to cytokinesis through the degradation 
of the midbody. The midbody is a structure formed when the mitotic spindle meets the 
contractile ring and controls the final separation of daughter cells. This signaling complex must be 
tightly regulated to stop aberrant signaling after this process is complete. The fate of the midbody 
has been disputed. There have been models proposing midbody release, where they can be safely 
phagocytosed [165-167], or alternatively, suggestions that after cell division the midbody is 
targeted and degraded by the autophagy machinery [168, 169]. An interesting paper looked at 
combining both of these theories to assess whether LAP is involved in midbody degradation, 
where the midbody is released and phagocytosed, then targeted by some of the autophagy 
machinery in non-canonical autophagy [170]. The study was done using time lapse imaging in 
Caenorhabditis elegans (C .elegans) embryos. They found that indeed the midbody was released 
and phagocytosed by the daughter cells. These phagosomes were then lipidated with Atg8 
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homologs in C. elegans, independent of the canonical autophagy proteins UNC-51 and EPG-8 
(homologous to mammalian ULK1 and Atg14) [170].  
A similar phenomenon utilizing LAP in C. elegans has been observed in clearance of polar bodies 
in early embryonic development [171]. Polar bodies are produced after a meiosis event and 
contain extra genomic information often produced because of asymmetric division, therefore it is 
essential that these are programmed for apoptosis and then cleared. This process occurs via LAP 
and shows that undifferentiated pluripotent cells are capable of LAP, knockdown of EPG-8, a 
homolog of Atg14, was used to show that canonical autophagy did not have a role [171]. Both 
worm homologs of LC3 (LGG-2) and GABARAP (LGG-1) were shown to localise to phagosome 
membranes and knocking out Atg7 stopped Atg8 lipidation [171]. The lack of Atg8 lipidation did 
not affect LMP-1 recruitment (worm homolog of LAMP proteins) but did slow the degradation 
and breakdown of polar body membrane for degradation [171]. 
1.4.4 Antigen presentation  
 
In the adaptive immune response pathogen derived antigen fragments are presented on the 
surface of antigen presenting cells (APCs). They are presented by major histocompatibility 
complexes (MHC) that come in two classes, MHC-I and MHC-II. Antigens can originate 
intracellularly or exogenously (extracellularly) to be presented, they can also be cross-presented.  
A basic overview, as summarised in (FIGURE 1.6), is that extracellular peptides are processed by 
the lysosome and loaded onto MHC-II complexes at an endosomal MHC loading compartment, 
while intracellular peptides are processed by the proteasome and loaded onto MHC-I at the ER, to 
then be presented at the cell surface. This is an oversimplified view and actually, autophagy is 
another way intracellular peptides are processed and loaded onto MHC-II for presentation. 
FIGURE 1.6 visualises MHC-II antigen presentation in the context of LAP and autophagy. Once the 
antigens are presented on the cell surface MHC-I, antigen complexes are recognised and activate 
CD8+ T cells and the MHC-II antigen complex activates CD4+ T cells.  
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There have been studies implicating autophagy in MHC-II antigen presentation in vitro, where this 
has a knock on effect for efficient CD4+ T cell priming. These studies were done by inhibiting 
autophagy via the PI3K complex [172-174], or by knocking down Atg12 [175]. In vivo studies were 
done in a mouse model where Atg5 was knocked out in dendritic cells, a form of antigen 
presenting cell (APC) [176]. This showed a defect in MHC-II antigen presentation in response to 
HSV and Listeria infections and T cell priming [176]. The defect was not due to functionality of 
dendritic cell migration, co-stimulatory signalling, MHC-II expression, cytokine secretion, ROS 
production or the phagocytosis or endocytosis of the antigen itself [112, 176]. What was affected 
was the delayed phago-lysosome fusion and delivery of cathepsins to the lysosome [176]. 
Interestingly, there was no impact on MHC-I antigen presentation or cross presentation [176]. 
However, when canonical autophagy is activated, for instance by starvation, this does not 
regulate or enhance antigen presentation [176]. Furthermore, when TEM was performed, the 
structures were single membrane phagosomes. These data suggest the defect in antigen 
presentation from knocking out Atg5 in vivo may be dependent on non-canonical autophagy 
[176].  
It has also been reported that knocking out LC3B in dendritic cells does not affect their 
functionality, but there is an impairment in processing and presentation of MCH-II antigen 
presentation and subsequent T cell priming [112]. The delay in antigen presentation on MHC-II 
has been suggested to be due to delayed fusion of phagosomes with the lysosome and therefore 
less processing for antigen presentation [112]. This is the classical view that LC3 lipidation leads to 
efficient lysosomal fusion and degradation.  
Conversely, one lab reports that LAP is actually needed more for the fine-tuning of antigen 
presentation, and that LC3 on phagosomes maintains antigens for delayed antigen presentation 
[177]. The kinetics of lysosome phagosome fusion, with and without LC3, showed that in the 
presence of LC3, fusion took more than 4 h and phagosomes were negative for Rab7 and LAMP2, 
suggestive of slowed maturation [177]. This maturation process was much faster where LC3 was 
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absent. This was in human antigen presenting cells, whereas the other studies were all in mouse 
cells in vitro and in vivo, therefore, this observation could be cell type specific [177].  
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Figure 1.6: MHC II loading extracellular and intracellular antigens 
Adapted from [178] 
A. A peptide is internalised by a cell and the phagosome is targeted for LC3 lipidation. This 
membrane fuses with an endosomal MHC loading compartment where lysosomal enzymes 
break down the peptide into fragments and load them onto MHC-II molecules for trafficking to 
the cell surface for antigen presentation.  
B. An intracellular peptide is targeted by the autophagy machinery and the autophagosome fuses 
with the endosomal MHC loading compartment where lysosomal enzymes break down the 
peptide into fragments and load them onto MHC-II molecules for trafficking to the cell surface 
for antigen presentation. 
C. Intracellular peptides are also targeted by the proteasome where fragments are loaded onto 
MHC-I molecules and trafficked to the cell surface for antigen presentation. 
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1.4.5  Receptor signaling in B cells 
B-cells are essential immune cells in the adaptive immune response; they are activated by the 
binding of antigens to receptors leading to B-cell proliferation and antibody production. TLRs are 
among the receptors that can contribute to B-cell activation [179]. Some TLRs recognise foreign 
nucleic acid but can also recognise host derived nucleic acids. In the case of DNA it is TLR9 that 
can be activated and if inappropriately activated can lead to inappropriate B-cell proliferation and 
autoimmunity. Integrins have also been implicated in activation of signaling that follows antigen 
binding to immune receptors [180]. For instance, αv integrins regulate B-cell activation, through 
promotion of LC3 to TLR containing endosomes, which promotes TLR containing endosome 
maturation, resulting in decreased receptor mediated B-cell activation [181]. Conversely if the αv 
integrins, LC3B or Atg5 are knocked out, this leads to autoantibody production as a consequence 
of uncontrolled B cell proliferation, through the persistence of NF-κB (nuclear factor kappa-light-
chain-enhancer of activated B cells) signalling [181]. The maturation of these endosomes is 
thought to be similar to LAP and is dependent on ROS and Syk [181]. Therefore, this could 
indicate that non-canonical autophagy has an additional role in controlling immune responses to 
auto antigens. This notion is further validated by the fact some polymorphisms found in human 
Atg5 implicate this process and are linked to SLE [182, 183]. Furthermore, potentially linking to 
this, mice lacking αvβ5 integrin have age related blindness due to less efficient phagocytosis in 
RPE cells [184].  
1.4.6 Role of Atg8 lipidation 
 
In non-canonical autophagy LC3B, as well as GABARAPL1 and GABARAPL2, localise and lipidate to 
endolysosomal membranes [41, 120]; a more in depth analysis of the Atg8 proteins is currently 
being carried out within the Florey lab. As previously mentioned, the role of the Atg8 family 
members have been studied with regard to autophagy, but more needs to be done to elucidate 
their role in non-canonical autophagy. Similar experiments, such as knocking out the individual 
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Atg8 proteins [64], could now help elucidate the function of the different Atg8 members in non-
canonical autophagy.  
As outlined above, in non-canonical autophagy, LC3 lipidation is needed for homeostasis and 
control of immune responses. Without the LC3 lipidation in LAP, pathogen and apoptotic cell 
clearance is slower and less efficient, with evidence that this is due to slowed phagosome 
lysosome fusion [109, 111]. However, more work needs to be done when looking at LAP and the 
other non-canonical autophagy pathways. This is particularly important as recently there is 
contradictory evidence that LC3 is not universally required for phagosomal maturation in all 
systems [185]. This was shown in MEFs and bone marrow derived macrophages that were 
deficient for Atg5 or Atg7 and therefore could not lipidate LC3. In this system, despite the lack of 
LC3 lipidation, there was no defect in phagosome maturation [185]. Their conclusions did not 
exclude LAP, but suggested there is not a universal requirement for LC3 in phagosome 
maturation, and there must be further details to be uncovered [185].  This idea that the role of 
Atg8 is more complex is further supported by studies in which LC3 lipidation was shown to slow 
phagosome maturation to enable prolonged MHC II antigen presentation [177].  
Together, published studies have uncovered non-canonical autophagy as an essential, parallel 
signalling pathway with critical functions in health and disease. The molecular mechanisms that 
distinguish canonical and non-canonical pathways remain to be fully understood.    
1.5 Atg16L1  
 
1.5.1  Structure 
 
This project focuses on the key autophagy protein Atg16. Atg16 was initially found in yeast, 
designated Apg16 [24], and then further characterised in mice. The human Atg16L1 gene sits on 
the long arm of chromosome 2 at position 37.1 (2q37.1), the mouse Atg16L1 gene sits on 
chromosome 1 D. There are two paralogues of Atg16: Atg16L1 and Atg16L2; and Atg16L1 has 
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three splicing isoforms: α, β, γ [25]. Atg16L1 forms a ~800 kDa complex with Atg5 and Atg12 [25]. 
The domain structure of the human Atg16L1 protein is outlined in (FIGURE 1.7).   
The N-terminal domain (amino acids: 1-79) of Atg16L1 is required for Atg16L1 binding to Atg5. 
Atg5 and Atg12 form an irreversible complex [29] and are required for LC3 lipidation activity: this 
was originally shown in Atg5 knockout MEFs [186]. The crystal structure is available for the Atg5-
12-16 interaction, but this only includes the first 33 residues of Atg16L1[187]. The E3 like function 
of Atg12-5-16 [30], and its role in LC3 lipidation, has already been discussed, see figure 1.1.  
The middle region of Atg16L1 includes the coiled coil domain (CCD) (amino acids: 79-230), which 
is required for Atg16L1 homo-dimerisation and therefore functionality [25, 188]. Amino acids 
230-265 make up the rest of this middle region, containing the FIP200 binding domain 
(FBD)(residues 229-242)[32, 189] and WIPI2b binding sites (amino acids 226,230)[33]. 
Furthermore, Itoh et al.[190] screened for Rab effectors and found that Atg16L1 interacts directly 
with Golgi resident Rab33B via residues 141-265 in Atg16L1. The interaction is GTP-dependent 
and is thought to be important in autophagosome biogenesis; if GTPase activity is impaired, more 
Rab33B and Atg16L1 bind and this increases LC3 lipidation on autophagosomes [190]. The crystal 
structure is available of the central region of Atg16L1 residues 72-307 [191]. 
The C-terminal part of the protein contains seven WD-40 repeats. This domain is absent in yeast 
and its function is yet to be fully determined [25]. The structure has now been solved [192]. This 
domain will be discussed and introduced in further detail below in section 1.6.  
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Figure 1.7: Atg16L1 domain structure of mouse Atg16L1. 
The N-terminal domain of Atg16L1 amino acids 1-79 is responsible for Atg16L1 interacting with Atg5, 
essential to the formation and function of the Atg16L1-5-12 complex. The CCD is the coiled coil domain 
(79-230) and is responsible for the homo-dimerisation of Atg16L1. The 79-265 part of the protein is also 
responsible for Atg16L1 interacting with proteins such as FIP200 and WIPI2b required for LC3 lipidation to 
autophagosomes. Finally the WD40 C-terminal domain of Atg16L, where the function is yet to be fully 
elucidated.  
  
48 
 
1.5.2 Autophagy protein recruitment 
 
Atg16L1 is indispensable for autophagy and the knockout mouse for this gene shows lethality 
within one day of delivery due to the inability to survive starvation conditions [1, 164]. In 
knockout cell lines and mouse models, where Atg16L1 has been knocked out in specific cells of 
the mice, no LC3 lipidation is observed to autophagosomes [32, 164, 186].  
In autophagy, Atg16L1 directly interacts with WIPI2b on the forming autophagosomes [33]. 
WIPI2b is a PI3P effector and therefore binds the PI3P-enriched autophagosomes. Pull-down 
experiments with truncated mutants of Atg16L1, and further mutational studies, showed that 
amino acids at positions 226 and 230 in the coiled coil domain of Atg16L1 are important for 
WIPI2b binding [33]. Furthermore, this interaction between Atg16L1 and WIPI2b is important to 
localise the lipidation complex to specify the location of LC3 lipidation. If WIPI2b is forced to the 
plasma membrane using a CAAX motif, Atg16L1 binds WIPI2b at the plasma membrane and is 
able to lipidate LC3 to the plasma membrane [33]. 
Atg16L1 also interacts directly with FIP200 [32, 189] and this interaction is independent of other 
Atg protein involvement. Residues 229-242 of Atg16L1 are required for FIP200 binding (the 
FIP200 binding domain, FBD); notably, one of the WIPI2b binding sites also fall within this region. 
The recruitment of the Atg16L1 complex in canonical autophagy is summarised in (FIGURE 1.8). 
The E226R E230R mutant Atg16L1, that no longer binds to WIPI2b, still binds FIP200, and in 
FIP200 knockout MEFs WIPI2b still binds Atg16L1, so this interaction is independent of FIP200 
[33].   
Interestingly, in ULK1 knockout cells that have undergone glucose starvation, which is a condition 
distinct from canonical amino acid starvation-induced autophagy, the ∆FBD mutant of Atg16L1 
still supports LC3 lipidation [32]. This observation is consistent with the idea of a different 
mechanism for LC3 lipidation in processes distinct from canonical autophagy, independent of 
WIPI2, FIP200 binding and ULK1 involvement.   
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Figure 1.8: Atg16L1 recruitment in autophagy 
Atg16L1 as a homodimer, each Atg16L1 interacts with Atg12-5 to form a functional complex to lipidate 
LC3. The middle region domain shown in red represents the domain that contains the FIP200 and WIPI2b 
binding sites. The double membrane structure is the autophagosome sequestering cytosolic components, 
where the PI3K complex containing Vps34 builds up PI3P shown in red on the autophagosome. WIPI2b 
and FIP200 are PI3P effectors that independently recruit Atg16L1 to autophagosomes specifying where 
the LC3 will become lipidated to the membrane.  
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1.5.3 Atg16L2 
 
Atg16L2 is a paralogue of Atg16L1 with similar domain structures. Atg16L2 is conserved in 
mammals [193]. Like Atg16L1 it has splice variants, but only two, αand β Atg16L2, where the β is 
the more dominant in mouse tissues [193]. The N-terminal domain of Atg16L2 has 32% amino 
acid identity to Atg16L1; the WD domain has 43% and the middle region has 20.7% amino acid 
identity [193]. Atg16L2 forms a ~800 kDa complex with Atg12-5, just like Atg16L1 [193]. However, 
Atg16L2 does not bind WIPI2b [33] or FIP200 [32] and has a much weaker affinity for Rab33b 
[193]. Atg16L2 is not recruited to the phagophore in canonical autophagy and is unable to 
activate autophagy when expressed in Atg16L1 knockout cells. When Atg16L2 is knocked down 
there is no negative effect on the cell’s ability to carry out autophagy [193]. This is interesting 
because when Atg16L2 is forced to the plasma membrane it can function to lipidate LC3; 
therefore, the Atg16L2-Atg12-Atg5 complex is functional but is not recruited to autophagosomes 
[193]. To date, it has not been tested whether Atg16L2 is involved in endolysosomal LC3 lipidation 
events. 
1.6 Atg16L1 WD domain 
 
1.6.1 Structure  
 
In general, the WD40 domain consists of a 6-8 blade, beta propeller structure. The WD40 domain 
is extremely common and often functions as a platform for protein-protein interactions to 
regulate signalling. Although the domain is common, there is low sequence conservation between 
WD domain containing proteins [192, 194-196]. It is the variable regions, not important for the 
folding, that are most likely to be responsible for specific protein-protein interactions.  
Before the crystal structure was solved for the WD domain of Atg16L1, an online database was 
available to predict the structures of WD domains based on their primary sequence. This offered 
predictions for potential amino acid ‘hotspots’ that would be important in protein-protein 
interactions, including the WD domain of Atg16L1 [195]. The crystal structure of the WD domain 
51 
 
of human Atg16L1 (1.55 Å) was solved part way through this project and offered further insight 
into which sites in the domain could be strong candidates for protein binding and thus good 
mutagenesis targets [192].  
The crystal structure is useful because it shows the properties of different regions of the domain. 
For instance, the top face is largely acidic and has a lot of hydrophobic residues, whereas the 
bottom face is basic with negatively charged residues [192]. Furthermore, there is a positively 
charged cavity, accessible from the bottom and the side of the beta propeller, between blades 3 
and 4 [192]. The WD domain has important residues that allow for the dimerization of two WD 
domains [192]. The published structure of the WD domain of Atg16L1 will be a good tool to help 
define the role of this domain in canonical and non-canonical autophagy.  
1.6.2 WD domain in canonical autophagy  
 
It has been shown that the WD domain of Atg16L1 is dispensable for canonical autophagy. Fujita 
et al. expressed a ∆WD mutant of ATG16L1 (1-249) in Atg16L1-deficient MEFs [197] and showed 
that the C-terminal deleted Atg16L1 still formed the complex with Atg12-5 and the dimerization 
of the complex was not impaired [197], which supports previous literature [25] . Furthermore, the 
WD domain was dispensable for Atg16L1 recruitment to punctate structures, upon starvation 
induced canonical autophagy, and subsequent LC3 recruitment and lipidation at these 
membranes [197].  
The effect of deleting the WD domain on xenophagy was also studied, where the re-
complemented cells were challenged with S. typhimurium and the lipidation of LC3 was 
measured, as well as the replicative ability of the bacteria [197]. There was no difference in the 
LC3 lipidation to the bacteria and the replicative ability of the bacteria was the same in cells with 
the FL Atg16L1 or the ∆WD mutant of ATG16L1 (1-249) [197].  
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The conserved nature of the WD domain of Atg16L1 in eukaryotes is suggestive of an important 
function, but this is yet to be determined, and is distinct from the role of Atg16L1 in canonical 
autophagy.  
1.6.3 Known binding partners 
 
A range of proteins have been found to bind to the WD domain of Atg16L1. There is some 
literature to suggest that WD proteins can bind Ubiquitin (Ub) [198], this was shown for the WD 
domain of Atg16L1, playing a role in selective and starvation induced autophagy in conjunction 
with other interactors such as FIP200 [199]. 
TMEM 166 (transmembrane protein 166) is another protein that interacts with the WD domain of 
Atg16L1. Knocking down TMEM 166 reduces autophagy and Atg16L1 localisation to 
autophagosomes [200]. This is a beclin independent initiation of autophagy.  
Another protein that interacts with a large subset of autophagy related proteins is interferon 
induced TRIM 20 (tripartite motif containing protein). These interactions include binding to the 
WD domain of ATG16L1 [201]. TRIM20 acts as an autophagy receptor and a platform to assemble 
autophagy components thought precision autophagy and is implicated in inflammasome 
signalling [201]. So far these examples are not relevant to non-canonical autophagy.  
There are other known interactors of the Atg16L1 C-terminal WD domain that implicate this 
domain in bacterial clearance. TMEM59, a glycosylated transmembrane protein found 
predominantly on late endosomes and lysosomes, binds Atg16L1 and results in LC3 lipidation to 
endosomal and lysosomal membranes [202]. This process seems to be distinct from autophagy, 
as the signalling is independent of starvation and p62 levels are unchanged, furthermore electron 
microscopy confirms that LC3 is lipidated to non-autophagosome membranes [202]. TMEM59 co-
localises with LAMP2, CD63 and transiently with EEA1, suggesting a conventional endocytosis 
pattern of events. TMEM59 is responsible for LC3 lipidation directly onto endocytic 
compartments, this is an example of an unconventional autophagy pathway [202]. Furthermore, 
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TMEM59 was shown to directly interact with the WD domain of Atg16L1, and using site directed 
mutagenesis, the important residues for this interaction were uncovered. This interaction occurs 
between a specific binding motif on the intracellular domain of TMEM59 [YW]-X3-[ED]-X4-[YWF]-
X2-L and the WD domain of Atg16L1 [202]. Using this novel motif, a flexible prosite search was 
carried out to identify other proteins with this Atg16L1 binding motif. The flexible input was 
([YW]-X(2,6)-[ED]-X(2,6)-[YWF]- X2-L), where the square brackets are OR, and the round brackets 
represent the number of amino acids in between defined residues [202]. This search identified 
CARD1, a domain of NOD2, interestingly NOD1 lacked this motif. TLR2 also had this motif. These 
interactions were confirmed by co-IP. In line with the idea the WD domain of Atg16L1 could 
mediate bacterial clearance, when TMEM59 was knocked down, LC3 lipidation to staphlococcos 
aureus containing vacuoles was decreased [202]. Other interactors that have not been previously 
implicated in autophagy included T3JAM and DEDD2 [202].  
The Atg16L1 WD domain also binds NOD like receptor proteins.  These are cytosolic proteins that 
bind pattern recognition receptors of invading bacteria [203, 204]. A signalling cascade is 
activated in response to this recognition. NODs have caspase activation and recruitment domains 
(CARD) and it is via this domain of NOD that the interaction with Atg16L1 occurs. Interestingly, 
NOD2 contains the same [YW]-X3-[ED]-X4-[YWF]-X2-L motif found in TMEM59, and also TLR2, 
indicating a conserved binding mechanism shared by several interactors [47, 22]. The role of NOD 
is to recruit Atg16L1 to the site of bacterial entry; for instance, this occurs in the case of Shigella 
flexneri [205]. However, NODs’ involvement in bacterial clearance is linked to selective 
autophagy, not LAP [205]. 
Whether TMEM59 mediated LC3 lipidation is due to non-canonical autophagy and a LAP-like 
phenomenon is unclear, but evidence suggests it is bafilomycin independent and PI3K 
independent, suggesting it may be another form of unconventional autophagy [202]. Therefore, a 
more extensive search needs to be done for novel Atg16L1 binding partners in the context of 
54 
 
endolysosomal LC3 lipidation in non-canonical autophagy. This could provide the mechanistic 
answers for the recruitment of Atg16L1 in non-canonical autophagy.  
1.6.4 Crohn’s Disease 
 
Atg16L1 has been extensively studied in the context of Crohn’s disease after a single nucleotide 
polymorphism (SNP), close to the WD domain of Atg16L1, was picked up in a genome wide screen 
of SNPs associated with the disease [206]. The nucleotide change from adenine to guanine causes 
a change in amino acid sequence, threonine to alanine at position 300 in Atg16L1 (T300A) in 
humans, T316A in murine models. There is a strong association between people with this Atg16L1 
variant and their risk of developing Crohn’s disease, but the variant itself is not sufficient to cause 
the disease. There are other identified SNPs, including other variants of Atg16L1, Atg16L2 [207] 
and NOD2 [208] to name a few, therefore the mechanisms in which these variants contribute to 
Crohn’s disease are unclear. A variant of NOD2 is associated with early onset and severity of 
Crohn’s disease, NOD2 is involved in targeting Atg16L1 to sites of bacterial entry [208]. But the 
focus here is on the T300A Atg16L1 variant.  
Crohn’s disease causes abnormal gut homeostasis and chronic inflammation and is one of the 
most common types of inflammatory bowel disease. The role of the Atg16L1 T300A variant is 
debated. In cells derived from a knock in mouse model of Atg16L1 T300A, selective autophagy is 
decreased and therefore anti-bacterial defence is compromised, increasing inflammatory 
cytokines such as IL-β [209], much like what is observed in Atg16L1 knockout cells [164]. Shigella 
Flexerni was used in this study due to its role in xenophagy, and infection with this bacteria in 
T300A Atg16L1 expressing MEFs has increased replication and IL-β production [209]. 
Furthermore, in this study there were morphological defects in Paneth and goblet cells in cells 
expressing the T300A variant suggestive of a role of Atg16L1 in gut homeostasis [209]. 
Furthermore, decreased bacterial handling has been observed in cells expressing the ATG16L1 
T300A variant with consequent implications on the innate immune response, for instance 
lowered T cell response due to reduced antigen presentation [210] [211] [212]. This has been 
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observed in the case of salmonella [212] and uptake and processing of E.coli in Crohn’s disease 
patient dendritic cells [211]. How the Atg16L1 T300A variant mediates these pathways is unclear.  
Recent evidence attributes the decline in selective autophagy to loss of functional Atg16L1, due 
to the T300A variant proceding a caspase 3 cleavage site (DxxD) on Atg16L1, amino acids 296-299 
[209, 213]. The variant of Atg16L1 promotes caspase cleavage in response to stress signals such 
as metabolic stress, tumour necrosis factor alpha (TNFα) signalling or gut infection pathogens 
such as Yersinia enterocolica [213]. The cleavage in vitro was studied using TNFα or staurosporine 
induced apoptosis, that activates caspase 3 cleavage, and the T300A variant of Atg16L1 was 
significantly more susceptible to cleavage following these treatments; uncleaved Atg16L1 and 34 
kDa and 36 kDa cleavage products could be observed by SDS PAGE. Increased cleavage of Atg16L1 
T300A, results in less functional protein and lower levels of autophagy [209, 213]. Challenging the 
Atg16L1 T316A mouse model with Y.enteroclica, a physiologically relevant bacterial infection to 
study, results in an increase in inflammatory cytokine production compared to WT mice [213].  
The observations of increased caspase cleavage of Atg16L1 T300A were followed up when looking 
at TMEM59 mediated autophagy [214]. As outlined previously TMEM59 can interact with the WD 
domain of Atg16L1 [202]. Therefore, stress mediated caspase-3 cleavage would result in less full 
length Atg16L1 to bind TMEM59, as the N-terminal region (1-299) gets uncoupled from the C-
terminal region (300-607) [214]. In cells expressing the cleavage products, no TMEM59 mediated 
autophagy was observed [214]. Canonical autophagy, in basal and rapamycin induced conditions, 
was not affected by the uncoupling of the two domains [214], providing further evidence that the 
WD domain is not involved in canonical autophagy. Furthermore, this study showed that 
TMEM59 interacts less efficiently with Atg16L1 T300A compared to WT Atg16L1 in basal 
conditions, where no caspase 3 has been activated, potentially due to structural changes of the 
WD domain of Atg16L1 resulting from the polymorphism [214]. Therefore, the T300A variant 
disrupts TMEM59 mediated autophagy through probable structural changes, changing the 
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binding affinity of this protein to Atg16L1. The stress induced caspase cleavage, that is more 
prominent in Atg16L1 T300A, results in uncoupling the C-terminal domain of Atg16L1 and 
therefore WD domain related functions of Atg16L1 such as xenophagy cannot be carried out 
[214].  
However, the story is not this simple, as reports also suggest that Atg16L1 T300A variant has 
protective functions against bacterial invasion, in the case of Salmonella [215], and Atg16 
knockout mice are protected against Citrobacter rodentium infection [216].  
It is to be noted that the crystal structure of the Atg16L1 WD domain does not characterise the 
T300A variant as being in the WD domain of Atg16L1 [192], however, it may still affect the 
function of the C-terminal contribution of Atg16L1.  
Atg16L1 T300A has not been looked at extensively in the context of endolysosomal LC3 lipidation 
events. A paper recently came out suggesting that the Atg16L1 T316A murine variant for Crohn’s 
disease had negligible impact on LAP in mouse BMDC upon the addition of fluorescent zymozan 
[120]. This project also includes investigation into whether Atg16L1 T300A affects LC3 lipidation in 
non-canonical autophagy. 
1.7 Aims of this study  
 
Currently there is very little known about the mechanisms regulating non-canonical 
autophagy. This project aimed to increase our understanding of the signalling 
underpinning endolysosomal lipidation and the important physiological processes in 
which it occurs [111]. At present distinguishing autophagy from non-canonical autophagy 
at a genetic level is difficult due to the  dependence on the same autophagy related 
proteins.  
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Therefore, this project aimed to determine which domains of Atg16L1 were required for 
LC3 lipidation in canonical versus non-canonical autophagy. The work quickly identified 
the WD domain of Atg16L1 as being dispensable for canonical autophagy but critical to 
non-canonical autophagy.  
Therefore, the next aim of the project was to develop an in vivo mouse model of Atg16L1 
ΔWD, a model that genetically can separate canonical and non-canonical autophagy. 
Where the long-term aim is to use this model to look at phenotypic consequences of 
specifically inhibiting LC3 lipidation to endolysosomal membranes.  
Alongside the generation of the in vivo model, site directed mutagenesis studies aimed to 
further refine our model, and pin point key residues in the C-terminal WD domain of 
Atg16L1 that were important for LC3 lipidation to endolysosomal membranes. This then 
directed the generation of another in vivo model of Atg16L1 K490, that in the cellular 
system phenocopied the WD deletion of Atg16L1.  
Whilst generating our own mouse models, we aimed to use an existing model of an 
Atg16L1 WD deletion, E230 from a collaborator, to show a functional consequence of the 
lack of LC3 lipidation to endolysosomal membranes.  
The final aim was to use the characterised cellular system from this project, to do 
subtractive proteomics to look for binding partners of Atg16L1 in non-canonical 
autophagy.  
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Figure 1.9: Summary of Atg16L1 recruitment and aims of project. 
On the left this depicts a growing double membrane autophagosome sequestering cytoplasmic material. 
The pre-initiation complex made up of Ulk1, Atg13, FIP200 alongside the PI3K complex made up of 
Beclin1, Vps34, Vps15 and Atg14 allow autophagy to be initiated and PI3P to enrich the autophagosome. 
This recruits PI3P effectors such as WIPI2b and the middle domain shown in red of Atg16L1 interacts 
directly with WIPI2b and FIP200. This position Atg16L1 in complex with Atg5 and Atg12 to help conjugate 
LC3 to the autophagosome membrane. The right hand picture shows that at single membrane 
endolysosome compartments following an engulfment event Atg16L1 in complex with Atg5 and Atg12 
lipidates LC3 onto these membranes. The recruitment of Atg16L1 in this context is unknown and this is 
the main aim of this project.  
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2 Materials and Methods 
 
2.1 Materials 
 
All materials were purchased from Sigma, Corning or Thermo Fisher Scientific unless otherwise 
stated.  
2.2 Cell culture 
All cells were maintained in an incubator at 37◦C with 5% CO2, in medium containing penicillin 
and streptomycin (10,000 Units/ml and 10,000 µg/µl, respectively; Gibco Life Technologies).  
2.2.1 HCT116 (human colorectal carcinoma cells)  
Cells were cultured in McCoy’s 5A with L-Glutamine (Lonza BE12-688F) medium with 10% Fetal 
Bovine Serum (FBS, Gibco Life Technologies F9665 lot 034M3398). Several derivatives of this line 
were used all from Dr David Boone: HCT116 WT GFP-LC3, HCT116 KO Atg16L1 GFP-LC3 and 
HCT116 Atg16L1 T300A GFP-LC3 cells [215]. Other clonal HCT116 GFP-LC3 cells were used, 
deficient for Atg16L1 and were engineered by Dr Rupert Beale’s lab using CRISPR/Cas9. These 
cells are expressing GFP-LC3B. 
2.2.2 J774.A1 (mouse macrophage cell line), HEK293T (transformed Human Embryonic 
Kidney cells) and Mouse Embryonic Fibroblasts (MEFs)  
Cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM; Gibco Life Technologies, 
41966-029) containing 10% Fetal Bovine Serum (FBS). The following MEF derivatives were used: 
MEF KO Atg16L1 GFP-LC3, a cell line produced by traditional methods based on homologous 
recombination [197] and re-constituted with Atg16L1 constructs kindly provided by Dr Noor 
Gammoh [32] to give MEF FL ATG16L1 GFP-LC3, MEF ΔWD Atg16L1 GFP-LC3 and MEF ∆FBD 
Atg16L1 GFP-LC3. Atg16L1. These cells are expressing GFP-LC3B.  
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2.2.3 MCF10A cells (human mammary epithelial cells, female)  
 
MCF10A were cultured in DMEM F12 (Gibco,11320-074) containing 5% horse serum (Gibco, 
16050-122) EGF (20 ng/ml, Peprotech), Hydrocortisone (0.5 mg/ml), cholera toxin (100 ng/ml) 
and insulin (10 µg/ml). These cells are expressing GFP-LC3A.  
2.2.4 Mouse Embryonic Stem cells (ES cells) 
Media, gelatin and trypsin were all kindly made and donated by Dr Dominik Spensberger and the 
cells were frozen and stored by the Babraham Institute Gene Targeting facility. The media 
consisted of knockout Dulbecco’s Modified Eagle’s Medium (KO-DMEM) (GIBCO, 10829-018), 
GlutaMAX/Glutamate 2mM (Invitogen, 35050061), 1x 2-mercaptoethanol (Sigma, M7522), 3 ml 
Penicillin/Streptomycin final 50 U/ml (Invitrogen, 15140-122), 300 µl LIF – from prepared stock 
2000U/ml (Miltenyi Biotech), FBS final 15 %. Gelatin was made with 0.1 % w/v gelatin (Sigma 
9391) in water or 1X PBS.  Autoclaved to dissolve the gelatin and stored at 4 °C. 
2.2.5 Stable cell line creation 
Briefly, Atg16L1 constructs were used to virally transduce various knockout Atg16L1 cell lines. 
Atg16L1 constructs, with N-terminal Flag-S tags in the retroviral pBABE expression vector, were 
kindly donated by Dr Noor Gammoh (see tab 2.6 for information of DNA constructs).  
Virus production and cell infections were performed by Oliver Florey in a CatII lab, as follows. 
Retroviral preparation: HEK293T cells were seeded onto Poly-L-lysine coated plates. Triple 
transfections were performed in a tissue culture hood, using Lipofectamine 2000 (Invitrogen) and 
OptiMEM (Gibco) with the following amounts of DNA: 0.4 µg of expression retroviral vector, 0.2 
µg VSV-G packaging proteins and 0.25 µg packaging Gag/Pol commercial retroviral enzymes. The 
method involved preparing two tubes, one with the DNA and 100 µl of OptiMEM and another 
with 100 µl of OptiMEM and 2.5 µl of Lipofectamine 2000. These tubes were incubated at room 
temperature for 5 min and then combined and mixed and incubated for a further 20 min. The 
cells were then washed with OptiMEM and 800 µl was added to each well before dropping on the 
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transfection mix. Cells were incubated for 6-16 h with the transfection mix and then the medium 
was replaced with growth medium for the collection of viral supernatant. Cell debris was 
removed by centrifugation x300 g for 5 min and virus was aliquotted and stored at -80 ˚C. 
Cells to be virally infected were plated at 70 000 cells per well of a 6-well plate. Cells were 
incubated with viral supernatant and 8 µg/ml of polybrene, using a plate spinner to aid infection 
of the cells. The plates were spun at 22 ˚C at 1400 rpm for 45 min.  
After 24-48 h, cells were selected with puromycin for the pBABE plasmid (HCT116 0.8 µg /ml, MEF 
1.5 µg /ml, MCF10A 2.5 µg /ml) for 2-5 days. Protein expression was checked via western blot.  
2.2.6 Transient Transfections 
 
HCT116 cells were seeded at 200 000 cells per well onto a 6-well plate for 48 h. When cells were 
70-90% confluent they were transfected in a tissue culture hood with 1 µg of DNA using 
Lipofectamine 2000 (Thermo Fisher Scientific) and OptiMEM (Gibco). For each well of a 
transfection, tubes were prepared where one tube contained 200 µl of OptiMEM and 1 µg of DNA 
to be combined with a tube of 190 µl of OptiMEM and 10 µl of Lipofectamine 2000 for 20 min at 
room temperature. Fresh media was put on the cells, 1.6 ml per well, and the transfection mix 
was added dropwise. 24 h later cells were re-seeded onto glass coverslips in a 12-well plate for 
imaging or onto a 6-well plate for western blotting.  
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2.3 Drugs and antibodies  
 
2.3.1 Drugs 
 
The following drugs were used in this project in order to study Atg16L1 in the context of canonical 
and non-canonical autophagy.  
Drug Function  Working concentration  Company  Duration of 
treatment  
Monensin  Ionophore, 
exchanging sodium 
and hydrogen ions. 
Blocks autophagic 
flux and induces 
endolysosomal LC3 
lipidation. 
100 µM (stock solution 
in methanol) 
Sigma (M5273) 1 h 
Bafilomycin A1 Inhibits V-ATPase 
activity. Blocks 
autophagic flux.  
100 nM (stock solution 
in DMSO) 
R&D systems 
(1334) 
1 h 
PP242 Potent and selective 
inhibitor of ATP 
domain of mTOR. 
Activates autophagy.  
1 µM (stock solution in 
DMSO) 
Sigma (P0037) 1 h 
Hank’s Balanced 
Salt Solution HBSS 
Serum and amino 
acid starvation.   
Commercial  Sigma (H3934) 1 h 
Starvation media 
from Dr Nicholas 
Ktistakis.  
Serum and amino 
acid starvation.  
140 mM NaCl, 1 mM 
CaCl2, 1 mM MgCl2, 5 
mM glucose, 20 mM 
Hepes pH 7.4 + 1% BSA  
[19] 1 h- 2 h 
(depends on 
cell type).  
Wortmannin Potent and specific 
inhibitor of PI3K. 
67 µM (DMSO) Sigma (W1628) 1 h 
Table 2.1: Details of pharmacological modulators of canonical and non-canonical autophagy.  
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2.3.2 Western Blot Antibodies 
 
  
Primary Antibody (animal, size, company, storage)  Dilution in Blocking buffer (5% BSA TBS-T) 
Anti-LC3 A/B (rabbit, 14, 16 kDa, Cell Signalling 
#4108, -20 ◦C) 
1:1000 
Anti-GAPDH (rabbit, 37 kDa, Santa Cruz #25778, 4 
◦C) 
1:2000 
Anti-ATG16L1 (rabbit, 68 kDa, Cell Signalling #8089, -
20 ◦C) 
1:1000 
Anti-ATG5 recognises Atg5-12 complex (rabbit, 55 
kDa, Cell Signalling #2630, -20 ◦C) 
1:1000 
Anti-ATG16L2 (rabbit, 68 kDa, Abcam #136093, -20 
◦C) 
1:1000 
Anti-Atg13 (rabbit, 72 kDa, Cell Signalling #13273, -
20◦C) 
1:1000 
Anti-s tag (mouse, Novagen #71549-3 , -20◦C) 1:1000  
Anti-WIPI2 2A2 (mouse, 54 kDa, Biorad 
#MCA5780GA, 4◦C ) 
1:1000 
Anti-RB1CC1 (FIP200) (Rabbit, 200 kDa, Protein Tech 
#10043-2-AP, -20◦C) 
1:1000 
ATP6 V0d1 (V-ATPase subunit) (mouse, 37 kDa, 
Abcam #ab56441, 4◦C) 
 
1:1000 
β-cop (From Dr Nickolas Ktistakis, mouse, dilution 
at) 4 ◦C 
1:1000 + azide 
Lamp1 (mouse, 110 kDa, BD pharmingen #611042, -
20◦C) 
1:500  
PLEKHF1 (rabbit polyclonal, 31 kDa, Protein tech, -
20◦C) 
1:1000 
Primary Antibody (animal, company, storage) Dilution in TBS-TWEEN 20 with 3-5% milk 
(block and secondary also in TBS-TWEEN 20 
with 3-5%milk) 
Anti-FLAG (mouse, Sigma #f1804, -20 ◦C) 1:1000 (3%) 
Anti- cleaved caspase 3 (rabbit, 17, 19 kDa, #9661S 
Cell Signalling, -20◦C) 
1:1000 (5%) 
Β-1 Integrin (rabbit, 115,135 kDa, Giancotti lab 
MSKCC Cyto SM158) 
1:2500 (5%) 
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Secondary Antibody (animal, company, 
storage)  
Dilution in Blocking buffer  
Horseradish Peroxidase (HRP)-conjugated anti- 
mouse or anti rabbit-antibodies (Cell Signalling 
#7076 #7074, -20 ◦C) 
1:1000 
Anti-streptavidin HRP (Cell Signalling #3999, -20 
◦C) 
1:5000 
Table 2.2: Antibodies for detection of specific proteins by western blot. 
2.3.3 Immunofluorescence Antibodies 
 
Primary Antibody (animal, company, storage)  Fixation and dilution in Blocking buffer  
Anti-ATG16L1 (rabbit, Cell Signalling #8089, -20 ◦C) 3.7% PFA, 1:100 
Anti-ATG16L1 (rabbit, MBL #PM040, -20 ◦C) preferable  3.7% PFA 1:100 
LAMP1 (human CD107a) (Mouse, BD Pharmingen #555798, 
4 ◦C) 
MetOH, 1:100 
LAMP1 (mouse CD107a) (Rat, BD Pharmingen #555792, 4 
◦C) 
MetOH, 1:100 
Anti-LC3 A/B (rabbit, Cell Signalling #4108, -20 ◦C) MetOH, 1:100 
Anti-s tag (mouse, Novagen #71549-3, -20◦C) 3.7% PFA, 1:200 
Secondary Antibody (animal, company, storage)  Dilution in Blocking buffer  
Alexa fluor 568 (goat anti mouse, Life Technologies, 4 ◦C) 1:500 
Alexa fluor 568 (goat anti rabbit, Life Technologies, 4 ◦C) 1:500 
Alexa fluor 568 (goat anti-rat, Life Technologies, 4 ◦C) 1:500 
Alexa fluor 488 (goat anti rabbit, Life Technologies,  4◦C) 1:500 
Table 2.3: Antibodies for detection of specific proteins by immunofluorescence. 
2.4 Molecular Biology 
2.4.1 Polymerase chain reaction (PCR) 
 
Different polymerases were used depending on the PCR. For genotyping and diagnostics MyTaq 
red mix (Bioline) was used. For generating plasmids or fragments, to be sequenced and used for 
future work, a higher fidelity DNA polymerase was used, Phusion (Thermo Fisher Scientific).  
PCR was also performed from bacterial colonies for diagnostic work, to directly check for the 
presence of specific DNA. In order to do PCR from bacterial colonies, the colony was picked with 
an inoculating loop and re-streaked onto a new agar plate to store for future work. The remaining 
bacteria on the loop was put into 50 µl of water and boiled for 5 min to lyse the bacterial cells. A 
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PCR was set up with 2 µl of this acting as the DNA template. PCR was done using specific primers, 
detailed in subsequent methods, to amplify specific DNA, where a negative control of just water 
was used and a positive control was used where possible. PCR products were purified as per the 
manufacturer’s instructions with the GeneJET kit from Thermo Fisher Scientific, eluting in 20 µl of 
water. TABLE 2.4 summarises the different reaction set ups used for PCR and TABLE 2.5 
summarises the reaction conditions, where the temperature cycles were achieved using an 
Eppendorf MasterCycler.  
Phusion High Fidelity 
(HF) PCR reaction 
Volumes for 1x 
reaction 
MyTaq Red Mix PCR Volumes for 1x 
reaction 
5x Phusion HF buffer  4 µl MyTaq red mix: 
loading dye, buffer, 
dNTPs, polymerase 
12.5 µl 
10 mM dNTPs 
(Invitrogen) 
0.4 µl - - 
10 µM Forward 
primer  
1 µl 10 µM Forward 
primer 
1 µl 
10 µM Reverse 
primer   
1 µl 10 µM Reverse 
primer   
1 µl 
Phusion Taq 
Polymerase  
0.2 µl - - 
Template DNA 100 ng  100 ng  Template DNA 100 ng  100 ng  
H2O  Make up to volume   H2O  Make up to volume   
    
Total volume  20 µl  Total volume  25 µl 
 Table 2.4: PCR reaction reagents and quantities.  
Denature  94˚C 2 min  
Denature 94 ˚C 20 s 
Anneal 58 ˚C 20 s 
Extend 72 ˚C 20 s 
Extend 72 ˚C 5 min  
Hold  4 ˚C Infinity  
Table 2.5: Thermocycler programme for PCR. 
2.4.2 Agarose gel electrophoresis 
 
In order to separate DNA by size agarose gels were used. 1-2% agarose was prepared in 1xTBE 
buffer, depending on the size of the DNA fragments/vectors. This mixture was boiled, then cooled 
for 10 min, before adding ethidium bromide at 0.5 µg/ml (Bio-Rad) or 1:10 000 SYBR safe 
(Invitrogen), both allow for visualisation of the DNA. The DNA samples were then prepared with 
sample buffer (Thermo Scientific R0611) and either a 100 bp or 1 kbp (GenRuler Plus, Thermo 
X35 
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Scientific) ladder. The agarose gel was run at 75 V for varying times and then the DNA was 
visualised under UV light using a BioRad gel dock.   
2.4.3 Restriction digests and ligations  
 
Restriction digests were set up as per the manufacturer’s instructions (NEB) and following the 
online tools, NEBcutter, to help choose appropriate restriction enzymes, and NEBcloner, for 
protocol information. Various restriction enzymes were used in this project; specifics are detailed 
where appropriate, with digests incubated for at least 30 min at 37˚C.  Linearised plasmids were 
treated with a calf intestinal phosphatase (CIP) if the restriction enzyme left compatible ends, to 
de-phosphorylate the 5’ ends to stop the vector re-circularising. This was done by heat 
inactivating the restriction enzyme at 65 ˚C for 20 min, adding the CIP at 1 Unit per pmol of DNA 
ends for 1 h at 37˚C and then inactivating the enzyme at 65˚C for 20 min.  Restriction digests were 
run on agarose gels to check the expected DNA band pattern, and then gel purified (gel extraction 
kit from Qiagen as per manufacturer’s instructions). DNA was eluted in 20 µl of water and 
quantified to set up ligation reactions. Ligations were done using the manufacturer’s instructions 
using T4 DNA ligase (NEB) and the NEBiocalculator. 100 ng of vector was used with various ratios 
of insert for standard ligations, 1:1, 1:3 and 1:10.  
2.4.4 Transformation  
 
Plasmid DNA was transformed into chemically competent commercial bacteria using heat shock. 
Either One Shot Stbl3 Chemically Competent E.coli (ThermoFisher Scientific), or DH5α E.coli High 
efficiency (NEB #C29871), were used. 20 µl of Stbl3 or 50 µl of the DH5α were thawed on ice and 
added to pre-chilled 40 ml round bottom falcons (BD). 1 µl- 2 µl of (~2 ng vector) was added to 
the bacteria and left on ice for 30 min. Heat shock was performed in a water bath at 42 ◦C for 30-
40 s. The tubes were then added to ice for 2 min and then 1 ml of room temperature super 
optimal broth SOC (NEB) or lysogeny broth (LB) medium was added and the tubes were shaken 
(Infors HT multitron standard) at 37 ◦C for 1 h at 225 rpm. The bacteria were then spun down in a 
table top centrifuge at 2000 rpm for 2 min and 800 µl of supernatant was removed and the 
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pelleted bacteria were re-suspended in the remaining media and plated onto 100 µg/ml 
ampicillin or kanamycin (Melford #A0104) agar plates and incubated for 16 h at 37 ◦C. Controls 
included a positive control (2 ng/µl of an existing plasmid), and re-ligated vector with and without 
phosphatase treatment.  
2.4.5 DNA extraction and purification from bacterial cultures 
 
Bacterial colonies were picked and re-streaked onto antibiotic agar plates in order to save for 
future use. In parallel, the picked colony was grown up in 3 ml of LB, containing the relevant 
antibiotic, at 37˚C shaking for 16 h. The DNA was then extracted using a Qiagen miniprep kit as 
per the manufacturer’s instructions, eluting the DNA in 50 µl of water. The extracted DNA was 
then either tested via restriction digest for successful plasmid production or sent for Sanger 
sequencing using Cogenics Lark. Bacterial colonies that had the desired plasmid were then grown 
up in 100 ml of LB (volume for high copy plasmids) containing the relevant antibiotic at 37˚C 
shaking for 16 h. The DNA was extracted using a Qiagen maxiprep kit as per the manufacturer’s 
instructions, eluting the DNA in 250 µl of water. All plasmids were sequenced using Sanger 
sequencing (Cogenics Lark) and the DNA quality and quantity was check using a Nanodrop 2000 
(Thermo Fisher Scientific).  
2.4.6  DNA extraction from cells or tissue 
 
ES cells in a 96 well format were taken to extract the DNA. The plate was spun at 2000 rpm for 10 
min at RT. The media was flicked out and 30 µl of water was added to each well and then 
incubated for 95˚C for 10 min. 10 µl of proteinase K (final concentration 100 µg/ml) was added to 
each well and incubated for 1 h at 56˚C, then 95˚C for 10 min. This plate was stored at 4˚C.  
For genotyping, ear clips were taken from mice at 10 days old, this was done by the Biological 
Support Unit (BSU) at the Babraham Institute. DNA was extracted from this tissue using 200 µl of 
lysis buffer: 100 mM TRIS-HCL (pH=8.0), 5 mM EDTA, 0.2% SDS, 200 mM NaCl with the addition of 
100 µg/ml proteinase K before use. This was incubated at 55oC shaking for 1 h at 1000 rpm. 200 µl 
of isopropanol was added and inverted, to precipitate the DNA, and pelleted by centrifugation for 
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5 min at 13000 rpm. The aqueous phase was removed and the pellet was washed with 70% 
ethanol, then air dried and finally re-suspended in 50 µl of water. This could then be used as 
template DNA for PCR.  
2.4.7 Constructs  
 
Plasmid 
Antibiot
ic 
resistan
ce Information 
pBABE F-S-Atg16L1  AMP Mouse Atg16L1 aa 1-623 (Dr Noor Gammoh) Flag-
S tag N-terminus  
pBABE F-S-Atg16L1 ∆FBD  AMP Mouse Atg16L1 aa ∆229-242 (Dr Noor Gammoh) 
Flag-S tag N-terminus 
pBABE F-S-Atg16L1 ∆WD  AMP Mouse Atg16L1 aa 1-335 (Dr Noor Gammoh) Flag-
S tag N-terminus 
pBABE F-S-Atg16L1 ∆N  AMP Mouse Atg16L1 aa 80-623, made as part of this 
project. Atg16L1 ΔN: Subcloned by using a) 
restriction sites XhoI and SalI to cut pBABE F-
S-Atg16L1 vector and b) PCR to generate the 
Atg16L1 ΔN sequence, introducing SalI 
restriction sites, this gives compatible ends 
with XhoI cut sites. The primers used to do 
this were: 
Fwd: 5’-3’ 
GCAGCAGTCGACATGAGTCAACTACAAGAAAT
GGCCCAG and  
Rev 5’-3’ 
CTTAAGTCGACTCAAGGCTGTGCCCACAGCAC  
pBABE F-S-Atg16L1 Just the WD domain  AMP Mouse Atg16L1 aa 336-623 (Dr Noor Gammoh) 
Flag-S tag N-terminus.  
pcDNA3.1 Atg16L1 1-230 ∆WD AMP Dr Sharon Tooze 
pBABE F-S-Atg16L1 E324A AMP Site directed mutagenesis from pBABE F-S-
Atg16L1.  
pBABE F-S-Atg16L1 N326A AMP Site directed mutagenesis from pBABE F-S-
Atg16L1. 
pBABE F-S-Atg16L1 M342A AMP Site directed mutagenesis from pBABE F-S-
Atg16L1. 
pBABE F-S-Atg16L1 N386A AMP Site directed mutagenesis from pBABE F-S-
Atg16L1. 
pBABE F-S-Atg16L1 K410A  AMP Site directed mutagenesis from pBABE F-S-
Atg16L1. 
pBABE F-S-Atg16L1 L412A AMP Site directed mutagenesis from pBABE F-S-
Atg16L1. 
pBABE F-S-Atg16L1 H428A AMP  Site directed mutagenesis from pBABE F-S-
Atg16L1. 
pBABE F-S-Atg16L1 N453A AMP Site directed mutagenesis from pBABE F-S-
Atg16L1. 
pBABE F-S-Atg16L1 F467A  AMP Site directed mutagenesis from pBABE F-S-
Atg16L1. 
pBABE F-S-Atg16L1 K490A AMP Site directed mutagenesis from pBABE F-S-
Atg16L1. 
69 
 
pBABE F-S-Atg16L1 D536A AMP Site directed mutagenesis from pBABE F-S-
Atg16L1. 
pBABE F-S-Atg16L1 N581A AMP Site directed mutagenesis from pBABE F-S-
Atg16L1. 
pEGFP-C1 CRISPR repair complex ΔWD 
Atg16L1  
 
KAN See further information in text.  
pSpCas9(BB)-2A-GFP Guide 2 Atg16L1 
for Atg16L1 KO 
AMP Cloned by Dr Elise Jacquin sgRNA to knockout 
human Atg16L1. See details in text. 
pSpCas9(BB)-2A-GFP Guide 2 Atg16L1 
for Atg16L1 ΔWD 
AMP Made as part of this project to target to mouse 
Atg16L1 to produce Atg16L1 ΔWD. See details in 
text.  
 pQCXIN-BirA-Myc Atg16L1 FL AMP Mouse Atg16L1 aa 1-623 (Dr Noor Gammoh) BirA- 
Myc C-terminal 
pQCXIN-BirA-Myc Atg16L1 Atg16L1 
∆WD 
AMP Mouse Atg16L1 aa 1-335, BirA- Myc C-terminal, 
made as part of this project  
pQCXIN-BirA-Myc Atg16L1 Atg16L1 
K490A 
AMP Mouse Atg16L1 K490A, BirA- Myc C-terminal, 
made as part of this project 
Table 2.6: Plasmids 
 
2.4.8 Sequencing Primers  
 
BirA Atg16L1 constructs 5’-3’ NotI Fwd 
GCAGCAGCGGCCGCATGTCGTCGGGCCTGCGCGC 
5’-3’ BirA Rev GGCTCTGCTCATTCCCAGGGTCTC 
SgRNA plasmid pSpCas9(BB)-2A-GFP U6 fwd primer, bottom strand of ordered sgRNA 
used as a reverse primer.  
pcDNA3.1 Plasmids CMV fwd CGCAAATGGGCGGTAGGCGTG and BGH 
rev TAGAAGGCACAGTCGAGG primers, supplied 
primers by Cogenics Lark.  
pBABE plasmids  pBABE forward and reverse supplied primers by 
Cogenics Lark.  
pEGFP-C1 CRISPR repair complex ΔWD Atg16L1  
 
EGFP-C fwd (Cogenics Lark supplied) 
CATGGTCCTGCTGGAGTTCGTG 
Genotyping ΔWD fwd: 
TGGAGGGTCTAGAAAGACAAC 
Table 2.7 Primers to confirm sequence of plasmids.  
 
2.5 Site-directed mutagenesis 
 
Primers were designed to introduce single amino acid changes to alanine for different residues of 
Atg16L1. The primers were re-constituted in water to 100 ng/ µl, see TABLE 2.8 for the list of 
primers. The method for the mutagenesis was based on the QuikChange Site-directed 
Mutagenesis Kit (Stratagene). This involved a 50 µl reaction consisting of: 1 x Pfu UltraII buffer 
(Agilent Technologies), 0.2 mM dNTPs (Invitrogen), 10 % DMSO (Sigma), 1 µl PfuUltra II (Agilent 
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Technologies), 250 ng of forward primer and 250 ng of reverse primer, 50 ng of Flag-S Atg16L1 p-
BABE DNA template made up to the total volume with water. A negative control consisted of a 
reaction without the primers, that resulted in just the template DNA. A thermocycler was used to 
create the mutation and amplify the DNA.  The thermocycler programme was set at 95 ˚C for 2 
min, 95 ˚C 30 s, 55˚C for 1 min, 68 ˚C for 10 min and this was cycled 16 times.  
Position of Atg16L1 for 
alanine substitution Primers 5’-3’ 
E324A For CGCATGACGGAGCGGTCAACGCAGTG 
E324A Rev CACTGCGTTGACCGCTCCGTCATGCG 
N326A For CATGACGGAGAGGTCGCCGCAGTGCAGTTCAG 
N326A Rev CTGAACTGCACTGCGGCGACCTCTCCGTCATG 
M342A For GCCACTGGAGGCGCGGACCGCAGGGTG 
M342A Rev CACCCTGCGGTCCGCGCCTCCAGTGGC 
N386A For CTTACCTATTAGCAGCTTCAGCTGATTTTGCAAGCCGAATC 
N386A Rev 
GATTCGGCTTGCAAAATCAGCTGAAGCTGCTAATAGGTAA
G 
K410A For GGCCACAGCGGGGCAGTCCTCTCTGCC 
K410A Rev GGCAGAGAGGACTGCCCCGCTGTGGCC 
L412A For CACAGCGGGAAAGTCGCCTCTGCCAAGTTCC 
L412A Rev GGAACTTGGCAGAGGCGACTTTCCCGCTGTG 
H428A For GATTGTCTCAGGAAGTGCCGACCGGACCCTCAAAC 
H428A Rev GTTTGAGGGTCCGGTCGGCACTTCCTGAGACAATC 
N453A For GCAGGATCCAGCTGCGCTGACATTGTTTGCAC 
N453A Rev GTGCAAACAATGTCAGCGCAGCTGGATCCTGC 
F467A For GTGTAATGAGTGGACATGCTGACAAGAAAATTCGTTTCTG 
F467A Rev CAGAAACGAATTTTCTTGTCAGCATGTCCACTCATTACAC 
K490A For GATGAACTGTTAGGGGCGATCACTGCTCTGGAC 
K490A Rev GTCCAGAGCAGTGATCGCCCCTAACAGTTCATC 
D536A For CAAATGCGGCTCTGCCTGGACCCGGGTTG 
D536A Rev CAACCCGGGTCCAGGCAGAGCCGCATTTG 
N581A For CAGCTCTTCTATCGCTGCGGTGGCGTGGG 
N581A Rev CCCACGCCACCGCAGCGATAGAAGAGCTG 
Table 2.8: Primers for site directed mutagenesis of Atg16L1  
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The product was digested using 1 µl DpnI 10 U/ul (Promega) 1 h at 37 ◦C. This digested 
methylated DNA and therefore destroyed the starting template DNA, leaving just the new 
mutated plasmid. The negative control, where no primers were added, acted as a control for the 
DpnI digestion; it should have digested all of the template DNA and no colonies should grow on 
antibiotic agar plates. 2 µl of Dpn1 treated DNA was transformed into high efficiency DH5α E.coli 
and the DNA was extracted and sequenced to confirm the mutation. 
2.6 CRISPR  
 
2.6.1  CRISPR to generate a cell line.  
 
A HEK 293 knock out Atg13 GFP-LC3 cell line was created by Dr Elise Jacquin, a previous member 
of the Florey lab. This cell line was used to produce a double knockout line by also editing 
Atg16L1. An existing sgRNA plasmid to target Atg16L1 for knock out was used as follows; this was 
produced and validated by Celine Judon and Dr Elise Jacquin: 5’ CACCGGTCAGATCTTCATTCAGTGT 
3’ pSpCas9 (BB)-2A-GFP plasmid. HEK ATG13 KO cells were plated on a 6-well plate and co-
transfected with the guide Atg16L1 plasmid and a puromycin plasmid in order to select for the 
transfected cells. The transfection used Lipofectamine 2000 as previously described (Transient 
transfections), using 1 µg in total of DNA (where the plasmids were at a 50:50 ratio). 24 h post 
transfection fresh media was added containing 2 µg/ml of puromycin, a control of untransfected 
cells was also used. Selection with puromycin was achieved in 48 h and a proportion of cells were 
frozen down. The transfected population of cells was checked by western blot for knockdown of 
Atg16L1 in comparison to WT cells. A limiting dilution of the transfected population was 
performed in order to get one cell per well of a 96 well plate. Four 96 well plates were prepared, 
with a more concentrated cell dilution in one well to help focus the microscope. After ~ 10 days, 
single cells started grow in well of the 96 well plate, cells were grown and propagated until clonal 
populations could be tested for Atg16L1 knockout via western blot. Some were tested by imaging 
the GFP-LC3 response to chloroquine. Among the successful double knock out cells, clone 3C11 
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was used subsequently to produce stable HEK Atg13 KO Atg16 KO cells re-expressing the different 
Atg16L1 constructs.  
2.6.2 In vivo CRISPR reagents 
 
Chapter 4 outlines the theory and method for how CRISPR/ Cas9 technology was used to generate 
two mouse models please refer to this section for more information.  
2.6.2.1 Guide sequences: design and cloning  
 
Two sgRNA sequences to target mouse Atg16L1 were designed using the online software DNA 
2.0. The sgRNA were resuspended at 100 µM in water. These guide sequences were cloned into 
an expression plasmid with Cas9. This is important to direct the Cas9 to the desired part of the 
genome to produce a double strand break.  
 
sgRNA Top oligo 5’-3’ sgRNA bottom oligo 5’-3’ 
Sequence 1 (Atg16L1 ΔWD): CACCGATGGACACTCATCCTGCTTC Sequence 1 (Atg16L1 ΔWD): 
AAACGAAGCAGGATGAGTGTCCAT
C 
Sequence 2 (Atg16L1 ΔWD): CACCGAGACATACGAGGCAGTAGTT Sequence 2 (Atg16L1 ΔWD): 
AAACAACTACTGCCTCGTATGTCTC 
Ordered synthetic guide sequence for K490A  
GUUAGGGGCCAUCACGGCUCGUUUUAGAGCUAUGCUGUUUU
G (20 nmol) with synthetic tracrRNA 5 nmol.(Dharmacon) 
 
Table 2.9:  Guide oligos to clone into a Cas9 vector to form the sgRNA for Atg16L1 ΔWD 
targeting and synthetic single stranded guide sequence and tracrRNA for Atg16L1 K490A 
targeting.  
 
The oligos were annealed together by setting up the following reaction: SgRNA top and bottom 1 
µl each, T4 DNA ligation buffer 10x 1 µl (NEB), T4 Polynucleotide kinase (PNK) 1 µl (NEB), this 
catalyses the transfer and exchange of a phosphate from the gamma position of ATP onto the 5’ 
hydroxyl terminus of the nucleotide and also removes the 3’ phosphate. The volume was made 
up to 10 µl with water. This reaction was then put in a thermocycler set to 37˚C for 30 min, 95˚C 
for 5 min, and the temperature was ramped down 5˚C per min to 25˚C. This reaction was then 
diluted 1 in 200 with water.  
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A single reaction was set up to digest 100 ng of plasmid pSpCas9(BB)-2A-GFP (PX458 from Dr 
Dominik Spensberger) and 2 µl of the diluted sgRNA were ligated into this linearised vector. The 
reaction also had 2 µl of 10 x Tango Buffer (Thermo Fisher Scientific), 1 µl of 10 mM DTT (Melford 
Biolaboratories), 1 µL 10Mm ATP (NEB), 0.5 µL T4 DNA ligase (NEB), 1 µL BbsI high fidelity (aka 
Bpil Thermo Fisher Scientific), made up to a total volume of 20 µl with water. A thermocycler was 
used to do six cycles of 37˚C for 5 min and 21˚C for 5 min.  
The resulting product, the Cas9 plasmid also containing the guide sequence, was transformed into 
Stbl3 E.coli and the bacterial colonies were screened by PCR, using the U6 forward primer (that 
will bind to the promotor region just before the sgRNA) and the sgRNA bottom oligo as a reverse 
primer. The PCR product was checked on an agarose gel. The successful bacterial colonies were 
grown up and the DNA was extracted and sequenced.  
2.6.2.2 Surveyor assay: to test the guide efficiency 
 
A surveyor assay is a way to assess how efficiently and accurately the guide sequence navigates 
the Cas9 to the DNA region of interest, to then form a double strand break. This is then repaired 
by the error prone method of NHEJ in cells and leads to the production of mismatches. A specific 
nuclease can be used to cleave the sites where a mismatch has occurred. This can be visualised by 
size separation of DNA fragments on an agarose gel to visualise the untargeted DNA versus the 
targeted Cas9 cleaved DNA. FIGURE 4.6 and Chapter 4 have more information.  
Primers were designed to amplify regions of Atg16L1 around the site that was targeted for 
editing. It was important that the primers gave a clean single PCR product, and that when 
targeted by Cas9 the cleaved products were not of equal size. The following primers were 
designed and tested for this assay.  
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Primer Forward 5’-3’ Primer Reverse 5’-3’ 
Amplify region for Atg16L1 ΔWD edit 
TGAGACTGCTTCAGTGCTGG 
Amplify region for Atg16L1 ΔWD edit 
TGCTCCAGAGGATGTCCCTA 
Amplify region for Atg16L1 K490A edit 
TGCTTAGTTCCCCAAGAACA 
Amplify region for Atg16L1 K490A edit 
GTTAGCAGCCGCCTACAGTG 
Table 2.10: Surveyor assay primers. 
 
The efficiency of the guides to target Cas9 to the specific site on the DNA for cleavage was tested 
by transfecting the sgRNA into ES cells. In the case of the Atg16L1 ΔWD targeting, 2 ug of sgRNA 
plasmid was added to 50 µl of serum free media. Another tube with 8 µl of Lipofectamine 2000 in 
50 µl of serum free media was prepared and left for 5 min. The tubes were then combined and 
incubated at RT for 20 min. During this time a 6-well plate was coated with gelatin and full ES 
media was pre-equilibrated. One million ES cells were re-suspended in 100 µl of full media and 
were added to the transfection mixture dropwise over two wells.  Cells were fed 24 h later and 48 
h after transfection. The cells were sorted for the expression of GFP by flow cytometry. 
Trypsinised and filtered cells were taken on ice to the Flow Cytometry facility at the Babraham 
Institute and 100 000 GFP positive, transfected cells were saved to extract DNA with the Blood 
extraction kit (Qiagen) as per the manufacturer’s instructions.  
For the Atg16L1 K490A targeting, Dr Dominik Spensberger transfected ES cells with crRNA for 
ATG16L1 K490A, tracrRNA and Cas9. Cells were lysed and DNA was extracted. From this point on 
the samples were treated the same.  
A PCR was performed, to amplify the region around the edit site, and the PCR product was then 
purified. A hybridisation was then set up with 300 ng of DNA in total, where 150 ng WT PCR 
product was hybridised with 150 ng of Atg16L1 ΔWD PCR product or K490A. This reaction was 
made up to 20 µl in water with 2 µl of NEB buffer 2. The DNA was left to hybridise in a 
thermocycler set to 37˚C for 30 min, 95˚C for 5 min, and the temperature was ramped down 5˚C 
per min until it reached 25˚C. Then, 1 µl of T7 endonuclease (NEB), the nuclease that cleaves 
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mismatched DNA, was added to this reaction and left at 37 ˚C for 20 min. The product was run on 
a 1.5% agarose gel to detect indel formation. Expected DNA band sizes are summarised in the 
table below.  
Atg16L1 ΔWD surveyor  Atg16L1 K490A surveyor 
PCR: 549 bp PCR: 608 bp 
Cleaved DNA Cas9: 334 
bp, 215 bp 
Cleaved DNA Cas9: 431 
bp, 177 bp 
Table 2.11: Surveyor assay expected size in base pairs of DNA fragments. 
 
2.6.2.3 Homologous directed repair templates 
 
Once the efficiency and precision of the guide sequence had been tested, a repair template 
needed to be designed to allow for homology directed repair (HDR). This allowed for the double 
strand break at the targeted region of DNA to be repaired in a controlled manner to introduce an 
‘edit’.  
The repair complexes were ordered as PAGE purified ultramer ssDNA. See Chapter 4 for details of 
the repair template sequences.  
The final Atg16L1 ΔWD repair template was made in a slightly different way, in order to add an 
SV40 termination sequence to enhance stability of the edited mRNA. A PCR was used to generate 
two flanking homology sequences complementary to the targeted DNA. Then an additional PCR 
was done to amplify an SV40 termination sequence. Please refer to TABLE 2.12, for details of the 
primers. Primers were designed using NEBuilder Assembly tool v1.12.12. The PCR products were 
purified and a pEGFP-C1 vector was linearised with EcoR1 (NEB) and treated with CIP 
phosphatase (NEB). These components were then taken to do a complex ligation using Gibson 
Assembly mix (NEB), as per the manufacturer’s instructions using a linearised vector to PCR 
product ratio of 1:2:2:2. The negative control was linearised vector without inserts. These 
reactions were transformed using DH5α high efficiency E.coli and colonies were screened via PCR, 
using the genotyping primers for Atg16L1 ΔWD, (TABLE 2.13), where a positive colony gave a PCR 
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product of 586 bp and a negative colony gave no PCR product. Colonies were grown, and DNA 
was extracted and quantified and confirmed by Sanger sequencing (See table of sequencing 
primers, TABLE 2.7).   
Primer name and description  Primer sequence 5’-3’ 
Fwd 1 Left Homology arm Atg16L1  ACTCAGATCTCGAGCTCAAGCTTCGCGCTCTTGATGCTCTTCTC 
Rev 1 Left Homology arm Atg16L1  CAGTTATCTAGATCTACTAGAAGACATACGAGGCAGTAGTTGGTACTC 
Fwd 2 SV40 termination sequence  TGTCTTCTAGTAGATCTAGATAACTGATCATAATCAG 
Rev 2 SV40 termination sequence AAAGCATACTTACTAAGATACATTGATGAGTTTGG 
Fwd 3 Right homology arm Atg16L1 TCAATGTATCTTAGTAAGTATGCTTTGTACTCAG 
Rev 3 Right homology arm Atg16L1  GGGCCCGCGGTACCGTCGACTGCAGAGGCCAGAAGAGTATGTC 
Table 2.12: Primers in order to make HDR template for creation of Atg16L1 ΔWD.  
2.6.3 Screening and genotyping CRISPR targeted cells   
 
See chapter 4 for full details on screening ES cell colonies for edited DNA, and for genotyping 
strategies. DNA was extracted from cells or ear clips from mice as previously described. PCR was 
performed with MyTaq red polymerase with the previously described method. TABLE 2.13 shows 
the primers used in this part of the project with a summary of their use and the expected PCR 
product sizes. Where relevant, restriction digests were also used to see if the CRISPR Cas9 
targeting had worked, Bfa1 (NEB) and Bcl1 (NEB) were used as advised by the manufacturer and 
details are summarised in TABLE 2.13. Genotyping part way through the project, after the embryo 
transfers, was outsourced to Transnetyx.  
Primer name/description 
or Restriction enzyme. 
Sequence 5’-3- or restriction site Expected PCR product sizes, 
base pairs (bp) and restriction 
digest where relevant. 
Genotyping primers Atg16L1 Δ
WD common to all protocol 
design.  
Fwd 
TGGAGGGTCTAGAAAGACAAC 
Rev AGTCAGCAATGGAAAGCCTAG 
WT template 344 bp  
Edited DNA template 362 bp,  
Edited DNA template SV40 
method: 590 bp  
Bfa1 digest of genotyping PCR 
product (first Atg16L1 ΔWD 
strategy, polyA repair)  
TCTA WT: Bfa1 product 315 bp 
Edited DNA: Bfa1 232 bp, 101 
bp. 
Screening primers Atg16L1 ΔWD 
for triple stop codon repair.  
Fwd  
TGGAGGGTCTAGAAAGACAAC 
Rev 
CAAAGCATACTTACTCACTATTA 
 
WT template: no PCR product 
Edited Template: 255 bp 
Bcl1 digest of genotyping PCR 
product (Atg16L1 ΔWD strategy, 
triple stop codon repair) 
TGATCA WT: 344 bp (no restriction site) 
Edited DNA: 239 bp and 105 bp 
77 
 
Screening primers Atg16L1 ΔWD 
for SV40 repair. 
Fwd  
TGGAGGGTCTAGAAAGACAAC 
Rev 
AAATTTGTGATGCTATTGC 
WT template: no PCR product 
Edited Template: 801 bp 
Genotyping primers for Atg16L1 
K490A 
Fwd TGCTTAGTTCCCCAAGAACA 
Rev  
GTTAGCAGCCGCCTACAGTG 
WT template: 608 bp 
Edited template: 608 bp 
Table 2.13:  Summary of primers and restriction enzymes for screening and genotyping. 
2.7 Western blotting  
 
2.7.1 Sample preparation and protein quantification 
 
HCT116 cells were seeded at 150,000 cells per well of a 6-well plate. 48 h later cells were 
subjected to experimental treatment and lysed. MEF or MCF10A cells were seeded at 150 000 
cells per well of a 6-well plate for 24 h and then treated and lysed. Cells were lysed on ice, using 
Radio Immunoprecipitation Assay (RIPA) buffer (50 mM Tris HCL pH 7.4, 150 mM NaCl, 1 mM 
EDTA, 0.5 % sodium deoxycholine, 1 % Triton, 0.1 % SDS, protease/phosphatase inhibitor cocktails 
were added 1:200, 1:100 respectively (ready to use protease and phosphatase inhibitors Sigma 
P8340 and P0044). Protein quantification assays were performed using a spectrophotometric BCA 
assay, (ThermoFisher Scientific) as per manufacturer’s instructions. Lysates containing 15 µg of 
protein were mixed with 1 x sample buffer diluted in RIPA buffer (5 x Sample Buffer: 0.2 M Tris-
HCl pH 6.8, 10 % SDS w/v, 20 % glycerol v/v, 10 mM β-mercaptoethanol, 0.05 % Bromophenol 
Blue w/v, H2O) and boiled at 100 ◦C for 5 min. 
2.7.2 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Prepared samples were loaded onto hand-cast acrylamide gels (Biorad system). Different 
percentage resolving gels were needed depending on the size of the proteins being separated for 
detection, TABLE 2.14 shows the most common gels used for this project. The stacking gel is the 
same for all gels.  
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Resolving/Running Gel  10%  15%   Stacking 
Gel 
Number of gels  2 2 2 
1.5M TrisHCL pH 8.3+0.4% SDS 2.8 ml 2.8 ml 2.5 ml 
30% Acrylamide 0.8% Methylene 
bis acrylamide (BioRad) 
3.72 ml 5.56 ml 1 ml  
H2O 4.92 ml 2.52 ml 6.4 ml 
10% Ammonium persulfate (APS) 40 µl 40 µl 100 µl 
TEMED (BioRad) 9.2 µl 9.2 µl 10 µl 
Table 2.14: Volumes of reagents to make poly-acrylamide gels. 
Gels were run at 125 V for ~90 min in 1x running buffer diluted in water from a 10 x stock: 25 mM 
Tris, 192 mM Glycine, 0.1% SDS pH 8.3 (10x TGS Biorad) and a pre-stained molecular weight 
marker was run alongside samples (Fisher BioReagents EZ-Run™ Prestained Rec Protein Ladder).  
 
2.7.3 Transfer of proteins onto a membrane 
 
Wet transfers were performed using PVDF membranes (Immobilon Millipore). The following 10 x 
transfer buffer (250 mM Tris (30.2 g), 1920 mM Glycine (144.1 g) 1 L H2O) was diluted in water 
giving a final concentration of 20 % methanol and 1 x transfer buffer.  Transfers were carried out 
at 100 V for 1 h, an ice pack was used to keep the transfer cold.  
2.7.4 Detection of specific proteins 
 
Membranes were blocked with 1 x Tris buffered saline TBS- 0.1 % TWEEN20 diluted in water from 
10 x TBS (200 mM Tris (24.22 g) 1370 mM NaCl (80.06 g) 1 L H2O Adjust pH 7.6 with 37% HCl ~14 
ml) with the addition of 5 % BSA or 3 % milk (Marvel powdered milk, Harts Office Supplies),on a 
shaker at room temperature for 1 h. Primary antibodies were prepared in blocking buffer, and 
incubated overnight at 4 ◦C. Membranes were washed for 3 x 5 min with TBS-TWEEN20, shaking 
vigorously at room temperature. The secondary antibody was used at a dilution of 1:1000 in 
blocking buffer, shaking for 1 h at room temperature; Horseradish Peroxidase (HRP)-conjugated 
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anti-mouse or anti rabbit-antibodies (Cell Signalling) were used. The TBS-T washes were then 
repeated. 
Blots were developed using enhanced chemiluminescent reagent (Invitrogen) or a more sensitive 
ECL reagent (Millipore Immobilon Western #WBKLS0500), film (Scientific Laboratory Supplies Ltd 
(Sls)) and an automated developer (Varispeed X150 developer, Xograph Imaging Systems Ltd.). 
ImageJ software was used to quantify the detected band, taking into account the loading control. 
LC3 quantification was expressed as a ratio of LC3II/LC3I. 
2.8 Cell based assays and imaging  
 
2.8.1  Immunofluorescence  
 
Cells were plated onto 12-well plates containing autoclaved 18 mm coverslips (SLS Scientific 
laboratory supplies). Cells were fixed for immunofluorescence by two different methods, refer to 
the methods below and see TABLE 2.3 for the antibodies. The coverslips were protected from the 
light throughout.  
The first method was methanol fixation, where cells were washed twice with PBS and then fixed 
with ice cold methanol for 5 min at -20˚C. The cells were then washed at room temperature for 5 
min with PBS three times. Cells were left in PBS at 4˚C until they were ready to block at room 
temperature with PBS 5 % BSA for 1 h. Coverslips were placed face down on parafilm with 80 µl of 
the primary antibody dilution per coverslip, see table 2.3 of antibodies for dilution. This was then 
placed in a humidified container and left overnight at 4˚C. The coverslips were then put face up 
into a 12-well plate and washed at room temperature for 5 min with PBS three times. 500 µl of 
the secondary antibody dilution was added to each coverslip at room temperature for 1 h; see 
the antibody table 2.3 for dilution in blocking buffer. The PBS washes were repeated and then 
DAPI was used to stain the nuclei, at a final concentration of 1 µg/ml, protected from the light 
and added for 10 min at room temperature. The cells were then mounted onto 76x26mm 
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microscope slides (ThermoFisher Scientific) using Prolong gold anti-fade reagent (Life 
Technologies).  
The alternative method of fixation was used for some antibodies, see antibody TABLE 2.3, and 
was adapted from a protocol used by Dr Nicholas Ktistakis, Babraham Institute. The cells were 
washed twice with room temperature 3.7 % paraformaldehyde (PFA) and left at room 
temperature for 20 min. The PFA was quenched using DMEM with 10 mM HEPES, the cells were 
washed twice with the HEPES solution and left at room temperature for 10 min. The cells were 
then washed with NETgel (NaCl 150 mM, EDTA pH 8 5 mM, Tris-HCL  pH 7.4 50 mM, NP40 aka 
igepal 0.05 %, gelatin (type 4 bloom 6650) 0.25 %, Sodium Azide 0.02%.), gently shaking for 5 min. 
The cells were then permeabilised using 0.25% NP40 (Nonidet nonionic, non-denaturing 
detergent now purchased as IGEPAL CA-630) for 15 min, gently shaking at room temperature. 
Washes with NETgel were performed 3 x 5 min, gently shaking, and the plate was left at 4˚C 
overnight. The primary antibody dilution was added, as explained previously, but only for 30 min 
at room temperature and diluted in NETgel. The coverslips were then washed in NETgel for 3 x 5 
min with gentle shaking. The secondary antibody was diluted and added, as described previously, 
for 30 min at room temperature. The following steps of washing and mounting the coverslips are 
the same as the methanol fixation method.  
2.8.2 Microscopes 
 
Fixed cells were viewed using an oil emersion 63 x lens objective on the Zeiss 780 confocal 
microscope (Carl Zeiss Ltd.).  
Live cell imaging was carried out using a Zeiss 780 confocal or a wide field Nikon live cell imager 
(Nikon), where both had an incubation chamber heated to 37 ˚C and 5 % CO2 supply.  
2.8.3 Latex bead assay  
 
3 µm uncoated polystyrene beads (Polysciences) were washed and re-suspended in PBS. The 
beads in PBS were vortexed and added to culture cell media at a 1:200 dilution. The cells were 
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incubated in media containing the beads for 4 h, to allow time for engulfment, before they were 
treated with 100 µM monensin for 1 h, to stimulate non-canonical autophagy. The cells were then 
washed and fixed for immunofluorescence.  
2.8.4 Entotic corpse assay 
 
MCF10A cells were plated on glass coverslips in a 12-well plate, 80 000 cells per well. The cells 
were incubated for 24 h to allow cell-in-cell structures to form and corpses to be generated. The 
cells were then treated with 100 µM monensin for 1 h, to stimulate non-canonical autophagy. The 
cells were then washed and fixed for immunofluorescence.  
2.8.5  Entosis cell fate assay  
 
HCT116 cells were seeded onto glass bottomed 6-well plates (Matek Corporation) at 150 000 cells 
per well and incubated for 48 h. The Nikon Live cell imager was set up to image at 8 min intervals 
for 20 h with the 40 x oil lens. NIS Elements software was used to analyse the videos for LC3 
positive entotic deaths.  
2.8.6 Macropinocytosis assay  
 
MEF cells were plated on 35 mm glass bottomed dishes (MatTek corporation) at 100 000 cells per 
dish for 24 h. The cells were then serum starved overnight (DEMEM + 1% penicillin and 
streptomycin), and stimulated with 0.1 µg/ml PDGF (Peprotech (100-14B)) in the presence of 0.1 
mg/ml Tetramethylrhodamine conjugated 10 000 MW Dextran (fluoro-Ruby) (D-1817 Life 
Technologies). Cells were imaged immediately via confocal microscopy and representative images 
were captured. 
2.8.7 Apoptotic corpse LC3 associated phagocytosis (LAP) assay 
 
These assays were performed using MEF cells (engulfing hosts) and Hct116 cells (apoptotic 
corpses). First, MEF cells were plated on 35 mm glass bottomed dishes (MatTek corporation), 150 
000 cells per dish for 24 h.  HCT116 cells were prepared by adding cell tracker red CMTPX 
(Invitrogen #C34552) at a final concentration of 10 µM to a 10 cm dish of cells for 30 min at 37˚C. 
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To induce apoptosis, the Hct116 cells were washed and 16 J/m2 of energy was applied, using a UV 
stratalinker 2400 (Stratagene), in full media with the lid was off the dish; the cells were then 
returned to the incubator for 5 h. The dying/dead HCT116 cells were washed and added to the 
plated MEFs at a ratio of 5 apoptotic cells to 1 plated cell. The cells were then left for 14 h in the 
incubator and imaged using the Zeiss 780 confocal with the 63 x oil lens. Engulfed apoptotic cell 
corpses were marked in red and twenty corpses were counted, scoring whether they were 
negative or positive for LC3. This was repeated three times and plotted on a graph showing the 
standard error of the mean (SEM).  An unpaired Student’s t-test was performed to look at 
statistical significance, where p≤0.5 is significant.  
2.8.8  VacA toxin assay 
 
MEFs cells were plated on 35 mm glass bottomed dishes (MatTek corporation) at 150 000 cells 
per dish for 24 h. Purified vacuolating toxin A, VacA, was kindly provided by Dr Tim Cover as 
previously acknowledged [98]) and was stored at 4 ◦C in PBS, 1mM EDTA, 0.2% sodium azide 
pH7.5. In order to disassemble the oligomeric structure, the pH was adjusted to 2-3. This was 
achieved by the addition of 60 µl of 200 mM HCL to 50 µl of toxin and left at room temperature 
for 30 min. This was then made up to a final concentration of 10 μM, with 5 mM ammonium 
chloride in full culture media. The cells were incubated with this solution for 4 h and then imaged 
via live Zeiss 780 confocal microscopy with the 63 x oil lens, where representative images were 
captured from two experiments.  
2.9 Primary cell assays 
 
2.9.1 Primary bone marrow derived macrophages (BMDM) and bone marrow derived 
dendritic cells (BMDC) isolation and culture 
In order to culture BMDCs and BMDMs, complete RPMI media was used: RPMI 1640 (Gibco), 10 % 
FBS, 1 % Pen/Strep, 50 µM 2-Mercaptoethanol (Life Technologies). For differentiation: BMDC 
differentiation medium: Complete RPMI supplemented with 20 ng/ml murine GM-CSF 
(Peprotech), 10 ng/ml IL-4 (Peprotech) and 50 ng/ml (Peprotech) and Fungizone (Amphotericin B, 
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Gibco); BMDM differentiation medium: Complete RPMI supplemented with 30 ng/ml murine M-
CSF (Peprotech) and Fungizone (Amphotericin B, Gibco).  
BMDCs or BMDMs were isolated by sacrificing two 13-15 week male mice per condition. Their 
legs were dissected to leave the tibias and femurs. The following steps were all done with cold 
reagents including culture media. Bones were kept in sterile 1x PBS + 2 % FBS on ice and 
incubated for approximately 15 min to soften the tissues. In a tissue culture hood the bones were 
cleaned of all flesh and tendons on a sterile bacterial culture plate using a sterile scalpel and 
tweezers. The extremities of the bones were cut with the scalpel to allow the bone marrow to be 
flushed through. Then, using a 16 gauge sterile needle (Camlab limited), the bottom of a sterile 
0.5 ml Eppendorf was pierced and the lid was cut off, it was important to ensure there was 
minimal touching of the sides of the tube to ensure sterility. The 0.5 ml tube was placed in a 1.5 
ml sterile Eppendorf containing 100 µl of 1x PBS + 2 % FBS. The tubes were spun at 13 000 rpm 
for 20-30 s. The bone marrow was flushed through into the solution and a red pellet in the 1.5 ml 
Eppendorf was visible. The pellet was re-suspended in the media that had been flushed through, 
transferred to a 15 ml tube containing 14 ml of complete RPMI media, and then spun for 5 min at 
1800 rpm to wash the cells. The cell pellet was re-suspended in 1 ml of 1x red blood cell lysis 
buffer diluted in water (10x stock (100 ml) : 8.99 g NH4Cl, 1g KHCO3, 37 mg Na2 EDTA, pH to 7.3 in 
H2O) and incubated at room temperature for 1 to 2 min with occasional agitation of the tube. The 
red blood cell lysis was stopped by the addition of 15 ml of complete RPMI. Cells were centrifuged 
for 5 min at 1800 rpm and the supernatant was discarded. The cells were re-suspended in 50 ml 
of differentiation media, pooling two mice into a T175 flask. On day three the majority of the 
media was removed and cells were fed with 50 ml of fresh differentiation media and fed with an 
additional 50 ml of differentiation media on day six. Cells were plated on day eight by gently 
scraping the cells from the flask. 
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2.9.2  Antigen presentation assay by flow cytometry  
 
An antigen presentation assay was used in vitro to look at MHC II antigen presentation in bone 
marrow derived dendritic cells (FIGURE 2.1). This assay involved the addition of a fluorescent 
antigen to the cells in culture. The cells were cultured for 24 h with the antigen to allow uptake. 
The cells were then processed and analysed by flow cytometry where CD11b and CD11c 
transmembrane proteins were used to gate for the BMDC population. An antibody that 
recognises the antigen in complex with MHC II was used to assess antigen presentation. There is 
also a theory that the fluorescence of the antigen is affected by presentation and processing 
therefore the GFP fluorescence was measured. 
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Figure 2.1: Antigen presentation assay in vitro 
An outline of the method, where BMDCs were plated for 24 h with the EαGFP fluorescent antigen. The 
cells were then re-suspended and transferred to flow cytometry tubes. The cells were then blocked to stop 
non-specific binding of antibodies. Antibodies were used to detect CD11c and CD11b in order to gate for 
the BMDCs to then analyse the amount of antibody detecting the MHC II receptors in complex with the 
antigen, Yae. Furthermore, the GFP fluorescence was also measured.  
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2.9.2.1 Plating, blocking and staining cells 
 
BMDCs were plated on a 24-well plate at 250 000 cells per well and mixed with 0 µg/ml, 25 
µg/ml, 50 µg/ml or 100 µg/ml of Eα-GFP antigen (kindly donated from Dr Michelle Linterman), 
then incubated for 24 h. Cells were gently scraped from the plate and transferred to cold flow 
cytometry tubes. 4 ml of PBS 2% FBS was added per tube and cells were spun at 1800 rpm, 4⁰C 
for 5 min. The supernatant was removed and the cells were re-suspended in 50 µL of FC Block (FC 
Block: Anti-Mouse CD16/CD32 Clone 93 eBioscience #14-0161-82 (100 µg) (stored at 4⁰C, working 
dilution 1:200). The tubes were vortexed briefly to homogenise and incubated for 10 min at 4⁰C 
to block FC receptors and reduce non-specific signal. The cells were then washed by adding 4 ml 
PBS 2% FBS per tube and spinning cells at 1800 rpm, 4⁰C for 5 min.  
The cells were then stained with biotin‐labelled Y‐Ae antibody (eBioscience, 13‐5741‐85), which 
recognises the Eα‐MHCII complex. The tube was vortexed briefly to homogenise and incubated 
for 1h at 4⁰C. The cells were then washed and incubated with PE‐labelled anti‐CD11b (clone 
M1/70, BD Horizon, 562287), APC‐eFluor780‐labelled anti‐CD11c (clone N418, eBioscience, 47‐
0114‐82), Alexa Fluor 700‐labelled anti‐MHC class II (clone M5/114.15.2, eBioscience, 56‐5321‐
82) and PE‐labelled streptavidin (eBioscience, 12‐4317‐87) for 1 h at 4°C. 
The cells were then washed and re-suspended in 150 µL of PBS 2% FBS. 
2.9.2.2 Preparing for flow cytometry compensations 
 
Tubes for flow cytometry compensations were prepared by distributing a drop of beads (One 
Comp eBeads Compensation Beads Invitrogen (Thermo Fisher Scientific) #01-1111-42) into flow 
cytometry tubes. There was one tube of single stained beads for each antibody used to stain the 
cells. 1 µL of each of the antibodies used above was added to each tube to single-stain the beads. 
An additional tube was set up using a FITC-conjugated antibody for E-GFP compensation. The 
beads were incubated for 1 h at 4⁰C. The beads were not washed but 150 µL of PBS without FBS 
was added per tube. 
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2.9.2.3 Flow cytometry analysis 
 
Flow cytometry analysis was performed with assistance from Dr Elise Jacquin and the Flow 
cytometry facility at The Babraham Institute, on the Fortessa A machine (Beckton Dickinson). The 
voltage for the cells was set and the compensation was done on the single-stained beads. Cells 
were gated on the single cell population, to remove debris from the analysis, and gated on 
CD11b+/CD11c+ cells, assumed to be the BMDC cellular population. The data was analysed by Dr 
Elise Jacquin using FlowJo software. Graphs were produced to show the cell gating and FSC-A was 
plotted against SSC-A to determine where the single cell population was. Then CD11b expression 
was plotted over CD11c expression to show the gating for the double positive cell population 
assumed to be the dendritic cells. Then the mean fluorescence intensities (MFI) for the Eα GFP 
alone, the Eα peptide in complex with MHCII and MHCII alone, were analysed. Graphs detailing 
the MFI at different antigen concentrations were plotted and error bars represent standard 
deviation. 4 technical repeats were plotted on graphs and the trend was compared across three 
independently repeated experiments. Graphs presented are representative where the error bars 
represent the standard deviation and a Student’s t-test was the statistical test used.  
2.9.3  LAP in primary cells.  
 
Autoclaved glass coverslips were added to a 12-well plate and coated with 1 mL of Poly-L-lysine 
(0.1 mg/mL in TC-grade H2O) per well and incubated at 37⁰C for 10 min. The Poly-L-lysine was 
kept to be re-used and the coverslips were washed 2 or 3 times with 1 mL of tissue culture grade 
H2O and one more time with complete culture medium. BMDCs or BMDMs were collected and 
seeded at 100 000 cells per well. 24 h-48 h later 5 µl of zymosan at a final concentration of 
25µg/ml, was added to each well. This gave a ratio of five zymosan particles to one plated cell. 
This zymosan stock suspension was made up in PBS to a concentration of 5 mg/ml, 10x107 
particles/ml and vortexed to homogenise. The zymosan particles were incubated with the cells for 
15-30 min. Cells were then fixed with methanol and immunofluorescence was done to visualise 
the localisation of LC3 and LAMP1.  
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2.10  Biochemical Assays 
 
2.10.1 Subcellular Fractionation  
 
HCT116 cells were seeded 2.5 million cells per condition on a 15 cm dish and cultured for 48 h. 
Cells were treated with and without 100 μM monensin for 1 h. Cytosolic and membrane proteins 
were fractionated using the Mem‐Per Plus Membrane Protein Extraction Kit (89842, Thermofisher 
Scientific) following the manufacturer’s guidelines. The protein concentration from fractions was 
measured by BCA assay, where equal amounts of proteins were then separated by SDS-PAGE. 
Western blots were done to look at levels of specific proteins in the membrane or cytosol using 
control proteins to account for purity of fractions and loading (membrane proteins such as LAMP1 
and cytosolic proteins such as tubulin). Quantification of the western blots was done using 
ImageJ, to quantify the protein levels in relation to the relevant control protein. This was 
repeated three times and the data was plotted on a graph to show the standard error of the 
mean (SEM).  An unpaired Student’s t-test was performed to look at statistical significance, where 
p≤0.5 is significant. 
2.10.2  Immuno-precipitation (IP) using FLAG-S tagged Atg16L1 constructs 
 
MEF Atg16L1 -/- GFP-LC3 cells stably re-expressing Flag-S tagged Atg16L1 constructs were seeded 
onto four 144 x 20mm tissue culture dishes at 1.5 million cells per dish for 48 h. MEF wild type 
cells were used as a negative control, that are not expressing Flag-S tagged proteins. Cells were 
unstimulated or treated with monensin, 100 µM, for 1 h. The treatments were staggered so only 
four dishes were being lysed at any one time. The dishes were washed twice with ice cold PBS 
before being lysed in 2 ml of lysis buffer either 1% Triton buffer (50 mM Tris HCL, 15 mM NaCl, 1 
mM EDTA, 1% Triton X-100) or 0.3% CHAPs buffer (0.3% CHAPS (Melford), 50 mM TrisHCl, 150 
mM NaCl, 1 mM EDTA) where protease/phosphatase inhibitor cocktails were added 1:200, 1:100 
respectively (ready to use protease and phosphatase inhibitors Sigma P8340 and P0044) and 1 
mM PMSF and 10 mM Sodium orthovanodate on the day. The dishes were scraped and the 
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lysates were left in iced 15 ml falcon tubes before spinning at 4 ◦C 4000 rpm for 15 min. The 
Triton or CHAPs soluble material was transferred to a new iced 15 ml falcon tube and the pellet of 
insoluble material discarded. A proportion of the lysates were saved here. The lysates were pre-
cleared using 160 µl of Immunoglobulin G (IgG) conjugated 4% agarose bead slurry (Sigma, 4◦C ); 
these had been pre-washed three times with the full lysis buffer described above with a 10-20 s 
1500 rpm centrifugation step after each wash in order to pellet the beads. The lysates were left to 
slowly rotate at 4◦C with the IgG agarose beads for 1 h. The tubes were centrifuged for 5 min 
1500 rpm in order to pellet the IgG beads and anything that was now bound to the beads.  The 
supernatant was transferred to a fresh 15 ml tube and added to 160 µl of an S-protein agarose 
bead slurry (Novagen) designed to bind S-tagged proteins. The beads had been washed in 
preparation in the same way as the previous beads. The lysates were left to slowly spin at 4◦C 
with the S-beads for 6 h. The tubes were centrifuged for 5 min 1500 rpm in order to pellet the S-
beads and anything that was now bound to the beads, a proportion of the supernatant was saved 
here to analyse the depleted sample. The bead pellets were washed three times in full lysis buffer 
and then replaced with 50 µl of 1x SB, the samples were then boiled at 100 ◦C for 5 min to elute 
the bound proteins and centrifuged in order to remove the beads. The samples were analysed via 
western blotting for the presence of tagged protein in the total lysate (input sample), in the 
depleted sample and in the IP sample. A silver staining kit (SilverQuest Invitrogen) was used to 
sensitively visualise proteins in the IP samples. This was done by running pre-cast acrylamide 
gradient gels (Mini-protean TGX gels Bio-Rad) for sterility and optimal separation range, and then 
the silver staining was performed as per the manufacturer’s instructions.  
Once optimised the samples were sent for mass spectrometry analysis (Core facility at The 
Babraham Institute headed by Dr David Oxley). At the core facility, the samples were run on an 
SDS-PAGE gel ~5 mm into the gel and then the proteins were stained with Coomassie. The stained 
proteins were excised and put into individual tubes to be de-stained, reduced and alkylated 
before being digested with trypsin [217]. The digested products were then labelled with Thermo 
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Fisher Scientific TMT10plex label regent set prior to mixing. [218]. The principal of mass 
spectrometry is to identify molecules based on their mass to charge ratio. The TMT labelling 
offers a robust way to allow relative abundance of peptides to be compared.  
2.10.3  BioID  
 
This method was adapted from the referenced paper [219], with advice from Dr Noor Gammoh. 
Chapter 5 has further information on the theory of the method. In short, this method utilises a 
promiscuous biotin ligase that is fused to a protein of interest. Upon the addition of biotin, the 
promiscuous biotin ligase on the protein of interest biotinylates proteins that are in close 
proximity. After this process had occurred, cellular lysates were generated and 
immunoprecipitation of biotinylated proteins were prepared for analysis.  
The pQCXIN-BirA-Myc plasmid with Atg16L1 FL expressing the BirA (promiscuous biotin ligase) 
and myc at the C-terminal was kindly donated by Dr Noor Gammoh. This was then taken to 
produce pQCXIN-BirA-Myc vectors expressing Atg16L1 K490A and Atg16L1 ΔWD. This was done 
using PCR to introduce Not1 and Pac1 restriction sites flanking either the genetic sequence for 
Atg16L1 K490A or the ΔWD using the primers in TABLE 2.15. The pQCXIN-BirA-Myc plasmid and 
the PCR products were then digested with Pac1 and Not1. The PCR digested products were then 
ligated into the BirA plasmid and grown in DH5α E.coli where the colonies were screened and 
DNA sequenced. See molecular biology techniques for more detail.   
Primer sequence to introduce Not1 to the start of 
Atg16L1 sequence. (Common to cloning for 
Atg16L1 K490A and ΔWD). 5’-3’.  
Primer sequence to introduce Pac1 to the end of 
the sequence of Atg16L1 or the end of Atg16L1 Δ
WD. 5’-3’. 
GCAGCAGCGGCCGCatgtcgtcgggcctgcgcgc GCAGCATTAATTAAaggctgtgcccacagcacag 
GCAGCATTAATTAAtcaatcgaagacatacgaggcagtag 
Table 2.15:  Primers for cloning Atg16L1 K490A from p-BABE to pQCXIN-BirA-Myc vector. 
 
MEF Atg16L1 -/- GFP-LC3 cells stably re-expressing C-terminally tagged BirA Atg16L1 constructs 
were plated at a density of 1.5 million cells per 15 cm dish per condition for 48 h. The cells were 
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treated with 50 µM biotin (Sigma B4639) alongside 1 µM PP242 to modulate canonical autophagy 
or 100 µM monensin to modulate non-canonical autophagy. Cells were then washed three times 
with ice cold PBS and lysed in 1 ml of RIPA buffer with phosphatase and protease inhibitor 
cocktails per 15 cm dish. Cells were scraped and lysed on ice and lysates were pipetted up and 
down and left on ice for 10 min. Lysates were spun at 13000 rpm for 15 min at 4 ◦C. 10% of the 
supernatant was kept here as the total lysate (input) sample. The protein concentration was 
determined through a BCA assay, see western blot method. Equal amounts of protein were added 
to pre-washed streptavidin conjugated Dynabeads (MyOne Streptavidin C1; Invitrogen). Washing 
of the beads involved three washes with lysis buffer, pelleting the beads with a magnetic rack 
(Cell Signalling). 30 µl of bead slurry per condition was used and this will give 15 µl of beads per 
condition where the binding capacity for this amount of beads is ~12 mg of protein. The total 
amount of beads for all conditions were washed together and then separated into the respective 
tubes.  It is important to ensure pipette tips are cut at the end (<1000 µl) to preserve the 
integrity of the beads. The lysates were left rotating at 9 rpm at 4 ◦C overnight. The beads were 
pelleted using the magnet and the supernatant was kept as the depleted sample. The beads were 
then washed four times in RIPA lysis buffer with phosphatase and protease inhibitors.  To elute 
the bound proteins 30 µl of 2x SB was added to each tube and boiled at 95 ◦C for 10 min, the 
beads were then removed to leave the IP sample. The samples were analysed by western blot 
where 15 µg of total lysate and 10 µl of IP sample were separated via SDS-PAGE and specific 
protein levels were detected by western blot. For mass spectrometry, the samples were handed 
over to the Babraham Institute mass spectrometry facility and the samples were prepared and 
TMT labelled as previously described.  
2.11 Statistical analysis 
 
Statistical analysis of data was performed using GraphPad Prism software. Two-tailed unpaired 
Student’s t-test was the common statistical analysis used.  
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3 Results: The molecular mechanisms of Atg16L1 function during 
non-canonical autophagy. 
 
3.1 Introduction: non-canonical autophagy and Atg16L1. 
 
It is now accepted that the lipidation of LC3 cannot be purely used as a readout of canonical 
autophagy because LC3 can be lipidated to single membrane endolysosomal compartments, 
through a so-called ‘non-canonical’ autophagy pathway [91, 98, 109, 111]. This single membrane 
lipidation is dependent on the canonical autophagy lipidation machinery, where Atg16L1 plays a 
key role, acting in complex with Atg12 and Atg5 to direct the site for LC3 lipidation [25, 31, 91]. 
However, non-canonical LC3 lipidation is independent of some upstream signals involved in 
autophagy, such as the ULK1 complex [91, 120], with the underlying molecular mechanisms 
largely unknown.  
To investigate non-canonical autophagy, this project utilises the ionophore monensin, which 
exchanges hydrogen ions for sodium ions in the lysosome, raising the lysosomal pH but also 
changing the osmotic balance of endolysosomal compartments[220, 221]. This alteration of 
endolysosomal osmotic properties has been shown to induce LC3 lipidation to these single 
membranes [98].Monensin induced LC3 lipidation to single membranes is independent of the 
PI3K complex needed for canonical autophagy [41, 98]. While Atg16L1 is recruited in canonical 
autophagy via direct interaction with FIP200 and the PI3P effector protein WIPI2b [32, 33, 189], 
these signals are not important for non-canonical LC3 lipidation to membranes of the 
endolysosome.  
The aim of this chapter was to explore the mechanisms controlling Atg16L1 recruitment in non-
canonical autophagy. Using a structure function approach, existing Atg16L1 mutants [32] were 
expressed in Atg16L1 knockout cells, to uncover which domains are important for Atg16L1 
localisation and LC3 lipidation in the context of non-canonical autophagy. Further refinement of 
the role of Atg16L1 was achieved using site directed mutagenesis. Biochemical assays alongside 
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imaging were the methods used to analyse LC3 lipidation in non-canonical autophagy, in 
pharmacologically stimulated or physiological settings. The results from the structure function 
approach led to a collaboration with Dr Rupert Beale looking at the effect of Influenza A on LC3 
lipidation to begin to assess the functional consequences of the developed cellular system based 
on Atg16L1 manipulation. The Atg16L1 T300A variant associated with Crohn’s disease was also 
assessed to see if it had a role in non-canonical autophagy.     
3.2 Atg16L1 recruitment and LC3 lipidation during non-canonical autophagy is 
independent of canonical autophagy signals.  
 
Atg16L1 acts in complex with Atg5 and Atg12 to lipidate LC3 to PE and has been well studied in 
the context of canonical autophagy. Atg16L1 co-localises with LC3 puncta corresponding to 
autophagosomes upon nutrient starvation of cells [31]. Consistent with this, GFP-LC3 puncta 
formed and co-localised with Atg16L1 in HCT116 cells, following starvation, as shown in (Figure 
3.1A). LC3 can also be lipidated to single membrane endolysosomal compartments, dependent on 
the Atg16L1-Atg5-Atg12 complex. Therefore, the hypothesis was that LC3 would also co-localise 
with Atg16L1 at these membranes. Indeed, Atg16L1 was detected at LC3 positive, single-
membrane phagosomes containing zymozan in a macrophage cell line J7741 (FIGURE 3.1B). To 
further study this, the ionophore monensin was used to promote robust LC3 lipidation to acidic 
endolysosomal compartments. Examples of these endolysosomal membranes include the entotic 
vacuoles that form after cell cannibalism events or bead containing phagosomes that form 
following the phagocytosis of uncoated latex beads. In both of these cases, monensin stimulated 
LC3 lipidation to endolysosomal membranes as well as Atg16L1 recruitment; FIGURE 3.1C shows 
this on the entotic vacuole and FIGURE 3.1D on the bead containing phagosome. These data 
confirm that Atg16L1 recruits to autophagosomes, and importantly, show that it also recruits to 
single membranes during non-canonical autophagy.  
Published data from the Florey lab, showed that monensin induces LC3 lipidation to single 
membranes during non-canonical autophagy independently of VPS34 activity, a PI3K involved in 
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canonical autophagy [98]. In canonical autophagy, growing autophagosomes are enriched with 
PI3P, leading to the recruitment of the PI3P effector WIPI2b that subsequently interacts with 
Atg16L1. In agreement with this, cells treated with the PI3 Kinase inhibitor wortmannin did not 
form autophagosomes following starvation, as assessed by microscopy and GFP-LC3 puncta 
formation (FIGURE 3.2A). The same result was also seen analysing LC3 lipidation via western blot, 
wortmannin significantly reduced LC3 lipidation in response to starvation (FIGURE 3.2C and D). 
However, in keeping with previously published data [98], pre-treatment of cells with wortmannin, 
followed by activation of non-canonical autophagy with monensin treatment, did not affect LC3 
lipidation to entotic corpse vacuoles (FIGURE 3.2B). This again was supported by western blots to 
show that lipidated LC3 in response to monensin was not affected by the inhibition of PI3K 
(FIGURE 3.2 C AND D).  
In order to further support this conclusion, the localisation of the PI3P effector, WIPI2b, was 
looked at in the context of canonical and non-canonical autophagy. Following starvation induced 
canonical autophagy, WIPI2b puncta co-localised with GFP-LC3 puncta corresponding to 
autophagosome structures (FIGURE 3.2E). However, when cells were treated with monensin to 
drive LC3 lipidation to single endolysosomal membranes WIPI2b was absent from these 
membranes, supporting the dispensability of VPS34 and PI3P in monensin‐induced non‐canonical 
autophagy (FIGURE 3.2F). 
Together these data show that Atg16L1 is recruited to single-membrane endolysosomal 
compartmemts during non-canonical autophagy and that this is independent of known 
mechanisms that recruit Atg16L1 to autophagosome membranes. This suggests the existence of a 
novel molecular mechanism of Atg16L1 function during non-canonical autophagy. 
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Figure 3.1: Atg16L1 recruitment in canonical and non-canonical autophagy.  
A.  HCT116 GFP-LC3 cells -/+ starvation 1 h and fixed and stained for Atg16L1. Images were 
captured by confocal microscopy. The arrow heads show puncta positive for Atg16L1 and LC3. Scale bar is 
10 µm. 
B. J774A GFP-LC3 cells with engulfed zymosan, cells were fixed 30 min after zymosan addition and 
stained Atg16L1. Images were captured by confocal microscopy. The arrows indicate LC3 and Atg16L1 
positive zymosan containing phagosomes. The scale bar is 5 µm. 
C. MCF10A GFP-LC3 cells -/+ 100 µM monensin for 1 h and then fixed and stained for Atg16L1. 
Images were captured by confocal microscopy, arrows indicate an LC3 and Atg16L1 positive entotic 
vacuole where the asterisk marks the entotic corpse. The scale bar is 10 µm.  
D. HCT116 GFP-LC3 cells with engulfed latex beads -/+ 100 µM monensin for 1 h and then fixed and 
stained for Atg16L1. Images were captured by confocal microscopy, arrows indicate LC3 and Atg16L1 
positive bead containing phagosome. The scale bar is 5 µm. 
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*This work was produced in collaboration with Dr Elise Jacquin.  
  
Figure 3.2: Upstream signals for LC3 lipidation in non-canonical autophagy are distinct from 
canonical autophagy. 
A.  MCF10A GFP-LC3 cells were starved for 1 h or pre-treated for 15 min with 67 µM wortmannin 
(WM) followed by 1 h starvation still in the presence of WM. Cells were then fixed and the DNA was 
stained with DAPI and images were captured by confocal microscopy. The scale bar is 10 µm.  
B.  MCF10A GFP-LC3 cells were treated with 100 µM monensin for 1 h or pre-treated for 15 min 
with 67 µM wortmannin (WM) followed by 1 h monensin treatment still in the presence of WM. Cells 
were then fixed and the DNA was stained with DAPI and images were captured by confocal microscopy. 
The scale bar is 10 µm. 
C. HEK293 cells were starved or treated with 100 µM monensin for 1 h or pre-treated for 15 min 
with 67 µM wortmannin (WM) followed by these treatments. A western blot was used to detect 
unlipidated and lipidated LC3 (LC3I or LC3II) and GAPDH was used as a loading control.  
D. Quantification of the ratio of LC3II/I. n=3 where the error bars represent the standard error of 
the mean (SEM) *P<0.04 (unpaired Student’s t-test).  
E. HCT116 GFP-LC3 cells were starved for 1 h and fixed and stained for WIPI2b. Images were 
captured by confocal microscopy. Arrows indicate puncta positive for LC3 and WIPI2b. The scale bar is 
10 µm. 
F. MCF10A GFP-LC3 cells -/+ 100 µM monensin for 1 h. Fixed and stained for WIPI2b. Images 
were captured by confocal microscopy. The scale bar is 10 µm. 
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3.3 The C-terminal WD domain of Atg16L1 is dispensable for canonical autophagy.  
 
3.3.1 Atg16L1 Structure-function Analysis: cell lines and constructs 
To begin studying Atg16L1 in the context of both canonical and non-canonical autophagy a 
structure function approach was used. This exploited existing pBabe retroviral Atg16L1 
constructs: full length Atg16L1 (FL) (1-623), Atg16L1 lacking amino acids 219-242, which house 
the FIP200 and WIPI2b binding sites (ΔFBD), and Atg16L1 with a C-terminal deletion of the WD40 
domain (ΔWD) (1-335), where they all have N-terminal Flag and S tags (FIGURE 3.3A).  
These constructs were re-expressed in a variety of different Atg16L1 deficient cell lines: i) Clonal 
HCT116 GFP-LC3 cells, deficient for Atg16L1, were engineered by Dr Rupert Beale’s lab using 
CRISPR/Cas9. ii) Previous members of the lab, Dr Elise Jacquin and Celine Judon, used 
CRISPR/Cas9 technology to produce MCF10A Atg16L1 deficient cells expressing GFP-LC3, iii) this 
project also utilised an existing MEF Atg16L1 deficient GFP-LC3 cell line produced by traditional 
methods based on homologous recombination [197]. The cells deficient for Atg16L1 were 
complemented with ATG16L1 constructs, where re-expression was achieved by using viral 
transduction to stably express the constructs at equal levels, as shown in FIGURE 3.3B-D.  
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Figure 3.3: Atg16L1 constructs and expression in various cell lines. 
A.  Schematic representation of the different Atg16L1 Flag S (F-S) tagged constructs. Full length 
Atg16L1 (FL), Atg16L1 with a deletion of the FIP200 binding domain (∆FBD), Atg16L1 with a deletion of 
the C-terminal WD domain (∆WD).  
B-D. Western blot to detect Atg16L1 in various knockout Atg16L1 cell lines stably re-expressing 
Atg16L1 constructs to a similar level. The arrows show the specific Atg16L1 bands .B: HCT116 GFP-LC3 
Atg16L1 -/- C. MEF GFP-LC3 Atg16L1 -/- D. MCF10A GFP-LC3 Atg16L1 -/-. 
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3.3.2 Atg16L1 Domain Analysis: canonical autophagy assays 
 
Canonical autophagy assays were performed with the Atg16L1 re-complemented cell lines to see 
which domains of Atg16L1 control LC3 lipidation to autophagosomes. The first experiment was to 
test their response to nutrient starvation by observing and quantifying the GFP-LC3 puncta per 
cell through confocal imaging. In agreement with published work [32, 189], FIGURE 3.4 A-D shows 
that deletion of the FBD domain of Atg16L1, in MEF and HCT116 cells, impairs GFP-LC3 puncta 
formation, a measure of LC3 localisation and lipidation to autophagosomes. However, the 
deletion of the C-terminal WD domain of Atg16L1 had no significant effect on GFP-LC3 puncta 
formation in response to starvation [197]. Using PP242, an m-TOR inhibitor, as an alternative 
treatment to activate canonical autophagy, HCT116 cells re-expressing the Atg16L1 constructs 
were used to look at LC3 lipidation levels via western blotting (Figure 3.4 E-F). These data support 
the immunofluorescence results, in that the FBD domain of Atg16L1 is required for efficient 
canonical autophagy while the WD domain is dispensable.  
To reinforce these observations, the localisation of WIPI2b under starvation was analysed. WIPI2b 
localises to autophagosomes upstream of Atg16L1 recruitment. Therefore, as expected, there 
was no significant difference in WIPI2b recruitment to autophagosomes in cells expressing the 
different Atg16L1 constructs (FIGURE 3.4 G AND H). These results demonstrate that signalling 
upstream of LC3 lipidation was functional in all cell lines. 
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Figure 3.4: Atg16L1 structure function in canonical autophagy. 
A. Fixed confocal images of MEF GFP-LC3 Atg16L1 -/- cells complemented with full length (FL), 
∆FBD  
or ∆WD Atg16L1 -/+ starvation for 1 h. The scale bar is 10 µm. 
B. Quantification of GFP-LC3 puncta from A, 100 cells were counted per experiment and this 
represents n=3. Error bars represent the standard error of the mean (SEM) ***P<0.0001,**P<0.001 
(unpaired Student’s t-test).  
C. Fixed confocal images of HCT116 GFP-LC3 Atg16L1 -/- cells complemented with full length (FL), 
∆FBD or ∆WD Atg16L1 -/+ starvation for 1 h. The scale bar is 10 µm. 
D. Quantification of GFP-LC3 puncta from C, 100 cells were counted per experiment and this 
represents n=3. Error bars represent the standard error of the mean (SEM) ***P<0.0004,**P<0.002, 
(unpaired Student’s t-test).  
E. Lysates from HCT116 cells re-complemented with Atg16L1 constructs treated -/+ 1 µM m-TOR 
inhibitor PP242 for 1h.  
F.  Quantification of the ratio of LC3II/I. n=3 where the error bars represent the standard error of 
the mean (SEM) *P<0.02 (unpaired Student’s t-test). 
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Figure 3.4  continued: Atg16L1 structure function in canonical autophagy.  
G. Fixed confocal images of HCT116 GFP-LC3 Atg16L1 -/- cells complemented with full length (FL), 
∆FBD or ∆WD Atg16L1 -/+ starvation for 1 h. The cells were fixed and stained for WIPI2b. The scale bar is 
10 µm. 
H. Quantification of WIPI2b puncta from G, 100 cells were counted per experiment and this 
represents n=3. Error bars represent the standard error of the mean (SEM) ***P<0.0006,**P<0.005 
(unpaired Student’s t-test).   
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3.4 The C-terminal WD domain of Atg16L1 is essential for monensin induced LC3 
lipidation in non-canonical autophagy.  
 
Having established the domain requirements of Atg16L1 in canonical autophagy, the same cell 
lines were next used to assess Atg16L1 structure-function with regards to non-canonical 
autophagy. To do this, a series of experiments were performed, using pharmacological 
stimulations and a range of assays for non-canonical autophagy. 
3.4.1 Pharmacological assays: Bafilomycin versus Monensin 
 
Comparative analysis of the drugs Bafilomycin A and monensin can be performed to assay for 
canonical versus non-canonical autophagy. As outlined in the introduction, Bafilomycin A1 is a V-
ATPase inhibitor that blocks proton pump activity and raises lysosomal pH, leading to a block in 
autophagic flux and an accumulation of lipidated LC3, specifically on autophagosomes (LC3-II). 
Monensin also raises lysosome pH, but by exchanging protons for sodium ions, resulting in a block 
in autophagic flux and a similar increase in canonical LC3 lipidation. Importantly, however, 
monensin also stimulates parallel LC3 lipidation to single-membrane compartments through 
osmotic regulation of non-canonical autophagy [41, 98], in a manner that can be inhibited by 
Bafilomycin A1. As such, while both drugs increase LC3 lipidation at autophagosomes, they have 
opposing effects on non-canonical autophagy – monensin induces, while Bafilomycin A1 inhibits. 
These pharmacological differences provide a useful means by which to compare canonical versus 
non-canonical autophagy.  
Bafilomycin A1 and monensin were used to treat the Atg16L1 re-complemented cells and the LC3 
lipidation levels were assessed by western blot (FIGURE 3.5A). This assay enabled visualisation of 
the extra LC3 lipidation that monensin causes, beyond the blockage of autophagic flux. In HCT116 
cells re-expressing FL Atg16L1 or ∆FBD ATG16L1, there was more LC3 lipidation occurring when 
the cells were treated with monensin in comparison with bafilomycin (FIGURE 3.5A). Therefore, 
FL and ∆FBD Atg16L1 support monensin induced LC3 lipidation to endolysosomes. Strikingly, in 
cells where the Atg16L1 is lacking the C-terminal WD domain, there was little difference in the 
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lipidated LC3 levels in cells treated with bafilomycin or monensin (FIGURE 3.5A). This suggests 
that deleting the WD domain of Atg16L1 has stopped the additional LC3 lipidation to single 
membranes that is caused by monensin. These data provide the first evidence that the WD 
domain of Atg16L1 is required for LC3 lipidation in non-canonical autophagy.  
3.4.2 Monensin induced LC3 lipidation: PI3K dependence 
 
To complement the above work, another drug was used to help distinguish LC3 lipidation from 
canonical and non-canonical autophagy pathways. Wortmannin, a PI3K inhibitor, inhibits 
canonical autophagy but not monensin induced non-canonical LC3 lipidation (Figure 3.2A-D). It 
was evident in cells expressing FL Atg16L1 and ∆FBD Atg16L1 that there was wortmannin 
insensitive LC3 lipidation, which can be attributed to LC3 lipidation to single membranes in non-
canonical autophagy (FIGURE 3.6B). However, in the cells expressing the ∆WD Atg16L1, 
wortmannin significantly inhibited monensin driven LC3 lipidation. As such, when the C-terminal 
domain of Atg16L1 is deleted, LC3 lipidation induced by monensin can mostly be attributed to 
canonical autophagy and the blockage of flux, suggesting non-canonical autophagy is not active.  
3.4.3 Monensin-induced LC3 lipidation: phagocytosis assay 
 
In order to visualise LC3 lipidation to membranes of the endolysosomal system in non-canonical 
autophagy, an assay was developed using uncoated latex beads. Following bead engulfment, cells 
were treated with monensin, which induced LC3 lipidation to the bead containing phagosomes. 
Samples were fixed and stained for LAMP1 to identify phagosomes and GFP-LC3 localisation was 
quantified. The Florey lab have previously shown that this method detects LC3 lipidation 
independent of canonical autophagy [98]. The lab have also shown that monensin induced LC3 
lipidation to single membranes is not due to endolysosomal damage, as no galectin 3 or 8 were 
seen on endolysosomal membranes following monensin treatment [41]. This assay detected 
monensin induced LC3 lipidation to bead containing phagosomes in cells expressing the Atg16L1 
FL and ΔFBD, where ~35% of LAMP1 bead containing phagosomes were GFP-LC3 positive at a 
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fixed timepoint (FIGURE 3.6 A-B). Strikingly, in cells lacking the WD domain of Atg16L1 there was 
no incidence of GFP-LC3 localisation to bead containing phagosomes (FIGURE 3.6 A-B). LC3 
lipidation in this context was thus dependent on the C-terminal WD domain of Atg16L1, in a 
monensin dependent fashion.  
3.4.4 Monensin-induced LC3 lipidation: entosis assay 
 
To support these findings, another cell-based assay was utilised with MCF10A cells. These cells, 
following matrix deadhesion, have a high frequency of entotic live cell engulfment. During 
entosis, the internalised cell dies, while housed in an entotic corpse vacuole, an acidic, lysosome 
like compartment. It has previously been shown that monensin will promote the lipidation of LC3 
to entotic corpse vacuoles through activation of non-canonical autophagy [41, 98].  
Re-complemented Atg16L1 MCF10A cells were matrix detached, to induce entosis, then reseeded 
overnight, fixed and stained for LAMP1 to mark the resulting entotic corpse vacuoles; the GFP-
LC3 localisation was quantified (FIGURE 3.7A-B). The cells expressing either the FL or ∆FBD 
Atg16L1 supported monensin induced LC3 lipidation to entotic vacuoles, +80% of vacuoles 
captured were LC3 positive (FIGURE 3.7A-B). Again, there was no incidence of LC3 lipidation to 
entotic vacuoles when the cells lacked the C- terminal domain of Atg16L1 (FIGURE 3A-B).  
Taken together, these data show for the first time that the WD40 C-terminal domain of ATG16L1 
is essential in drug induced non-canonical autophagy. Next, this observation was extended to 
analyse physiological examples of non-canonical autophagy. 
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Figure 3.5: Pharmacological analysis of non-canonical autophagy Atg16L1 in re-
complemented cell lines. 
A. Lysates from HCT116 cells re-complemented with Atg16L1 constructs treated -/+ 100 
nM bafilomycin or 100 µM monensin for 1 h. A western blot was used to detect unlipidated and 
lipidated LC3 (LC3I or LC3II) and GAPDH was used as a loading control. Quantification of the 
ratio of LC3II/I. n=3 where the error bars represent the standard error of the mean (SEM) 
*P<0.02, ***P<0.001, not significant (NS)(unpaired Student’s t-test).   
B. Lysates from HCT116 cells re-complemented with Atg16L1 mutants were treated with  
-/+ 100 µM monensin or 67 µM wortmannin (WM) for 1 h or pre-treated for 15 min with 67 µM 
WM followed by a 1 h monensin treatment. A western blot was used to detect unlipidated and 
lipidated LC3 (LC3I or LC3II) and GAPDH was used as a loading control. Quantification of the 
ratio of LC3II/I. n=3 where the error bars represent the standard error of the mean (SEM) 
**P<0.0002 and not significant (NS) (unpaired Student’s t-test). 
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Figure 3.6: Using beads and monensin to study non-canonical autophagy in Atg16L1 re-
complemented cell lines. 
A. HCT116 GFP-LC3 Atg16L1 -/- cells re-complemented Atg16L1 constructs, where with 3 µm latex 
beads were added for 4 h -/+ 100 µM monensin for 1 h. The cells were fixed and stained for LAMP1 and 
images were captured by confocal microscopy. Cropped images show bead phagosomes. The scale bar is 5 
µm.  
B.  Quantification of GFP-LC3 positive bead containing phagosomes from A, 100 LAMP1 positive bead 
containing phagosomes were counted per experiment and this represents n=3. Error bars represent the 
standard error of the mean (SEM). 
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Figure 3.7: Entotic corpse vacuoles treated with monensin to observe non-canonical autophagy 
in Atg16L1 re-complemented cell lines 
A. MCF10A GFP-LC3 Atg16L1 -/- cells re-complemented with Atg16L1 constructs and treated  -/+ 100 
µM monensin for 1 h. The cells were fixed and stained for LAMP1 and images were captured by confocal 
microscopy. The cropped images represent entotic corpse containing vacuoles. The scale bar is 5 µm.  
B.  Quantification of GFP-LC3 positive corpse containing entotic vacuoles from A, 100 LAMP1 positive 
entotic corpse vacuoles were counted per experiment and this represents n=3. Error bars represent the 
standard error of the mean (SEM). 
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3.5  The C-terminal WD domain of Atg16L1 is essential for LC3 lipidation in 
physiological engulfment events involving non-canonical autophagy.  
 
3.5.1 LC3 associated phagocytosis (LAP) assays 
 
LC3 associated phagocytosis (LAP) is involved in the phagocytic engulfment of pathogens, but also 
of apoptotic cells, and is a physiological example of non-canonical autophagy. MEF cells are able 
to engulf apoptotic cells [222] and have previously been shown to be competent for LAP [223]. 
Therefore, using Atg16L1 knockout MEF cells, re-complemented with the Atg16L1 constructs, LAP 
was analysed following phagocytosis of apoptotic HCT116 cells.  
Cell tracker red labelled HCT116 cells were UV treated to induce apoptosis and added to MEF 
monolayers. Live cell imaging was performed to look at GFP-LC3 recruitment and lipidation to 
apoptotic corpse containing phagosomes. This assay showed that in FL and ∆FBD cells ~50% of 
apoptotic cell phagosomes were positive for GFP-LC3 (FIGURE 3.8 A and B). Strikingly, LAP was 
not supported in cells lacking the C-terminal WD domain of Atg16L1, as apoptotic cell 
phagosomes were negative for GFP-LC3 (FIGURE 3.8). These data support the conclusions from 
the monensin induced model and show that the WD domain of Atg16L1 is essential during LAP 
and non-canonical autophagy. 
3.5.2 Macropinocytosis assays 
 
It has been previously shown that LC3 can lipidate to macropinosomes [91]. This allowed another 
strategy to observe LC3 lipidation during non-canonical autophagy. MEF cells were serum starved 
overnight and stimulated with PDGF to activate macropinocytosis. A red dextran tracer was used 
as a fluid phase marker to observe the red macropinosomes and the localisation of GFP-LC3 via 
live cell imaging. It was found that GFP-LC3 was recruited to macropinosomes in cells expressing 
FL Atg16L1 or ∆FBD Atg16L1 but not in ∆WD Atg16L1 expressing cells (FIGURE 3.9A).  
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3.5.3 Vacuolating toxin A (VacA) assays 
 
Another system to study GFP-LC3 lipidation in non-canonical autophagy involves treatment of 
cells with Vacuolating toxin A (VacA) derived from Helicobacter pylori. It has previously been 
shown that VacA induces vacuolation of endolysosomal compartments, which are then targeted 
by LC3 lipidation [98]. In MEF cells, the FBD domain of Atg16L1 was dispensable for VacA induced 
LC3 recruitment to vacuoles. However, the WD C-terminal domain of Atg16L1 was essential for 
LC3 lipidation in this context (FIGURE 3.9B).  
Together, these data from three distinct cellular models show for the first time that the WD 
domain of Atg16L1 is essential for lipidation of LC3 during non-canonical autophagy and 
associated processes such as LAP.  
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Figure 3.8: LC3 associated phagocytosis assay in Atg16L1 re-complemented MEFs. 
A. Atg16L1 complemented GFP-LC3 MEF cells that have phagocytosed red-labelled 
apoptotic cells for 14 h and then live confocal microscopy captured representative images. The 
cropped image is of an apoptotic corpse phagosome. The scale bar is 5 µm.  
B.  Quantification of GFP-LC3 positive apoptotic corpse containing phagosomes from A, 20 
phagosomes were counted per experiment, n=3. The error bars represent the standard error of 
the mean (SEM), ****P<0.0001 (Unpaired Student’s t-test). 
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Figure 3.9: Macropinocytosis and VacA assays to observe LC3 lipidation in non-canonical 
autophagy. 
A. Atg16L1 complemented GFP-LC3 MEF cells were serum starved overnight and then stimulated 
with 0.1 µg/ml PDGF in media containing tetramethylrhodamine conjugated dextran to visualise 
macropinocytosis. Live confocal microscopy was used to capture representative images and the DIC 
channel was an additional way to visualise macropinocytosis. Images were cropped to show a single 
macropinosome. The scale bar is 5 µm.  
B.  Atg16L1 complemented GFP-LC3 MEF cells treated with vacuolating toxin A (VacA) at 10 µM for     
4 h. The cells were imaged by live confocal microscopy and representative images were captured. The DIC 
channel helped to visualise the vacuolation. The scale bar is 5 µm. 
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3.6 Atg16L1 ∆WD no longer localises to membranes of the endolysosomal system. 
 
Next the possible mechanism underlying the function of the WD domain of Atg16L1 during non-
canonical autophagy was explored. It has been assumed that the ∆WD Atg16L1 still has the ability 
to form a functional complex with Atg5 and Atg12 to support lipidation of LC3. This assumption is 
based on published work [209] and the fact that cells expressing ∆WD Atg16L1 still have the 
ability to lipidate LC3 to autophagosome membranes in canonical autophagy (FIGURE 3.4).  
It was confirmed that the ∆WD Atg16L1 does successfully form a complex with Atg5 and Atg12 to 
support LC3 lipidation. Following immunoprecipitation of FL Atg16L1 or ∆WD Atg16L1, both 
constructs can pull down the ATG5/12 conjugates (FIGURE 3.10A). ATG5 and Atg12 were also 
identified at similar levels in pull downs from both Atg16L1 constructs by mass spectrometry 
(FIGURE 3.10B). Thus, it can be concluded that Atg16L1 lacking the WD domain can form a 
functional complex with Atg5 and Atg12, and the lack of LC3 lipidation during non-canonical 
autophagy must be through a different mechanism.  
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Figure 3.10: Atg16L1 with a C-terminal deletion still forms a functional complex with Atg5-12. 
A. Lysates from MEF Atg16L1 -/- cells re-complemented with Flag-S tagged FL or ∆WD Atg16L1 
that had been treated for 1 h with 100 µM monensin were used to perform immunoprecipitation (IP) with 
anti-s-tag beads. A western blot was used to detect Atg16L1 or Atg5-12 in the total lysate/ input (IN) and 
IP sample. The negative (-/-) comes from WT MEFs.   
B. The graph represents data from n=2 mass spectrometry analysis for Atg5 and Atg12 levels 
pulled down in samples from cells expressing FL or ∆WD Atg16L1. 
114 
 
Next the recruitment of Atg16L1 to single-membrane compartments was tested to see whether it 
was affected by the WD domain. As shown earlier, Atg16L1 localises to bead containing 
phagosomes upon cellular treatment with monensin (FIGURE 3.1D and 3.11A). It was further 
found that, when the C-terminal domain of Atg16L1 is absent, it is no longer able to recruit to 
bead containing phagosomes upon monensin treatment (FIGURE 3.11A). This observation was 
extended by looking at Atg16L1 recruitment to entotic corpse vacuoles after monensin 
treatment. In MCF10A cells re-complemented with the FL Atg16L1 or the ΔFBD, it was evident 
that there was Atg16L1 localisation to corpse containing vacuoles in a monensin dependent 
fashion (FIGURE 3.11B). However, in the cells re-complemented with ΔWD Atg16L1, this version 
of Atg16L1 no longer recruited to corpse containing vacuoles (FIGURE 3.11B). Therefore, the WD 
domain of Atg16L1 is required for its correct localisation to single-membranes in non-canonical 
autophagy and the subsequent LC3 lipidation to these compartments. 
In support of this conclusion from the imaging based assays, a membrane fractionation protocol 
was optimised in re-complemented HCT116 cells, followed by western blotting, to look at 
Atg16L1 and Atg5-12 levels in the membrane fraction following monensin treatment (FIGURE 
3.12). Membrane proteins LAMP1 and V-ATPase subunit V0D1 were chosen as controls, to ensure 
purity of the fractionation and act as a loading control. Cytosolic protein alpha tubulin was also 
used to ensure that cytosolic proteins were not contaminating the membrane fraction (data not 
shown). It was evident that FL Atg16L1 was found at slightly increased levels at the membrane 
after monensin treatment, along with Atg16L1 lipidation complex partners Atg5-12 (FIGURE 3.12 
A, C AND D). These changes are subtle, perhaps due to the fact that this is data from total 
membrane fractions rather than specifically endolysosomal membranes, but nevertheless 
reproducible. However, such an increase after monensin treatment was not observed in ∆WD 
Atg16L1 levels at the membrane or in the levels of its Atg5-12 binding partners (FIGURE 3.12 B-D). 
These findings, alongside the imaging data, show that Atg16L1 lacking the C-terminal domain is 
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failing to recruit to membranes of the endolysosomal system, leading to a lack of LC3 lipidation at 
these membranes.   
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Figure 3.11: Atg16L1 lacking the WD domain no longer localises to bead phagosomes and 
entotic corpse vacuoles. 
A. HCT116 GFP-LC3 Atg16L1 -/- cells re-complemented with FL or ∆WD Atg16L1 where 3 µm latex 
beads were added for 4 h followed by treatment -/+ 100 µM monensin for 1 h. The cells were fixed and 
stained for Atg16L1 and images were captured by confocal microscopy. Cropped images show bead 
containing phagosomes. The scale bar is 3 µm. Line profile analysis of Atg16L1 and GFP-LC3 fluorescence 
intensity is shown for representative phagosomes and this was performed in ImageJ.  
B.  MCF10A GFP-LC3 Atg16L1 -/- cells re-complemented with FL or ∆WD Atg16L1 -/+ 100 µM 
monensin for 1 h and the cells were fixed and stained for Atg16L1. Images were captured by confocal 
microscopy and cropped images show representative corpse containing vacuoles. The scale bar is 10 µm. 
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Figure 3.12: Membrane fractionation to assess Atg16L1 and Atg5-12 at membranes in 
cells expressing FL or ΔWD Atg16L1. 
 
A. HCT116 GFP-LC3 Atg16L1 -/- cells re-complemented with FL Atg16L1 -/+ 100 µM monensin 
for 1 h. Cells were then lysed and fractionated, using a kit, into membrane and cytosolic fractions. 
Western blot analysis was done to detect Atg16L1 and Atg5-12 in the membrane fraction where 
LAMP1 and V-ATPase subunit D1 (VOD1) were used as known membrane proteins for loading purity 
control.  
B. At the same time as A the experiment was done in HCT116 GFP-LC3 Atg16L1 -/- cells re-
complemented with  ∆WD Atg16L1.  
C.  Quantification of A and B to show the amount of Atg16L1 and ∆WD Atg16L1 at the 
membrane with and without monensin stimulation. Western blots were quantified in ImageJ where 
numbers were normalised to the untreated sample, and corrected for loading and purity using 
LAMP1.These data were from n=3 and the error bars are the standard error of the mean (SEM). 
*P<0.02(Unpaired student t-test).  
D. Quantification of A and B to show the amount of Atg5-12 at the membrane in respective 
samples with and without monensin stimulation. Western blots were quantified in ImageJ where 
numbers were normalised to the untreated sample, and corrected for loading and purity using VOD1. 
These data were from n=3 and the error bars are the standard error of the mean (SEM). *P<0.02 
(Unpaired student t-test). 
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3.7 Identification of key residues on the top face of ATG16L1 WD40 C-terminal 
domain required for non‐canonical autophagy 
 
3.7.1 Atg16L1 WD domain sequence analysis 
 
To gain more insight into the molecular details of the WD domain, bio-informatic alignments 
were performed to look at the conservation of the WD domain of Atg16L1 in species that support 
non-canonical autophagy. The alignments showed that the WD domain is evolutionarily 
conserved in species known to support non-canonical autophagy and cemented the idea that the 
domain must be carrying out an important function. FIGURE 3.13 shows the amino acid homology 
of Atg16L1 WD domains in rat, mouse and human. Further alignments were done as part of 
FIGURE 3.18C.  
Atg16L2, a paralog of Atg16L1, which has a similar domain structure, was used to uncover 
important information on how specific the WD domain of Atg16L1 is in its function in non-
canonical autophagy. A sequence alignment of the WD domains from Atg16L1 and Atg16L2 was 
performed to look at sequence homology (FIGURE 3.14), there was 43% homolog. It has been 
previously shown that although Atg16L2 can act in complex with Atg12-Atg5, it is not sufficient 
for canonical autophagy [193]. Therefore, it was next interesting to see if Atg16L2 was able to 
support LC3 lipidation in non-canonical autophagy. This was done in HCT116 GFP-LC3 Atg16L1 KO 
cells, transiently transfected with Atg16L1 or Atg16L2. By western blot, re-expression of Atg16L1 
in HCT116 Atg16L1 KO cells supported LC3 lipidation in response to bafilomycin and monensin 
(FIGURE 3.15 A AND B). However, when the cells are just expressing Atg16L2, minimal LC3 
lipidation is observed in response to canonical or non-canonical autophagy stimulations (FIGURE 
3.15B). These conclusions were consistent when looking at GFP-LC3 via confocal microscopy, cells 
just expressing Atg16L2 no longer support monensin induced GFP-LC3 structure formation 
(FIGURE 3.15C AND D). These data suggest that Atg16L2 cannot support LC3 lipidation to 
endolysosomal membranes. The differences in the WD domain of these two Atg16 paralogs may 
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provide a clue to which residues may be essential for the function of the WD domain of Atg16L1 
in non-canonical autophagy.  
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Figure 3.13: Alignment of the WD domain of Atg16L1 from human, mouse and rat. 
Amino acid sequence alignment of the WD domain of human, mouse and rat Atg16L1. The single amino acids are listed and the graph shows the degree of similarity 
across the alignment. This was produced with the CLC sequence viewer 7 software.  
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Figure 3.14: Alignment of the WD domain of human Atg16L1 and Atg16L2. 
Amino acid sequence alignment of the WD domain of human Atg16L1 and Atg16L2. This depicts amino acid similarity in a graphical form and numerically there was 43% 
sequence homology. This was generated using CLC sequence viewer 7.   
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Figure 3.15: Atg16L2 does not support LC3 lipidation in non-canonical autophagy. 
A. HCT116 GFP-LC3 Atg16L1 -/- cells transiently transfected with FL Atg16L1 or Atg16L2, cells were 
lysed and a western blot was performed to analyse the expression of Atg16L1 and Atg16L2. GAPDH was 
used as a loading control.  
B. HCT116 GFP-LC3 Atg16L1 -/- cells transiently transfected with FL Atg16L1 or Atg16L2 -/+ 100 nM 
bafilomycin or 100 µM monensin for 1 h. Cells were lysed and a western blot was done to analyse 
unlipidated and lipidated LC3 (LC3I and LC3II). GAPDH was used as a loading control.   
C.  HCT116 GFP-LC3 Atg16L1 -/- cells transiently transfected with FL Atg16L1 or Atg16L2 -/+ 100 µM 
monensin. Cells were fixed and representative images were captured by confocal microscopy.  
D. HCT116 GFP-LC3 Atg16L1 -/- cells transiently transfected with FL Atg16L1 or Atg16L2 and 3 µm 
latex beads were added for 4h and then the cells were treated  -/+ 100 µM monensin for 1 h. Cells were 
fixed and stained for LAMP1.Representative images were captured by confocal microscopy and the 
cropped images show the bead containing phagosome. 
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3.7.2 Atg16L1 WD domain hotspot analysis 
 
Next, a recently described algorithm was used that predicts “hotspot” residues potentially 
involved in protein-protein interactions in different WD domain containing proteins [195]. Based 
on the mouse Atg16L1 protein, 12 potential “hotspots” were identified, all located on the top 
face of the predicted β-barrel structure of the WD40 domain (FIGURE 3.16). 
Site directed mutagenesis was done on these 12 candidate residues in the WD domain of 
Atg16L1, mutating each residue separately to alanine. This was done via an adaptation of the 
QuikChange II agilent technologies method and the results were sent off for Sanger sequencing. 
12 point mutant Atg16L1 constructs were successfully produced in the pBabe retroviral plasmid. 
The Atg16L1 C-terminal domain point mutants were virally transduced to re-constitute Atg16L1 
KO HCT116 GFP-LC3 cells in order to produce stable cell lines. The mutant Atg16L1 proteins were 
expressed at similar levels (FIGURE 3.17A). These cells were then used to assess whether the 
point mutation in the WD domain of Atg16L1 had changed the response of cells to non-canonical 
autophagy.  
The initial assay used to screen these mutant cell lines was western blotting analysis of LC3 
lipidation following monensin and/or wortmannin treatment, as previously used in (FIGURE 3.5B). 
It was evident that when canonical autophagy was inhibited by wortmannin, monensin was still 
able to stimulate non-canonical autophagy in some cells re-constituted with Atg16L1 point 
mutations (e.g. N326A, N342A) (FIGURE 3.17B). This suggests that these point mutations in the C-
terminal of Atg16L1 have not affected LC3 lipidation in non-canonical autophagy.  However, there 
were five point mutations (E342A, N386A, N453A, F467A, K490A) in Atg16L1 that seemed to 
impair monensin induced LC3 lipidation (FIGURE 3.17B). This result was promising as it suggested 
that Atg16L1 point mutants could phenocopy the C-terminal WD deletion of Atg16L1.  
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Figure 3.16: Atg16L1 WD domain using WDSP predicted amino acids required for protein-
protein interactions. 
Using the WDSP database as referenced in the text, using the amino acid sequence of Atg16L1, this is the 
predicted structure and potential residues important for protein-protein interactions. They are all shown 
on the top face of the beta barrel. The table shows the alanine substitutions made at various residues in 
the WD domain of Atg16L1 by site directed mutagenesis. 
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Figure 3.17: Screening Atg16L1 C-terminal WD point mutants for non-canonical autophagy. 
A. HCT116 Atg16L1 -/- GFP-LC3 cells re-complimented with Atg16L1 single point mutants. Cells 
were lysed and western blots were performed to detect Atg16L1 expression. GAPDH was used as a 
loading control.  
B.  Lysates from HCT116 Atg16L1 -/- cells re-complemented with Atg16L1 point mutants that had 
been treated with -/+ 100 µM monensin or 67 µM wortmannin (WM) for 1 h or pre-treated for 15 min 
with 67 µM WM followed by a 1 h monensin treatment. Western blots were used to detect unlipidated 
and lipidated LC3 (LC3I or LC3II) and GAPDH was used as a loading control. Quantification of the ratio of 
LC3II/I was done using ImageJ. n=3 where the error bars represent the standard error of the mean 
(SEM).The red asterisk marks those that are not conserved in Atg16L1.  
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3.7.3 Atg16L1 WD domain mutant analysis: F467A and K490A 
 
Two C-terminal Atg16L1 point mutants were taken forward for further validation: Atg16L1 F467A 
and K490A. These residues were mapped onto the recently reported crystal structure of the WD 
domain of Atg16L1 [192]. Atg16L1 F467, K490, and another positive hit N453, were all in close 
proximity to one another and generated a pocket on the top face of the WD40 C-terminal domain 
(FIGURE 3.18A AND B). Importantly, these particular residues were conserved across species 
(FIGURE 3.18C). Furthermore, F467 and K490 are not conserved in Atg16L2, which has a WD 
domain that does not support non-canonical autophagy, further validating that these residues 
could be essential in the WD domain of Atg16L1 that does support LC3 lipidation to single 
membranes (FIGURE 3.18D). 
The point mutants were next analysed for their ability to support canonical and non-canonical 
autophagy using the experiments described earlier. Firstly we showed that each point mutant has 
no effect on starvation induced canonical autophagy, as assessed by GFP-LC3 puncta formation 
(FIGURE 3.19 B AND C). Similarly, WIPI2b puncta formation was not affected by the point mutants 
(FIGURE 3.19 B AND D). Western blots supported the immuno-fluorescence data; all of the 
Atg16L1 mutants supported an induction in LC3 lipidation when the m-TOR inhibitor PP242 was 
used to induce autophagy (FIGURE 3.19E AND F). Therefore, the alanine substitutions at positions 
F467 and K490 in the C-terminal of Atg16L1 have no effect on LC3 lipidation in canonical 
autophagy.  
The initial screen by western blot identified the F467A and K490A Atg16L1 point mutants to 
impair monensin induced LC3 lipidation to endolysosomes in non-canonical autophagy (FIGURE 
3.17). In order to further investigate this inhibition of LC3 lipidation to single membranes, cell 
lines were used to look at LC3 lipidation to bead containing phagosomes after monensin 
treatment. Cells stably re-expressing the Atg16L1 point mutants were significantly impaired for 
LC3 lipidation to bead containing phagosomes after stimulation with monensin (FIGURE 3.20). 
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These data further confirm that the residues F467 and K490 in the WD of Atg16L1 are essential 
for its function in LC3 lipidation in non-canonical autophagy. 
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Figure 3.18: Atg16L1 point mutants mapped onto the crystal structure of the Atg16L1 WD 
domain and amino acid conservation. 
A. Ribbon model of the top face of Atg16L1 WD domain, with critical residues in ball and stick. 
Structural image generated in NGL viewer using Protein Database.  
B. Surface of Atg16L1 WD domain coloured to electrostatic potential (blue positive 2, red 
negative2). Cropped and zoomed area of critical residues. Image generated in Swiss-Protein database 
Viewer. 
C. Annotated alignment of Atg16L1 sequences amino acids (477-496) from different species. 
Asterisks shows conserved critical residues.  
D. Annotated alignment of a region of the WD domain of Atg16L1 in comparison to the WD domain 
of Atg16L2. Asterisks show un-conserved critical residues. 
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Figure 3.19: Canonical autophagy response of cells expressing the Atg16L1 WD domain point 
mutants. 
A. Lysates taken from HCT116 GFP-LC3 Atg16L1 -/- cells re-complemented with Atg16L1 mutants. 
Western blot to detect expression levels of  Atg16L1. GAPDH was used as a loading control.  
B. Confocal images of cells from A starved for 1 h and fixed and stained for WIPI2b.  
C  Quantification of GFP-LC3 puncta per cell -/+ 1 h starvation. 100 cells were counted per 
experiment and an average was taken. n=3 where the error bars represent the standard error of the 
mean. *P<0.03 **P<0.003 ***P<0.0001 (Unpaired Student’s t-test).  
D. Quantification of WIPI2b puncta per cell -/+ 1 h starvation. 100 cells were counted per 
experiment and an average was taken. n=3 where the error bars represent the standard error of the 
mean. **P<0.005 (Unpaired Student’s t-test). 
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Figure 3.19 continued… 
E. Lysates from re-complemented HCT116 cells  treated -/+ 1 µM m-TOR inhibitor PP242 for 1h. 
Western blot to detect unlipidated and lipidated LC3 (LC3I and LC3II) where GAPDH was used as a loading 
control. 
F.  Quantification of the ratio of LC3II/I using ImageJ. n=3 where the error bars represent the 
standard error of the mean (SEM) NS= not significant (unpaired Student’s t-test). 
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Figure 3.20: Atg16L1 point mutants in response to monensin induced non-canonical 
autophagy. 
A. HCT116 GFP-LC3 Atg16L1 -/- cells re-complemented with Atg16L1 mutants where 3 µm latex 
beads were added for 4 h -/+ 100 µM monensin for 1 h. The cells were fixed and stained for LAMP1 and 
images were captured by confocal microscopy. Cropped images show bead phagosomes. The scale bar is 
5 µm.  
B.  Quantification of GFP-LC3 positive bead containing phagosomes from A, 100 LAMP1 positive 
bead containing phagosomes were counted per experiment and this represents n=3. Error bars represent 
the standard error of the mean (SEM). 
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To extend our studies of these key residues identified in the WD domain of Atg16L1, a new cell 
line was developed. This involved the generation of an Atg13 and Atg16L1 double knock out, by 
taking an existing Atg13 KO cell line (FIGURE 3.21A), which is deficient for canonical autophagy 
[41], and using CRISPR/Cas9 to knock out Atg16L1. Single cell clones were screened through 
western blotting for LC3 and Atg16L1(FIGURE 3.21A AND B). The double knockout would render 
the cell deficient for LC3 lipidation associated with either canonical or non-canonical autophagy 
(FIGURE 3.21B). Indeed there was no evidence of GFP-LC3 re-localisation in these cells following 
monensin treatment (FIGURE 3.21C).  
The double knockout cell line was useful to study which Atg16L1 constructs specifically rescued 
non-canonical autophagy when stably re-expressed in these cells at similar levels (FIGURE 3.22A). 
This was a clean system as the KO of Atg13 allowed LC3 lipidation in these cells to be attributed 
solely to non-canonical autophagy. These cells were then tested for LC3 lipidation in response to 
bafilomycin and monensin treatment (FIGURE 3.22B). These data show that only cells re-
expressing the FL Atg16L1 rescued LC3 lipidation, while ΔWD Atg16L1 and selected point mutants 
were unable to support any LC3 lipidation in this background (FIGURE 3.22B). This validates our 
conclusions thus far that the WD domain of Atg16L1 and residues F467 and K490 are essential for 
Atg16L1 to function in non-canonical autophagy.   
The role of the Atg16L1 point mutants in a physiological LAP assay was tested next using Atg16L1 
KO GFP-LC3 MEFs re-constituted with FL Atg16L1, ΔWD Atg16L1, Atg16L1 F467A or K490A. As 
expected, the ΔWD Atg16L1 expressing cells did not support LAP (FIGURE 3.8). Furthermore, the 
point mutant Atg16L1 expressing cells also had a significant impairment for LC3 lipidation to 
apoptotic corpse phagosomes (FIGURE 3.23). These data show for the first time that mutating 
F467 or K490 in the WD domain of Atg16L1 does not affect canonical autophagy but impairs LC3 
lipidation to membranes of the endolysosomal system, including LAP.   
133 
 
 
  
 
Figure 3.21: Generating a double knockout Atg13 and Atg16L1 HEK293 cell line to test if 
Atg16L1 mutants respond to non-canonical autophagy. 
A. HEK293 GFP-LC3 Atg13-/- cells generated by Dr Elise Jacquin were used to further knockout 
Atg16L1. Western blots to show Atg13 and Atg16L1 expression.   
B. HEK293 GFP-LC3 Atg13-/- cells generated by Dr Elise Jacquin targeted by CRISPR/Cas9 to 
knockout Atg16L1. Colonies from single cell dilutions were tested for successful Atg16L1 knockout. 
Western blots to show Atg16L1 expression from different populations of cells, unlipidated and lipidated 
(LC3I and LC3II) was also probed where GAPDH is a loading control.  
C. HEK293 GFP-LC3 Atg13-/- cells or HEK293 GFP-LC3 Atg13-/- Atg16L1 -/- cells -/+ 100 µM 
monensin for 30 min. Cells were fixed and  representative confocal images were taken. The scale bar is 5 
µm. 
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Figure 3.22: Non-canonical autophagy response utilising a Atg13 and Atg16L1 knockout cell 
line re-constituted with Atg16L1 mutants.  
A. HEK293 GFP-LC3 Atg13 and Atg16L1 knockout cells re-complemented with Atg16L1 mutants. 
Cells were lysed and a western blot was performed to detect Atg16L1 protein expression levels.  
B. Lysates from HEK293 GFP-LC3 Atg13 and Atg16L1 knockout cells re-complemented with Atg16L1 
mutants treated -/+ 100 nM bafilomycin or 100 µM monensin for 1 h. A western blot was used to detect 
unlipidated and  lipidated LC3 (LC3I or LC3II) and GAPDH was used as a loading control.  
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Figure 3.23: Assessing Atg16L1 WD domain point mutants in response to a physiological LAP 
assay. 
 A. Atg16L1 complemented GFP-LC3 MEF cells that have phagocytosed red-labelled apoptotic cells 
for 14 h and then live confocal microscopy was used to capture representative images. The cropped 
images are of apoptotic corpse phagosomes.   
B.  Quantification of GFP-LC3 positive apoptotic corpse containing phagosomes from A, 20 
phagosomes were counted per experiment, n=3. The error bars represent the standard error of the mean 
(SEM), **P<0.002 ***P<0.0002 (Unpaired Student’s t-test). 
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Finally, similar to the WD domain truncation, the point mutants appear to be competent for 
binding Atg5-12, but defective in recruitment to single membranes.  As shown in FIGURE 3.24A, 
mutating residues F467 and K490 in the C-terminal of Atg16L1 did not affect the formation of the 
conjugation complex with Atg5 and Atg12. However, Atg16L1 is no longer recruited to bead 
containing phagosomes when F467 or K490 have been mutated to alanine (FIGURE 3.24 B AND C). 
Together, these data reveal that F467A and K490A mutations in the WD domain of Atg16L1 
phenocopy its deletion, as they fail to recruit to single membranes in non-canonical autophagy 
and therefore no longer support LC3 lipidation at these membranes. 
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Figure 3.24: Atg16L1 point mutants are able to form a complex with Atg5 and Atg12, but no 
longer recruit to bead containing phagosomes.  
A. Immunoprecipitation (IP) using anti s-tag beads from MEF Atg16L1 -/- cells re-complemented 
with Flag-S tagged FL or Atg16L1 F467A or K490A point mutants.  Cells were treated  for 1 h with 100 µM 
monensin and lysed (total lysate = IN) and from this an IP was performed. A western blot was used to 
detect Atg16L1 or Atg5-12 in the total lysate/ input (IN) and IP sample. The WT cells offer a negative 
control.  
B. HCT116 GFP-LC3 Atg16L1 -/- cells re-complemented with Atg16L1 mutants where 3 µm latex 
beads were added for 4 h -/+ 100 µM monensin for 1 h. The cells were fixed and stained for Atg16L1 and 
images were captured by confocal microscopy. Cropped images show bead phagosomes. The scale bar is 
5 µm.  
C. Quantification of B where cells had been treated with monensin. 100 bead containing 
phagosomes were counted per experiment, and of this, the number that were Atg16L1 and GFP-LC3 
positive were recorded. n=3 the error bars represent the standard error of the mean (SEM),***P<0.0003 
(Unpaired Student’s t-test).  
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3.8 Recruitment of the WD40 Atg16L1 domain. 
 
The data so far show the WD domain, and specific residues within the C-terminal domain, to be 
essential for Atg16L1 recruitment to endolysosomal membranes (FIGURE 3.11 AND 3.24). 
Therefore, it was interesting to look at whether the C-terminal domain alone was sufficient to 
localise to bead containing phagosomes. Using cells stably expressing a Flag-S-tag C-terminal WD 
domain of Atg16L1 (FIGURE 3.25 A), we were unable to detect any recruitment to bead 
containing phagosomes following monensin treatment (FIGURE 3.25 B) This leads to the 
conclusion that the C-terminal domain of Atg16L1 is necessary for recruitment in non-canonical 
autophagy, but is not sufficient.  
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Figure 3.25: WD domain of Atg16L1 is not sufficient to recruit to bead containing 
phagosomes.  
A.  HCT116 GFP-LC3 -/- Atg16L1 cells re-complemented with Flag-S tagged FL Atg16L1 or Atg16L1 
WD C-terminal domain (CTD). Cells were lysed and a western blot was used to detect the S-tag on 
Atg16L1.  
B. HCT116 GFP-LC3 Atg16L1 -/- cells re-complemented with Flag-S tagged FL Atg16L1 or Atg16L1 
WD C-terminal domain (CTD) where 3 µm latex beads were added for 4 h -/+ 100 µM monensin for 1 h. 
The cells were fixed and stained for the S-tag and images were captured by confocal microscopy. Cropped 
images show bead phagosomes. The scale bar is 5 µm.   
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3.9 Analysis of the T300A Atg16L1 Crohn’s disease mutant in non-canonical 
autophagy 
 
The Atg16L1 T300A variant is associated with increased risk of Crohn’s disease [206], which falls 
close to the start of the WD domain (FIGURE 3.26A). The molecular mechanisms of how this 
variant is associated with pathogenesis remains unclear, and considering our data demonstrating 
the importance of this domain in non-canonical autophagy, it was assessed whether the T300A 
variant impacted the pathway.  
HCT116 GFP-LC3 cells stably expressing the Atg16L1 T300A variant were used to compare with 
WT GFP-LC3 cells. Firstly, LC3 lipidation in response to starvation, bafilomycin and monensin was 
analysed by western blotting (FIGURE 3.26 B AND C). As described previously, starvation 
inactivates m-TOR and activates autophagy, bafilomycin blocks autophagic flux and monensin 
both blocks autophagic flux and induces single membrane LC3 lipidation. In WT cells and cells 
expressing the Atg16L1 T300A variant, there is a canonical autophagy response shown by the 
increase in LC3 lipidation upon starvation and upon blocking of the flux (FIGURE 3.26 B and C). 
When the cells were treated with monensin there was robust LC3 lipidation in both cell lines, 
beyond the LC3 lipidation detected from bafilomycin treatment, suggesting that both the WT 
T300 Atg16L1 and the T300A variant support LC3 lipidation to single membranes in non-canonical 
autophagy (FIGURE 3.26 B AND C). In order to visualise LC3 lipidation to non-canonical autophagy 
membranes, the cells were set up to engulf latex beads and then treated with monensin to 
provide the signal for LC3 lipidation to bead containing phagosomes. Both WT HCT116 cells and 
Atg16L1 T300A expressing cells support monensin induced LC3 lipidation to bead containing 
phagosomes to a similar extent (FIGURE 3.26 D AND E). In untreated cells there was a small 
difference in LC3 lipidation to bead containing phagosomes, however, the difference is not 
significant based on statistical unpaired Student’s t-test (FIGURE 3.26E). Both WT Atg16L1 and the 
T300A variant localised to bead phagosomes upon monensin treatment (FIGURE 3.26F). 
Therefore, the T300A variant in Atg16L1, that is associated with Crohn’s disease, does not affect 
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localisation of Atg16L1 to single membrane endolysosomes or its ability to lipidate LC3 to these 
membranes upon monensin stimulation.  
To complete these studies, the same cells were taken to assess whether LC3 lipidation in a 
physiological non-canonical autophagy setting might be affected by the Atg16L1 T300A variant. 
For this we used an entosis assay, where we image cells following a live cell engulfment [153]. 
Figure 3.27A shows an example of fluorescent time-lapse imaging of LC3 recruitment to the 
entotic vacuole housing a live engulfed cell. The number of entotic cell deaths were counted in 
wild type and T300A cells and the presence of LC3 re-localisation to the entotic vacuoles was 
quantified (FIGURE 3.27B). The T300A variant in Atg16L1 does not affect LC3 lipidation in entosis 
and the supports the conclusion that the T300A variant in Atg16L1 is not implicated in non-
canonical autophagy. 
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Figure 3.26: Atg16L1 T300A variant in non-canonical autophagy. 
A. Cartoon of Atg16L1 where the asterisk shows where the T300A mutant falls. 
B. HCT116 GFP-LC3 cells expressing WT Atg16L1 or the T300A variant were starved or treated with 
100 nM bafilomycin or 100 µM monensin for 1 h. Cells were lysed and a western blot was used to detect 
unlipidated and  lipidated LC3 (LC3I or LC3II) and GAPDH was used as a loading control.  
C. Quantification of the ratio of LC3II/I using ImageJ from B. This was done from n=2 and the 
treated samples were plotted as an increase from the untreated LC3II/I ratio.  
D. HCT116 GFP-LC3 cells expressing WT Atg16L1 or the T300A variant where 3 µm latex beads were 
added for 4 h -/+ 100 µM monensin for 1 h. The cells were fixed and stained for LAMP1 and images were 
captured by confocal microscopy. Asterisks mark the bead containing phagosomes and the arrows 
indicate GFP-LC3 positive bead containing phagosomes.  
E. Quantification of D, 100 LAMP1 positive bead containing phagosomes were counted per 
experiment and the number of GFP-LC3 positive beads was recorded. n=3 the error bars represent the 
standard error of the mean (SEM), NS= not significant (Unpaired Student’s t-test).  
F. HCT116 GFP-LC3 cells expressing WT Atg16L1 or the T300A variant where 3 µm latex beads were 
added for 4 h -/+ 100 µM monensin for 1 h. The cells were fixed and stained for Atg16L1 and images were 
captured by confocal microscopy. Asterisks mark the bead containing phagosomes that have been 
cropped and zoomed. The arrow head indicates GFP-LC3 and Atg16L1 positive phagosomes.  
143 
 
  
 
Figure 3.27: Live entosis assay with WT and T300A Atg16L1GFP-LC3 expressing cells. 
A. Representative stills from live cell imaging of entosis looking at GFP-LC3 fluorescence and DIC in 
HCT116 GFP-LC3 cells with WT Atg16L1 or stable expression of the T300A Atg16L1 variant. The asterisk 
marks the inner cell and the arrow head shows the GFP-LC3 on the entotic vacuole. The first panel shows 
the cell in cell that goes onto the middle panel where GFP-LC3 gets transiently recruited and in the final 
panel, after the LC3 has left, the inner cell dies. 
B. Quantification of A from n=1 where videos were analysed and counted for entotic events and the 
percentage of these events that had transient LC3 recruitment was plotted on a graph.  
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3.10 Functional implications of Atg16L1 mediated non-canonical LC3 lipidation 
 
The cellular system characterised so far defines a novel strategy to separate canonical autophagy 
from non-canonical autophagy through the dependence of the WD domain of Atg6L1 in LC3 
lipidation to endolysosomal membranes. Therefore, this provides a tool to find novel non-
canonical autophagy processes. This rationale led to a collaboration with Dr Rupert Beale’s group 
(University of Cambridge), who previously reported that Influenza A (IAV) infection leads to LC3 
lipidation at the plasma membrane and perinuclear region, dependent on the viral proton 
channel protein M2 [87]. Interestingly, this LC3 lipidation is independent of FIP200, suggestive of 
an involvement of non-canonical autophagy [87]. Thus, using the cellular systems outlined so far 
it was tested whether Influenza activates non-canonical autophagy.  
Our lab have previously implicated the importance of proton gradients in LC3 lipidation to single 
membranes induced by monensin and the VacA toxin [98]. Accordingly, one hypothesis is that the 
M2 proton channel offers a related mechanism that may induce non-canonical autophagy. 
However, there have been conflicting reports as to whether this LC3 lipidation depends on the 
proton channel activity of M2 [88, 224]. Therefore, the first experiments performed in Rupert 
Beale’s lab were to uncover further evidence for the involvement of M2 in Influenza A induced 
LC3 lipidation. This used the antiviral drug amantadine, which is a selective blocker of the M2 
proton channel in sensitive Influenza strains such as Udorn (Mud), but not in a laboratory-
adapted Influenza A virus (IAV) PR8 strain (amantadine resistant). Consistent with a role for the 
M2 protein, Beale and colleagues found that LC3 re-localisation in response to PR8 infection was 
not affected by amantadine, while it was blocked when using the sensitive Mud strain (FIGURE 
3.28A).  
Next HCT116 cells expressing various Atg16L1 mutants were tested for the effect of IAV infection 
on GFL-LC3 localisation. Interestingly, it was found that IAV induced LC3 re-localisation dependent 
on the WD domain of Atg16L1 and the key residue K490 (FIGURE 3.28B). 
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Therefore, the cellular system to separate canonical and non-canonical autophagy has uncovered 
that indeed IAV infection induces LC3 lipidation associated with non-canonical autophagy. This 
was further supported by western blot data. Cellular lysates were taken from the re-
complemented HCT116 Atg16L1-/- cells by Dr Rupert Beale, and the lysates and western blots 
were directly run as part of this project. The cells with the Atg16L1 C-terminal deletion induce less 
LC3 lipidation in response to IAV infection (FIGURE 3.28C). These data suggests there must be a 
role for non-canonical autophagy in the cellular response to IAV infection; this collaboration is 
ongoing to gain further insights into the mechanism and implications of these data. 
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Figure 3.28: Influenza A infection is dependent on the viral M2 protein and activates LC3 
lipidation through a non-canonical autophagy pathway.  
A. Confocal images of HCT116 GFP-LC3 cells infected at MOI 1 with IAV strains PR8 (amantadine 
resistant)or MUd (amantadine sensitive). Amantadine was added 3 h post infection. Samples were fixed 
at 16 h post infection and stained for M2 (red) and with DAPI. Scale bar is 10 µm. 
B. Confocal images of GFP-LC3 transduced WT or Atg16L1 -/- HCT116 cells re-complemented with 
the indicated Atg16L1 mutants. Samples were fixed at 16 h post infection with IAV PR8 at MOI of 5 and 
stained for M2 (red). Scale bar is 20 µm. 
C. Influenza-infected GFP-LC3 transduced WT or Atg16L1 -/- HCT116 cells re-complemented with 
the indicated Atg16L1 mutants. Lysates were taken 16 h post infection with PR8 IAV and western blotting 
was used to detect unlipidated and lipidated LC3 (LC3I or LC3II). GAPDH was used as a loading control. 
*A and B generated by Dr Rupert Beale et al and C was generated in collaboration.   
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3.11  Discussion  
 
This chapter has outlined a novel mechanism where Atg16L1 recruits to single endolysosomal 
membranes to lipidate LC3 in non-canonical autophagy, following engulfment processes such as 
LAP, or driven by lysosomotropic drugs. This project shows that the C-terminal WD domain of 
Atg16L1 is necessary, but not sufficient, for targeting Atg16L1 to single membrane 
endolysosomes, where it forms the complex with Atg5-Atg12 to lipidate LC3. This chapter has 
further identified novel sites within the top face of the WD C-terminal domain required for the 
non-canonical activity of Atg16L1.  
This chapter supports published data showing that the WD domain of Atg16L1 is not required for 
canonical autophagy [197] and the lack of the WD domain does not affect Atg16L1 ability to form 
the functional LC3 lipidation complex [209]. Interestingly, the WD domain of Atg16L1 is absent in 
yeast [25] and therefore it could be that higher eukaryotes have evolved to carry out non-
canonical autophagy.   
Data in this chapter also support published work on the FBD domain of Atg16L1, housing the 
FIP200 binding sites, that showed if this domain is deleted there is inefficient autophagy [32, 
189].Furthermore, this work has proven the FBD domain to be dispensable for LC3 lipidation in 
non-canonical autophagy, strengthening the existence of a distinct mechanism for Atg16L1 
recruitment during non-canonical autophagy. WIPI2b, a fundamental regulator of Atg16L1 
recruitment in canonical autophagy [33], was also shown to be absent from endolysosomal 
membranes. This is further supported by experiments that show that, unlike canonical 
autophagy, PI3P generation and VPS34 activity are not required for LC3 lipidation in non-
canonical autophagy. These findings could appear contradictory to recent work showing that LAP 
is dependent on Rubicon-mediated VPS34 activity and PI3P generation on the phagosome 
membrane [120]. However, it is possible that in the context of phagocytosis, VPS34 and PI3P are 
required at an upstream step to mature the phagosome to a state competent for LC3 lipidation, 
without being directly involved in Atg16L1 recruitment. This idea is supported by the experiments 
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using the ionophore monensin that show LC3 lipidation to be independent of VPS34 activity. This 
could be because the drug bypasses the PI3P dependent maturation of the single membrane, as 
monensin targets already mature endolysosome compartments for LC3 lipidation.  Therefore, 
there may be a distinct signalling pathway to PI3P generation that is required more directly in 
Atg16L1 recruitment to endolysosomal membranes.  
It is now accepted that there are non-autophagy roles for many autophagy proteins and that LC3 
lipidation is involved in more than just autophagy. Furthermore, due to overlap of some 
autophagy proteins in both canonical and non-canonical autophagy pathways it is possible that 
some processes historically attributed to canonical autophagy may actually have more relevance 
to non-canonical autophagy. Therefore, the work in this chapter has led to a clear genetic system 
that can separate canonical from non-canonical autophagy that will help to uncover novel 
pathways implicated in non-canonical autophagy. This rationale has already uncovered that 
Influenza A activates LC3 lipidation through non-canonical autophagy, rather than activating LC3 
lipidation to autophagosome.  
This clear separation of autophagy from non-canonical autophagy using Atg16L1 is the first clean 
system to study one pathway without the other. Previous methods focused on comparing cells 
deficient in canonical autophagy (knockouts for ULK1 complex proteins) to cells deficient for both 
pathways (knockouts for Atg proteins in involved in LC3 lipidation) and inferring a role for non-
canonical autophagy [94, 96]. Alternatively, in the context of phagocytosis, Rubicon has been 
used to separate canonical autophagy and LAP. This method focused on the different roles of 
Rubicon in the two distinct pathways: Rubicon is a negative regulator of autophagy but an 
essential component for LAP [120]. Thus, while knocking out Rubicon does provide a model 
deficient for LAP, it is not totally specific, as loss of Rubicon may have additional effects on 
endosomal maturation and canonical autophagy.  In addition, Rubicon is linked to PI3P signalling 
and, as touched on before, this signalling is specific to LAP. The work in this project suggests there 
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must be distinct signals that are more directly involved in Atg16L1 recruitment to endolysosomal 
membranes and can be applied to all non-canonical autophagy pathways.  
Therefore, this project offers an improved system where the C-terminal WD truncation or point 
mutations in ATG16L1 cause the cells to be deficient in non-canonical autophagy while remaining 
competent for canonical autophagy. Additional benefits are that Atg16L1 is a well-characterised 
autophagy protein and the C-terminal deletion of Atg16L1 affects all types of non-canonical 
autophagy processes including pharmacological and physiological processes.  
The WD domain of Atg16L1 which is essential for LC3 lipidation in non-canonical autophagy, 
would be expected to be involved in protein-protein interactions, although between different WD 
domains there is not a huge amount of homology. The published structure and directed 
mutagenesis studies [192, 195] could help to unravel how the WD domain of Atg16L1 is acting in 
the recruitment of Atg16L1 to single endolysosomal membranes. Further work looking at Atg16L1 
binding partners using the Atg16L1 truncation and point mutation is described in chapter 5.  
It will be intriguing to uncover if there is one mechanism of recruitment of Atg16L1 through the 
WD domain or whether there are process-specific mechanisms. For instance could it be that the 
mechanism for Atg16L1 recruitment to phagosomes is different to its recruitment to entotic 
vacuoles. Currently, these data show that the sites identified in Atg16L1 are important in all 
tested examples of non-canonical autophagy suggestive of a common mechanism and the domain 
could act  as a molecular hub for non-canonical autophagy processes. 
It is interesting to note that the WD domain of Atg16L1 alone is not sufficient for its recruitment. 
This may not be surprising however, as Atg16L1 normally acts as a dimer and the WD domain 
alone lacks the dimerization motif. Experiments could be done in the future to force dimerization 
of the WD domain, through the use of a GST recombinant version of the protein, to test whether 
this enables the domain to recruit to single-membrane compartments. Further, the WD domain 
alone is unable to bind with ATG5, which has been shown to play a role in recruitment of the 
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Atg16L1 complex to autophagosomes [25]. Consistent with this, our preliminary work, using an 
Atg16L1 mutant that lacks the N-terminal domain and can no longer complex with Atg5-12, hints 
that the N-terminal domain of Atg16L1 is also essential for its recruitment to single-membrane 
compartments during non-canonical autophagy (data not shown). There also may be other 
essential N-terminal Atg16L1 binding motifs that assist Atg16L1 recruitment in non-canonical 
autophagy and therefore this needs to be considered in future work.  
The WD domain of Atg16L1 has previously been implicated in the activation of an unconventional 
autophagy pathway through its interaction with TMEM59 and TMEM166/EVA1 [200, 202]. Both 
TMEM proteins have the same binding motif that interacts with the WD domain of Atg16L1 [202].  
However, as yet, it is not clear whether these represent true non-canonical autophagy pathways 
that fit in with the data presented here. The TMEM59 dependent autophagy is implicated in the 
role of Atg16L1 in Crohn’s disease [214]. The Crohn’s disease-associated point mutation, T300A, is 
located near the C-terminal domain of ATG16L1 and has been implicated in affecting autophagy 
processes. One mechanism is that, under stress conditions, the T300A Atg16L1 variant is more 
susceptible to caspase 3 cleavage and therefore the cell has less functional Atg16L1 [209, 214]. 
The cleaved Atg16L1 product, that lacked the WD domain, decreased TMEM59 dependent 
autophagy that is reliant on the WD domain of Atg16L1 [214]. However, as part of this project 
replication of apoptosis induced caspase cleavage of Atg16L1 was performed in accordance to the 
methods in the paper by Lassen et al [209]. The controls showed that apoptosis had been induced 
and caspase 3 had been cleaved however, there was no detectable Atg16L1 cleavage (data not 
shown).  Furthermore, this project showed that the Atg16L1 T300A variant had no significant 
effect on LC3 lipidation in non-canonical autophagy. These results support previously reported 
data where the T300A mutation was shown not to affect LAP [120]. 
The significance of LC3 lipidation, or lack of LC3 lipidation ,in non-canonical autophagy has 
previously been looked at with regard to impaired degradation of phagosome content and the 
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homeostatic consequences of this [225]. This chapter further shows Influenza A infection to be 
involved in non-canonical autophagy, but how this signalling pathway is involved in the Influenza 
infection model or host defence is yet to be elucidated; the collaboration with Dr Rupert Beale is 
ongoing. The function of LC3 lipidation in non-canonical autophagy is explored further in 
following chapters and is the remit of future work.  
This project has uncovered a powerful method to study the function of non-canonical autophagy 
without affecting canonical autophagy.  
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4 Results: In vivo functions of non-canonical autophagy: Atg16L1 
mutant mouse models.  
 
4.1 Introduction   
 
4.1.1  Atg16L1 mouse models 
 
The data presented so far show that the Atg16L1 WD domain, and specific sites within it, are 
indispensable for LC3 lipidation to endolysosomal membranes, but not required for canonical 
autophagy. As such, we have identified a genetic manipulation of Atg16L1 to separate LC3 
lipidation in canonical and non-canonical autophagy processes. 
In this chapter, this system is exploited to investigate the phenotypic consequences of inhibiting 
LC3 lipidation during non-canonical autophagy through in vivo studies, guided by the previous 
results. While the full extent of non-canonical autophagy function in cells is not completely 
understood, it has been implicated in a number of immune-related processes including pathogen 
clearance [109, 112] and presentation of exogenous antigens [112, 176]. Commonly this has been 
achieved by inhibiting the LC3 conjugation machinery, for instance knocking out Atg5 or Atg7. To 
begin to look at the functional consequence of impairing non-canonical autophagy more 
specifically, we have now developed studies of Atg16L1 mutant mice instead. 
Firstly, in collaboration with Dr Tom Wileman’s lab, from the University of East Anglia, a mouse 
model expressing the Atg16L1 1-230 truncation (E230), in essence a WD domain deletion, has 
been produced and analysed. The Atg16L1 1-230 construct was tested in vitro and in primary cells 
from WT or E230 mice, to look at the role of non-canonical autophagy in MHC II antigen 
presentation.  
Alongside this, using CRISPR/Cas9 technology, this project aimed to create new mouse models of 
Atg16L1 ΔWD and the Atg16L1 K490A variant, to complement the in vitro data shown in the 
previous chapter.  
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4.1.2 CRISPR technology and in vivo application 
 
A huge advance in the field of genomics has come with the the CRISPR Cas system, a highly 
efficient and precise technique, to target and edit mammalian genomic DNA, which has 
revolutionised the field of in vivo modelling, as editing the genome is now relatively fast and 
cheap. This technology came from the microbial adaptive immune response system that uses 
CRISPR to target and cleave foreign DNA.  
The type II system is the best characterised and uses the Cas9 nuclease from Streptococcus 
pyogenes, this is the system used in this project. The Nature protocols publication by Ran et al 
was used to direct the design of this part of the project [226]. The Cas9 enzyme is targeted to 
DNA via a short approximately 20 nucleotide guide sequence (crRNA), and requires a repetitive 
scaffolding sequence called the trans-activating tracrRNA, that positions the Cas9 nuclease to the 
targeted region of DNA to be cleaved. These components, if altogether on a plasmid, are known 
collectively as the sgRNA. The individual components can also be added separately as an 
alternative method. The Cas9 nuclease cleavage occurs three nucleotides upstream of a 
protospacer adjacent motif (PAM) sequence, the PAM for Cas9 is 5’ –NGG. The DNA is left with a 
double strand break (DSB) and the cell’s default would be to repair the DSB via non-homologous 
end joining (NHEJ) however, this is error prone and undirected. Therefore, usually homology 
directed repair is utilised, this concept is summarised in the simplified cartoon (FIGURE 4.1). This 
is where a repair template is provided that has two homology arms either side of the DSB and 
then a sequence in between these arms that will direct the editing of the DNA.  
This process of genome editing can be done in mouse embryonic stem cells to produce transgenic 
mice (FIGURE 4.2). The CRISPR/Cas9 reagents are transfected into the ES cells and these cells are 
then diluted to single cells, where the colonies are eventually screened for edited DNA. The 
selected ES cells are then injected into mice blastocysts resulting in a mix of cells with WT DNA 
and cells with the edited DNA. This gives rise to chimeric pups where hopefully the germline cells 
have edited DNA and therefore can breed to produce heterozygote mice (FIGURE 4.2). This 
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process involves a long screening step and success of germline transmission at the chimera stage 
can require multiple attempts [227]. It is estimated 12 months to produce a transgenic mouse 
using ES cell editing [227]. An alternative and quicker method, estimated closer to 7 months, is 
taking the CRISPR/Cas9 reagents and injecting them into the mouse zygote, this can directly 
produce offspring with edited DNA (FIGURE 4.2) [227]. Both methods were used as part of this 
project and this work was done with close supervision of Dr Dominik Spensberger (who at the 
time was Head of the Gene Targeting facility at The Babraham Institute).  
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Figure 4.1: Schematic to summarise the use of CRISPR/CAS9 to mutate Atg16L1. 
Cartoon to show how the nuclease Cas9 was targeted to Atg16L1 to introduce a double strand break 
(DSB). The targeting was achieved through a specific guide sequence that targets just upstream of the 
protospacer adjacent motif (PAM). The DSB is then repaired using donor mediated homologous 
recombination. In this diagram, the red box is depicting the added DNA sequence that in this case is a 
termination sequence, when the sequence is transcribed and translated, a truncated Atg16L1 protein will 
be produced. This same principal was used for producing the Atg16L1 with a single point mutation.  
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Figure 4.2: Gene editing workflow in mouse ES cells compared to mouse zygotes. 
Adapted from [227]: Two methods for producing transgenic mice using CRISPR/Cas9. This can be done in 
ES cells were the sgRNA is transfected into the mouse ES cells and the transfected cells are selected. The 
selected cells are then diluted into single cells and the colonies are expanded and screened for edited 
DNA. Edited ES cells are then injected into a blastocyst to get a mix of WT and edited DNA. The blastocyst 
is then transferred into a pseudo pregnant mouse and from this chimeric mice are born, this is the 
founder animal. The chimeras will have varying degrees of cells with edited DNA and the edited DNA 
needs to be present in the germline to be passed on. The chimeras are bred and if there is germline 
transmission heterozygote mice are produced and these can be bred to get homozygote mice. 
Alternatively CRISPR reagents can be injected into the mouse zygote and the zygote can be transferred to 
a pseudo pregnant mouse and from this a heterozygote or homozygous pup for the DNA could be born. 
There is still a chance that not all of the cells in the offspring will have the edited DNA this is what mosaic 
means. Therefore, founder mice must be bred to get heterozygotes and then bred again to get 
homozygotes.  
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4.2 Characterising Atg16L1 1-230 mouse model from collaborators (Tom Wileman 
University of East Anglia).  
 
4.2.1 Atg16L1 1-230 deletion 
 
Firstly, it is important to note, that the Atg16L1 1-230 (E230) construct from Dr Tom Wileman is a 
larger C-terminal deletion than the Atg16L1 1-336 ΔWD that has featured in the project so far. 
The cartoon domain structure of Atg16L1 depicts how much of At16L1 has been deleted in the 1-
230 construct compared to the FL Atg16L1 (FIGURE 4.3A), where the ∆WD Atg16L1 mutation is 1-
336 that we have characterised so far. The larger Atg16L1 E230 C-terminal deletion removes the 
middle region of Atg16L1, which could therefore also interfere with normal autophagy responses 
in cells. Nevertheless, whilst waiting for the generation of mouse models for Atg16L1 1-336 and 
Atg16L1 K490A that are more refined, this was a good model to test whether the E230 mice were 
deficient for LC3 lipidation associated with non-canonical autophagy and to develop assays.  
4.2.2 Atg16L1 1-230: in vitro validation 
 
The Atg16L1 E230 construct was transiently transfected into HCT116 GFP-LC3 Atg16L1 -/- cells in 
order to test the function of this truncated Atg16L1 in vitro. FIGURE 4.3B shows the successful 
transfection of Atg16L1 FL or 1-230 protein at similar levels. The transfected HCT116 cells were 
treated with bafilomycin, to inhibit autophagic flux, and with monensin, to inhibit autophagic flux 
but also lipidate LC3 to swollen lysosomal compartments. Western blot analysis from three 
independent experiments showed that the cells expressing the Atg16L1 1-230 construct support 
LC3 lipidation in response to bafilomycin but there is no additional LC3 lipidation after treatment 
with monensin (FIGURE 3.4C), indicating effective canonical autophagy but defective non-
canonical autophagy.  
Transiently transfected cells were also analysed by microscopy to look at the LC3 lipidation 
response as result of monensin treatment. The cells expressing the FL Atg16L1 have GFP-LC3 
localisation to swollen lysosomal compartments (FIGURE 4.3D). However, in the cells expressing 
the Atg16L1 E230 construct the cells were only able to form GFP-LC3 puncta, suggesting they still 
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support some canonical autophagy but the GFP-LC3 was not forming larger ring like structures 
indicative of LC3 lipidation to swollen endolysosomal compartments (FIGURE 4.3D). Further 
analysis of primary cells from E230 animals (FIGURE 4.4B), including work done in Dr T. Wileman’s 
lab, are consistent with these data that the Atg16L1 230 still supports canonical autophagy.  
Further evidence supporting the lack of non-canonical autophagy in E230 Atg16L1 expressing cells 
is shown using the latex bead assay and monensin to stimulate LC3 lipidation to bead containing 
phagosomes (FIGURE 4.3E). The cells expressing the FL of Atg16L1 supported monensin induced 
LC3 lipidation however, there was no monensin induced LC3 lipidation to beads in cells re-
expressing E230 Atg16L1 (FIGURE 4.3E). Therefore, just like the Atg16L1 ΔWD characterised in 
the previous chapter, the Atg16L1 1-230 truncation does not support non-canonical autophagy. 
The 1-230 Atg16L1 truncation also seems to support some canonical autophagy, which is 
supported by results from the collaborating lab (data not shown). 
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Figure 4.3: In vitro characterisation of Atg16L1 1-230, C-terminal deletion. 
A. Cartoon of Atg16L1 domain structure showing the full length (FL) structure compared to the 
Atg16L1 1-230 truncation.  
B. HCT116 GFP-LC3 Atg16L1 -/- cells transiently transfected using Lipofectamine to express FL 
Atg16L1 or Atg16L1 1-230 C-terminal deletion, cells were lysed and a western blot was performed to 
analyse the expression of Atg16L1. 
C. HCT116 GFP-LC3 Atg16L1 -/- cells transiently transfected using Lipofectamine to express FL 
Atg16L1 or Atg16L1 1-230 C-terminal deletion were treated -/+ 100 nM bafilomycin or 100 µM monensin 
for 1 h. Cells were lysed and a western blot was done to analyse unlipidated and lipidated LC3 (LC3I and 
LC3II). GAPDH was used as a loading control.  
D. HCT116 GFP-LC3 Atg16L1 -/- cells transiently transfected using Lipofectamine to express FL 
Atg16L1 or Atg16L1 1-230 C-terminal deletion -/+ 100 µM monensin for 1 h and then fixed and imaged 
via confocal microscopy to look at GFP-LC3. Zoomed images represent the GFP-LC3 localisation upon 
monensin treatment. The scale bar is 5 µm.  
E. Transient transfection of HCT116 GFP-LC3 Atg16L1-/- cells with the FL Atg16L1 or the 1-230 
construct. Cells engulfed 3 µm beads for 4 h -/+ 100 µM monensin for 1 h and then the cells were fixed 
and stained for LAMP1. Cells were imaged via confocal microscopy to look at GFP-LC3 and LAMP1. 
*Atg16L1 1-230 constructs were provided by Dr Tom Wileman.  
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4.3 Using Atg16L1 1-230 to investigate non-canonical autophagy phenotypes.  
 
4.3.1  Atg16L1 E230 mice: LC3 lipidation and LAP 
 
The Wileman lab produced homozygote Atg16L1 E230 mice, which were viable and had no 
apparent phenotype in terms of their appearance compared to the WT mice. To explore non-
canonical autophagy in these mice, LC3 lipidation and LAP were examined in bone marrow 
derived dendritic cells (BMDCs) (FIGURE 4.4C). Western blotting confirmed the expression of the 
truncated form of Atg16L1 in cells from the E230 mice (FIGURE 4.4A). The BMDCs were first 
tested for their response to canonical autophagy stimulation, by using PP242, or for non-
canonical autophagy, by monensin treatment (FIGURE 4.4B). BMDCs from both WT and E230 
mice respond to canonical autophagy, PP242 has induced LC3 lipidation (FIGURE 4.4B). However, 
in the E230 BMDCs there is no longer a robust response of LC3 lipidation after monensin 
treatment (FIGURE 4.4B), consistent with a defect in non-canonical autophagy. The BMDCs were 
further tested by immunofluorescence to look at LC3 lipidation to zymozan containing 
phagosomes (FIGURE 4.4C). It was found that BMDCs from the WT mice supported LAP, 
evidenced by LC3 positive zymozan containing phagosomes, however, the BMDCs from the E230 
mice were deficient for LAP (FIGURE 4.4C). This is an important observation in which a novel 
mouse model is described which is specifically deficient in non-canonical autophagy.  
4.3.2 Atg16L1 E230 mice: antigen presentation 
 
BMDCs are professional antigen presenting cells. Autophagy proteins have previously been 
implicated in antigen presentation but the specific role of non-canonical autophagy is unclear. 
The E230 Atg16L1 in vivo system offered a way to address this question. Isolated mouse BMDCs 
were used to look at the presentation of exogenous antigen on MHC class II. This was done with 
guidance and materials from Dr Michelle Linterman’s lab, and experiments and analysis were 
done together with Dr Elise Jacquin, a former Post Doc from the lab. BMDCs were incubated with 
the GFP-Eα peptide, a fluorescent antigen (kindly donated by Dr Michelle Linterman), for 24 h. In 
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this time antigen is taken up by cells and processed for loading on MHC II for subsequent 
presentation at the cell surface. Cells were then prepared for analysis by flow cytometry. Single 
cell dendritic populations were gated by CD11c and CD11b positivity (FIGURE 4.5A). An antibody 
that detects the Eα peptide in complex with MHC II, YAe, was used to measure presentation 
within this population (FIGURE 4.5B) [228]. Strikingly, while WT BMDCs showed a dose dependent 
increase in antigen presentation, there was a significant defect in E230 BMDCs (FIGURE 4.5B). 
This defect was not due to a failure in uptake of the Eα peptide, as both WT and E230 cells 
displayed similar GFP signal (FIGURE 4.5C). Indeed, E230 BMDCs displayed increased GFP signal 
compared to WT cells, which could be explained by the fact the antigens are not being processed 
as efficiently in these cells and therefore have higher retention of the GFP signal (FIGURE 4.5C). 
These data demonstrate a functional consequence of inhibiting non-canonical autophagy through 
the targeting of the ATG16L1 WD C-terminal domain. It verifies a role for non-canonical 
autophagy in antigen presentation and provides a clean system with which to study this process. 
In the future these experiments will be repeated with the other refined mouse models expressing 
Atg16L1 1-336 ∆WD or the Atg16L1 point mutant K490A. 
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Figure 4.4: BMDCs from WT or E230 Atg16L1 mice, expression and LAP.  
A. Cell lysates were taken from WT and E230 Atg16L1 Bone marrow derived dendritic cells (BMDCs) 
and western blots were performed to detect Atg16L1. Arrows indicate Atg16L1, and asterisks mark non‐
specific band. 
B. Cell lysates were taken from WT and E230 Atg16L1 BMDCs -/+ 1 µM m-TOR inhibitor PP242 or 
100 µM monensin for 1 h. Western blots were done to analyse unlipidated and lipidated LC3 (LC3I and 
LC3II). GAPDH was used as a loading control, n=2.  
C. WT or E230 Atg16L1 BMDCs were left to engulf zymozan for 15 min and then the cells were fixed 
and stained for LC3 and DAPI. Confocal images were captured and the zoomed insert is a zymozan 
containing phagosome. Scale bar: 20 μm. 
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Figure 4.5: The C-terminal domain of Atg16L1 is essential for exogenous antigen 
presentation. 
A. Gating strategy for WT and E230 Atg16L1 bone marrow derived dendritic cells (BMDCs). The first 
plot is the forward and side scatter in order to gate on the cellular population, this excludes any debris. 
Then the side scatter and width of particles was plotted in order to gate just to obtain data from single 
cells. Finally gating was done to select the double positive population expressing CD11b and CD11c  to 
carry out the exogenous antigen presentation analysis just on the BMDC population.  
B. Mean fluorescent intensity (MFI) flow cytometry analysis of Y‐Ae an antibody that recognises 
MHC II in complex with the Eα-GFP antigen in wild‐type (open circles) and E230 (filled circles) BMDCs 
exposed to different concentrations of Eα‐GFP. Data are presented as mean ± SD from four replicates. 
Data are representative of three independent experiments **P < 0.002.  
C. Mean fluorescent intensity (MFI) flow cytometry analysis of Eα‐GFP in wild‐type (open circles) 
and E230 (filled circles) BMDCs exposed to different concentrations of Eα‐GFP. Data are presented as 
mean ± SD from four replicates. Data are representative of three independent experiments***P < 0.0001 
(Student's t‐test). 
*Reagents and guidance from Dr Michelle Linterman. Experiments done together with Dr Elise Jacquin. 
Analysis performed by Dr Elise Jacquin.  
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4.4 Using CRISPR/Cas9 to generate an Atg16L1 1-336 mouse model.  
 
CRISPR/CAS9 technology was exploited to generate a mouse model of the Atg16L1 1-336 C-
terminal WD domain deletion that matches the characterised Atg16L1 in vitro system described 
in the previous chapter. The diagram in the introduction to this chapter has a cartoon overview of 
how the CRISPR/Cas9 system was utilised (FIGURE 4.1).  
4.4.1 CRISPR Cas 9 guides 
 
First of all, using the mouse sequence of Atg16L1, two guide sequences were designed using the 
online tool DNA 2.0 (now ATUM). These guide DNA sequences were cloned into a GFP Cas9 
vector, PX458, that encodes the Cas9 and the sequence that allows the guide and enzyme to 
complex to target to the DNA. The plasmid was transfected into mouse ES cells, the cells were 
then sorted by flow cytometry (with assistance from the Flow Cytometry facility at The Babraham 
Institute) based on their GFP expression. 
4.4.2 Surveyor assay 
 
DNA was isolated from the sorted population of cells to check the efficiency of the targeting and 
cutting of Cas9 by the chosen guides. This was done using a surveyor assay. FIGURE 4.6 describes 
the principle of this assay.  
Both guide sequences specifically target Cas9 to nick the DNA just after exon 10 of Atg16L1 
(FIGURE 4.2 and 4.7). The DNA cleavage products were separated at the expected size on an 
agarose gel showing both guides targeted the Cas9 to the precise location on the DNA to cause a 
DSB (FIGURE 4.7). There was roughly 40% cutting efficiency, where the intensity of the uncleaved 
WT band was compared to the intensity of the bands of the cleaved products (analysis not shown 
from FIGURE 4.7). Guide sequence two was selected, as it was the better sequence to design the 
donor template to repair the DNA double strand break.  
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Figure 4.6: Surveyor Assay from IDT to test efficiency of guide targeted Cas9 DNA cutting. 
Adapted from https://thegenetherapynotes.wordpress.com/2016/02/15/surveyor-nuclease/, a 
schematic to explain how the surveyor assay works. Where cells transfected with the Cas9 and guide 
sequence will have a mixed population of WT DNA and DNA that has been cleaved by Cas9. Then the cell 
will have randomly repaired the double strand break to form an indel. DNA was extracted from the cells 
and PCR amplified the region of interest. The DNA was de-natured and re-hybridised to get a mixture of 
WT DNA and mismatched DNA, the mismatched DNA was cleaved by the surveyor nuclease and the DNA 
could then be analysed on an agarose gel to work out how efficiently and precisely the guide was 
targeting the Cas9 enzyme. 
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Figure 4.7: Validating the guide sequence to target Atg16L1 to produce a WD domain 
deletion. 
This figure outlines the two guide sequences highlighted in light blue and the red is the proto spacer motif 
(PAM) –NGG, this should direct the Cas9 to form a DSB in the DNA, 3 nucleotides from the PAM. The 
guides were tested using a surveyor assay as described in the previous figure and in the methods. The 
arrows indicate the nuclease cleaved DNA that correspond to the expected band sizes outlined to the side 
of the agarose gel picture. 
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4.4.3 Repair 
 
The repair donor sequence was designed based on the theory of homology directed repair, where 
the Cas9 induced double strand break is repaired through homologous recombination. The donor 
repair sequence has homology to the sequence either side of the edit site, but it also has 
additional nucleotides for the addition of stop codons and a PolyA tail (FIGURE 4.8). This should 
result in a genome edit that should encode Atg16L1 1-336 ΔWD.  
4.4.4  Zygote injection 
 
The donor repair sequence was ordered as PAGE purified single stranded (ss) DNA. The guide 
sequence was also ordered in ssRNA format alongside a TracrRNA sequence that is responsible 
for forming the secondary structure needed for the guide sequence and Cas9 to form a complex 
to target the DNA. Dr Dominik Spensberger injected these reagents alongside recombinant Cas9 
protein into mouse zygotes to directly edit mouse genomic DNA in the zygote (FIGURE 4.2). 33 
pups were born following these injections.  
4.4.5  Genotyping 
 
Ear clips were taken by staff at the BSU (Biological support unit, Babraham Institute) and then the 
DNA was isolated to genotype the pups. PCR was done to amplify the region of the Atg16L1 gene 
that was targeted for editing. FIGURE 4.8 shows the primers that were designed and the 
potentially inserted sequence that would be present in genome edited pups. The edited DNA 
sequence should have inserted an extra Bfa1 restriction site, therefore the amplified DNA was 
taken and a digest was done using Bfa1 (FIGURE 4.8 AND 4.9). Through this method all pups 
looked WT, this was confirmed by sequencing (FIGURE 4.9). The mouse zygote injections using 
CRISPR/Cas9 was a relatively new technology to the Institute at this time and therefore it was 
advised by Dr Dominik Spensberger to switch to using the CRISPR technology to edit mouse ES 
cells (FIGURE 4.2).  
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Figure 4.8: Original sequence and genotyping strategy for Atg16L1 truncated DNA. 
Nucleotide sequence of the Atg16L1 targeted region, showing the forward and reverse primers used to 
amplify the region of interest. The sequence in red is the “edited” inserted stop codons and poly A. The 
blue italics shows where the Bfa1 restriction enzyme will cut, where the edited sequence gives an extra 
cut site. Below is a schematic of the sequence where the red box is the inserted stop sequence and the 
table describes the size of the products expected for genotyping. 
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Figure 4.9: Original genotyping of pups from the direct zygote injections for edited Atg16L1 
sequence. 
A. DNA was isolated from 33 ear clips and PCR was used to amplify the DNA around the targeted 
site of Atg16L1 where WT DNA would give a product of 344 base pairs (bp) and edited DNA would give a 
product of 362 bp. The first lane is a negative control (PCR without DNA) and WT is DNA from WT mouse 
genomic DNA. 16-23 are representative of all PCR product results when run on a 2% agarose gel.  
B. The PCR product from A was PCR purified and a DNA digest was set up with or without the 
restriction enzyme Bfa1. The WT PCR product should be cut to give a 315bp product and 2x < 15 bp 
fragments. The edited Atg16L1 PCR product should give products at 232 bp and 101 bp.  
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4.4.6 Alternative strategy: injection of mouse ES cells 
 
The project switched to using CRISPR Cas9 technology in mouse ES cells to be able to screen for 
“edited” cells to then implant into a mouse blastocyst. The design for the edited sequence was 
also slightly different, switching to inserting a triple stop codon and creating a new restriction site 
for Bcl1, specific to the edited DNA sequence (FIGURE 4.10).  
Dr Dominik Spensberger transfected mouse ES cells with a CD4 expressing plasmid also containing 
the same guide sequence and scaffolding sequence, as previously, alongside the newly designed 
repair donor DNA. The transfected population was selected for using CD4 as a marker for 
positively transfected ES cells. He then took the transfected population and did a single cell 
dilution and expanded these colonies on a 96 well format, with 2 x 96 well plates of ES cells 
originating from single cells. The cells were returned as part of this project to be screened for 
edited DNA.  
The DNA was extracted and PCR was used to screen the DNA, where a PCR product was only 
produced if the genomic DNA from the ES cell colony had the edited Atg16L1 ΔWD, by designing 
the reverse primer to bind within the edited sequence (FIGURE 4.10). A reverse primer 
downstream of the edited region was also used to verify that the sequence downstream of the 
edit was unchanged (FIGURE 4.10). FIGURE 4.11 shows that one 96-well plate was screened in 
this way and had multiple positive ES cell colonies for the DNA edit. Therefore, the second 96 well 
plate was not screened. Furthermore, at random some of these were validated using a reverse 
primer that binds outside of the edited region of DNA (figure 4.11B). The colonies with the edited 
genomic DNA were selected based on experience of how healthy the cells looked, the asterisks 
mark the ES cell colonies taken forward (FIGURE 4.11A).  
The selected clones were taken and a PCR was performed to check the DNA downstream of the 
edit (FIGURE 4.12A). Also, a Bcl1 digestion was done, where the PCR product with edited DNA will 
be cleaved but the WT DNA will not have this restriction site and will be uncut (FIGURE 4.12B).  
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Therefore, on an agarose gel it was possible to make a comment on whether the cells were 
heterozygous or homozygous for the edit. WT DNA is uncut and there is only one band (FIGURE 
4.12B). DNA from ES cell colonies C7 and D6, look homozygous for the edit because the gel shows 
two bands, indicative of the PCR product being cleaved (FIGURE 4.12B). There is a faint shadow of 
uncleaved DNA which could be due to incomplete cutting of the PCR product by Bcl1. PCR 
amplified DNA from ES cell colonies C9, D3, D5 upon Bcl1 addition give three bands on a gel 
suggesting the genetic edit has only occurred in one allele (FIGURE 4.12B).  
The DNA from these selected ES cell colonies was sequenced to confirm that random mutations 
had not occurred and to give a clearer answer on whether the edits were homozygous or 
heterozygous (FIGURE 4.12C). The results matched the restriction digest results, except for D3; 
this could be explained by inefficient cutting of the PCR product in this tube. The sequencing 
confirmed that there were ES cell clones with the Atg16L1 ΔWD genetic sequence to take 
forward for implantation.  
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Figure 4.10: Re-designed strategy to insert a triple stop codon to form Atg16L1 WD deletion 
and genotyping strategy. 
Nucleotide sequence of Atg16L1 targeted region, showing the forward and reverse primers. Two reverse primers 
were designed, one  for screening where only edited DNA will give a PCR product, and another for validating the edit 
to check nothing has changed downstream of the edit. The sequence in red is the “edited” inserted triple stop codon. 
The blue italics shows where the Bcl1 restriction site has been introduced if the DNA is edited. Below is a schematic 
where the red box is the inserted triple stop codon and the table describes the outcome of genotyping PCRs.  
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Figure 4.11: ES cell colonies screened by PCR for Atg16L1 edited DNA and validation PCR. 
A. DNA was isolated from 96 ES cell colonies originating from single cells. The PCR was performed 
where the reverse primer had been designed to anneal if a stop codon had been inserted into the specific 
site of the Atg16L1 gene. Therefore, a PCR product was detected on an agarose gel at 255 base pairs (bp) 
only if the DNA from the ES cell colony had been edited. The red asterisk marks the ES cell colonies  
B. The screening PCR results shown above, were validated by performing another PCR on some of 
the DNA isolated from ES cell colonies D3-12. This used primers shown in the previous figure that amplify 
DNA around the edited site, both WT and edited DNA will give a DNA product, only differing a few base 
pairs in length. 
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Figure 4.12: Identified ES cell colonies positive for edited DNA, validation and sequencing. 
A. PCR to show that selected ES cell colonies still give a PCR product at the expected length with a 
forward and reverse primer either side of the edited region. Where – was a PCR reaction without DNA.  
B. The PCR product from A was PCR purified and a restriction digest was performed with the 
enzyme Bcl1. The DNA was then run on an agarose gel for analysis by size separation. The table shows 
the expected outcomes.  
C. The PCR products from A were sent off for Sanger sequencing and the table summarises whether 
the amplified DNA is representative of the WT Atg16L1 sequence or homozygous or heterozygous for the 
edit. 
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4.4.7 Alternative strategy: functional validation of edited ES cells 
 
Before, the ES cell colonies were implanted into pseudo pregnant mice, some of the ES cells were 
taken to verify Atg16L1 protein expression and function (FIGURE 4.13).  
Firstly, a western blot was performed to look at Atg16L1 protein expression. The Atg16L1 
antibody has non-specific bands as indicated (FIGURE 4.13A), but it was apparent that there was 
no WT or ΔWD Atg16L1 being expressed in ES cell colonies, despite them having the genetic 
sequence to encode ΔWD Atg16L1 (FIGURE 4.13A). This unexpected result was further confirmed 
by a western blot looking at LC3 lipidation in response to starvation, LC3 lipidation has been 
induced by starvation in WT ES cells, however, this is not evident in the cells with the DNA edit 
(FIGURE 4.13B).  
Taken together, these data suggest that Atg16L1 has been knocked out, due to the lack of protein 
detected by western blot and therefore the function of LC3 lipidation is not observed. 
Immunofluorescence experiments looking at endogenous LC3 and LAMP1 in response to 
starvation or monensin show that the WT ES cells respond to both canonical and non-canonical 
autophagy (FIGURE 4.13C). However, edited ES cells have no LC3 puncta in response to any of 
these signals, reminiscent of Atg16L1 knockout cells (FIGURE 4.13C). The unintended knockout of 
Atg16L1 in cells targeted for ‘ΔWD’ was assumed to be because of nonsense-mediated decay, 
where the m-RNA from the edited genomic DNA was recognised by the cell as an error due to an 
introduction of a premature stop codon.  
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Figure 4.13: Atg16L1 expression and function in WT and edited ES cells. 
A. WT mouse embryonic stem (ES) cells or ES cells positive for a ∆WD Atg16L1 DNA sequence(C7-
D6) were lysed and analysed by western blot to look at the expression of Atg16L1. The black asterisk are 
non-specific bands and the white asterisk marks the only specific Atg16L1 band.  
B. WT mouse embryonic stem (ES) cells or ES cells homozygous for the ∆WD Atg16L1 DNA 
sequence -/+ starvation 1 h. The cells were then lysed and a western blot was run to detect the levels of 
un-lipidated and lipidated LC3 (LC3I or LC3II). GAPDH was used as a loading control.  
C. WT mouse embryonic stem (ES) cells or ES cells homozygous for the ∆WD Atg16L1 DNA 
sequence -/+ starvation or 100 µM monensin for 1 h. Cells were fixed and stained for LC3 and LAMP1 and 
images were captured by confocal microscopy. The scale bar is 5 µm. 
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4.4.8 Troubleshooting of ES cell editing: revised repair template 
 
Re-design of the repair template was carried out in order to introduce a larger, more physiological 
SV40 termination sequence that the cell should not recognise as a mistake (FIGURE 4.14). The re-
designed donor repair DNA, with the SV40 stop poly A sequence, had two homology arms 
homologous to Atg16L1 either side of the targeted site. This was made by doing three PCRs, 
getting the homologous sequences using mouse ES cell genomic DNA as a template and the third 
PCR was using  c1-eGFP plasmid as a template to amplify the SV40 termination sequence.  
With the new repair template, and the same reagents as previously, the ES cell transfection was 
repeated by Dr Dominik Spensberger with the CRISPR reagents. The single cell dilution was done 
to give two 96 well plates of colonies where a similar screening approach was taken. A reverse 
primer for PCR was designed complementary to the DNA edit (FIGURE 4.14), this screening was 
again successful at a reasonable efficiency for DNA editing (FIGURE 4.15). PCR was also done with 
genotyping primers as outlined in (FIGURE 4.16A) to determine if the edit was heterozygote or 
homozygote. The figure shows the outcome of this, there was a mixture of homozygote and 
heterozygote edits and this was confirmed by sequencing (FIGURE 4.16). Sequencing confirmed 
edited DNA where there has been successful insertion of the SV40 sequence at the correct site to 
encode Atg16L1 ΔWD.  
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Figure 4.14: Re-design of strategy for Atg16L1 truncation and outline of the screening and 
genotyping strategy. 
Nucleotide sequence of Atg16L1 targeted region, showing two sets of primers, where the screening primers will be 
used to where only edited DNA will give a PCR product, and another for genotyping to look at whether the edit has 
occurred in both alleles. The sequence in red is the “edited” inserted SV40 termination sequence. Below is a 
schematic of a region of the Atg16L1 gene where the yellow box is the inserted SV40 sequence and the table 
describes the expected size of the PCR products with the various primers.  
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Figure 4.15: Screening DNA from ES cell colonies by PCR where one primer is complementary 
to the predicted edited sequence. 
DNA was isolated from 192 ES cell colonies originating from single cells. The PCR was performed where 
the reverse primer had been designed to anneal if a stop codon had been inserted into the specific site of 
the Atg16L1 gene. Therefore, a PCR product was detected on an agarose gel at 801 base pairs (bp) only if 
the DNA from the ES cell colony had been edited. The red asterisk marks the ES cell colonies taken 
forward for further analysis, where H12 has been selected as a WT.  
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Figure 4.16: Edited ES cells taken forward for sequencing and validation. 
A. PCR was performed using DNA from the selected ES cell colonies and using the genotyping 
primers. The – sample is where a PCR was set up without DNA and H12 was used as a WT control. The 
table shows the expected PCR product size, PCR products were run on an agarose gel for size separation 
where a 100 bp ladder was used as a reference.  
B. PCR products were also sent for Sanger sequencing where the table summarises these results. 
C. Example of sequencing trace to show successful edited DNA sequence introducing the SV40 
termination sequence compared with the WT sequence.  
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The selected ES cells were taken to look at Atg16L1 protein expression and functional analysis of 
LC3 lipidation by western blot and imaging (FIGURE 4.17). This time it was evident that there was 
Atg16L1ΔWD protein expression as well as some full length Atg16L1 protein expression (FIGURE 
4.17A). This was confirmed by immunofluorescence where the WT ES cells responded to 
starvation through an increase in LC3 puncta and monensin through colocalisation of LC3 with 
LAMP1 endolysosomal compartments (FIGURE 4.17B). However, an edited ES cell colony that was 
homozygote for the DNA sequence, that encodes Atg16L1 ΔWD, responded to starvation but no 
longer supported non-canonical autophagy (FIGURE 4.17B). This is the first time genome editing 
to produce Δ WD Atg6L1 in mouse ES cells confirms the in vitro system from Chapter 3, where the 
WD domain is dispensable for canonical autophagy but essential for LC3 lipidation to 
endolysosomal membranes.  
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Figure 4.17: Protein expression and function of Atg16L1 in WT and ΔWD edited ES cells. 
A. WT mouse embryonic stem (ES) cells or ES cells positive for a ∆WD Atg16L1 DNA sequence were 
lysed and analysed by western blot to look at the expression of Atg16L1. The black asterisk mark non-
specific bands and the arrow indicates specific Atg16L1 bands.  
B. WT mouse embryonic stem (ES) cells or ES cells homozygous for the ∆WD Atg16L1 DNA 
sequence -/+ starvation or 100 µM monensin for 1 h. Cells were fixed and stained for LC3 and LAMP1 and 
images were captured by confocal microscopy. 
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4.4.9 Injection of optimised mouse ES cells  
 
Dominik Spensberger injected edited ES cell colony plate 2 H8 into mice blastocysts and chimeric 
mice were born and genotyped (FIGURE 4.18A). These male chimeras were then bred with WT 
female mice. Unfortunately, this was unsuccessful as no germline transmission was evident and 
all pups were WT (FIGURE 4.18B).  
Another edited ES cell colony was selected, plate 2 D4, and injected into mice blastocysts and the 
rate and degree of chimerism was much stronger than previously (FIGURE 4.18C). Chimeric males 
were bred with females, with a successful germline transmission. Heterozygous pups were 
confirmed by Transnetyx genotyping (FIGURE 4.18D) and further breeding rounds led to 
confirmed homozygote mice for the WD C-terminal deletion of Atg16L1 (FIGURE 4.18E).  
Therefore, this project has successfully developed an in vivo mouse model for Atg16L1 ΔWD that 
will be an invaluable tool to observe the effects of specifically inhibiting non-canonical autophagy 
in a living system.  
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Figure 4.18: Generation of chimeric mice after edited ES cell injection and genotyping of 
subsequent breeding rounds. 
A. PCR using DNA extracted from ear clips from pups born from H8 ES cell injections where the 
genotyping primers were used. The table summarises the expected PCR product sizes and the PCR 
products were run on an agarose gel for size separation. Pups were chimeric if there was evidence of both 
WT PCR product and PCR products from the edited DNA sequence. A negative control was set up,-, where 
no DNA was present in the PCR reaction and a positive control was using edited ES cell DNA from the 
injected colony.   
B. A series of pups were born from breeding WT mice with the identified male chimeras from A. Ear 
clips from these offspring were used to isolate DNA and PCR was performed using the genotyping primers 
to assess whether there had been a germline transmission and production of heterozygote pups, the 
expected PCR sizes are the same as in A and were separated on an agarose gel by size. A negative control 
was set up,-, where no DNA was present in the PCR reaction and a positive control was using edited ES 
cell DNA from the injected colony. This is a representative image of multiple negative genotyping results.   
C. PCR using DNA extracted from ear clips from pups born from D4 ES cell injections where the 
genotyping experiment was the same as A. 
D. A series of pups were born from breeding WT mice with the identified male chimeras from C. Ear 
clips from these offspring were sent off to Transnetyx an external genotyping company. They do reverse 
PCR based on given information where they have designed two probes ones that will give a product with 
WT DNA and another that will give a product for edited DNA. The red asterisk marks examples of 
heterozygote pups. 
E. A series of pups were born from breeding heterozygote mice. Ear clips from these offspring were 
sent off to Transnetyx, the same as D. The red asterisk marks examples of homozygote pups that have the 
C-terminal WD deletion in Atg16L1. 
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4.5 Using CRISPR/Cas9 to generate an Atg16L1 K490A mouse model.  
 
The technology and capability within the Institute to do direct injection of mice zygotes with 
CRISPR reagents improved during the course of this project. Therefore, this method was used to 
generate a refined mouse model of Atg16L1 with a point mutation in the WD C-terminal domain, 
Atg16L1 K490A. This was identified in the previous chapter to act in the same way as deleting the 
WD domain of Atg16L1.  Reagents were designed to produce transgenic mice expressing Atg16L1 
K490A a single point mutation in the WD domain.  
A guide sequence was designed and tested for the precision and cutting efficiency of the Cas9, via 
a similar method as previously (FIGURE 4.6). FIGURE 4.19 shows that the guide cuts efficiently. 
Therefore a repair donor template was designed to introduce the point mutation and mutate the 
PAM sequence to stop re-targeting of the Cas9 complex to already edited DNA (FIGURE 4.20). 
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Figure 4.19: Surveyor assay to test the guide efficiency to produce a double strand break in a 
specific region of Atg16L1, to produce DNA to encode Atg16L1 K490A. 
This figure shows the results of a surveyor assay (see methods and Figure 4.6) for a guide sequence 
designed to target the Atg16L1 gene to cause a double strand break that will be targeted to repair to 
produce the sequence to encode Atg16L1 K490A. The arrows indicate the nuclease cleaved DNA that 
correspond to the expected band sizes outlined to the side of the agarose gel picture.     
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Figure 4.20: Summary of strategy to direct K490A point mutation in the genomic sequence of 
Atg16L1 
This figure shows the nucleotide sequence of a region of the Atg16L1 gene that is targeted for editing. 
The repair donor is introducing nucleotide changes that will cause an amino acid change from lysine (K) 
to alanine (A). There are two silent mutations that will stop the CAS9 from re-targeting to edited DNA, 
shown just upstream of the protospacer adjacent motif PAM sequence where the Cas9 will target to the 
DNA to cause a double strand break  ~3 nucleotides away from the PAM sequence.   
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Dr Dominik Spensberger injected the CRISPR/Cas9 reagents into mouse zygotes. Pups born from 
these injections were genotyped by extracting DNA from ear clips and using PCR to amplify the 
region around the potential point mutation. The PCR products were sent for Sanger sequencing, 
as the PCR products from WT DNA and edited DNA had the same number of base pairs and could 
not be genotyped by running an agarose gel, and there were no restriction sites introduced as 
part of the edit. The results came back with four heterozygote animals, two male and two female 
animals had successful introduction of the point mutation in one allele. FIGURE 4.21A shows the 
heterozygote sequencing profile for one of these mice, where there is evidence of the point 
mutation encoding an amino acid change from lysine (K) to alanine (A) and with silent mutations 
as expected, which do not encode a different amino acid (FIGURE 4.21A).  
These pups were taken forward as founder animals and bred with WT mice to get pure 
heterozygote animals to then breed to produce homozygote animals. Genotyping after the 
founder animals was done via Transnetyx to confirm heterozygote animals (FIGURE 21.B). Further 
breeding rounds led to confirmed homozygote mice for the Atg16L1 K490A (FIGURE 4.21C).  
Therefore, this project has successfully developed a second, even more refined in vivo mouse 
model for Atg16L1 K490A that will be an invaluable tool to observe the effects of specifically 
inhibiting non-canonical autophagy in a living system.  
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Figure 4.21: Sequencing of genomic DNA of pups from direct zygote injections and after 
founder breeding. 
A. Genomic DNA was extracted from pups born from direct zygote injections. Here is one 
representative example of a Sanger sequencing trace to show the nucleotide sequence in the edited 
region of Atg16L1 where the pup is heterozygote for the edited nucleotide sequence that should encode 
an amino acid change from lysine to alanine and the silent mutations are also evident. This is an example 
of a founder heterozygote Atg16L1 K490A mouse. 
B. Founder heterozygote mice were bred with WT mice and ear clips from these offspring were sent 
off to Transnetyx an external genotyping company. They do reverse PCR based on given information 
where they have designed a probe that will recognise the mutated DNA in the specific region of Atg16L1. 
The red asterisk marks examples of heterozygote pups, these are representative of other such 
heterozygote pups.   
C. Heterozygote mice such as those from B were bred and ear clips from these offspring were sent 
off to Transnetyx an external genotyping company. They do reverse PCR based on given information 
where they have designed a probe that will recognise the mutated DNA in the specific region of Atg16L1. 
The red asterisk marks examples of homozygous pups successfully expressing Atg16L1 K490A.    
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4.6 Discussion 
 
The mouse model of E230 Atg16L1 from collaborators offered a new way to study the 
consequences of deleting the C-terminal domain of Atg16L1. The mouse is viable, which is 
surprising because the E230 Atg16L1 deletion houses the FIP200 binding domain (229-242), sites 
that directly recruit Atg16L1 in autophagy [32, 189]. A knockout Atg16L1 mouse model would not 
survive birth [164]. The mouse model seems to still support some autophagy and data from the 
collaborating lab confirms this. This Atg16L1 mutant still has both WIPI2b binding sites at 
positions 226 and 230 [33] suggesting WIPI2b binding is enough to support canonical autophagy 
[33]. This has previously been shown in cells expressing Atg16L1 that cannot bind WIPI2b, FIP200 
is not enough to rescue autophagy [33]. Furthermore, the lack of FIP200 in cells does not affect 
WIPI2b binding and the autophagy response [33]. These data support the literature suggesting 
that WIPI2b is more important than FIP200 in the recruitment of Atg16L1 to support canonical 
autophagy.  
 
In the context of non-canonical autophagy, primary cells from mice with the C-terminal deletion 
of Atg16L1 were deficient for LAP and monensin stimulated non-canonical autophagy. 
Furthermore, in dendritic cells from these mice, exogenous antigen presentation via MHC II was 
impaired; this is hypothesised to be linked to the impairment of LAP. These conclusions support 
published work that show a dependence on autophagy proteins in antigen presentation, 
specifically MHC II antigen presentation [112, 176, 178]. This includes work where in the absence 
of LC3, fungal antigen presentation is impaired in mouse dendritic cells [112]. Furthermore, Lee et 
al showed a defect in in vivo antigen presentation in dendritic cells lacking Atg5. This was not due 
to differences in phagocytosis but in the absence of Atg5 there is inefficient fusion of the 
phagosome and lysosome and therefore acidification affecting the MHC II processing [176].  
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Non-canonical autophagy could be playing a similar role in antigen processing to its role in TLR 
signalling, where LC3 lipidation to TLR containing endosomes regulates B cell signalling through 
increased fusion of lysosomes to acidify and degrade the contents of the TLR containing 
endosomes [93]. In autophagy it has been shown that ~50% of autophagosomes fuse with MHC II 
loading compartments and this is dependent on the Atg16-12-5 complex and LC3 lipidation, this 
delivery is essential to efficient MHC II antigen presentation [229]. Therefore, LC3 positive 
phagosomes could have a similar role in delivering contents through the fusion to late endosomal 
compartments such as the MHC II loading compartment and this could explain why when 
lipidation of LC3 is inhibited there is a decrease in efficient MHC II antigen presentation.  
 
Vesicle trafficking has also been shown to be regulated by LC3, where LC3 on the outer 
membrane of autophagosomes can interact with FYCO1 (FYVE and coiled coiled domain 
containing 1) [230]. FYCO1 is a protein that has a LIR domain and therefore can interact with LC3 
to mediate microtubule transport [230]. FYCO1 also has a role in LAP and similarly interacts with 
LC3 in this non-canonical autophagy context to aid vesicle transport for increased maturation and 
acidification of phagosomes [113], this could be linked to the role of LAP in antigen presentation. 
These potential mechanisms for the role of LAP in antigen presentation will be looked at in future 
work from the lab with primary cells from the refined mouse models produced in this chapter.  
 
There is however contradictory literature, where one paper shows that Atg5 and Atg7 have no 
role in phagosome maturation [185]. Another paper even shows the opposite, that the presence 
of LC3 in human dendritic cells delays phagosome maturation. This leads to prolonged antigen 
presentation and it is the lack of LC3 that leads to rapid turnover of phagosomes [177]. Therefore, 
further analysis is needed to unpick the molecular mechanisms of how non-canonical autophagy 
is acting in phagosome maturation implicating antigen presentation.  
The complexity and role of the Atg8 family is relevant when thinking about the function of non-
canonical autophagy and its function in phagosome maturation and antigen presentation. This 
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study has only looked at LC3 lipidation which is inhibited in the model of the Atg16L1 WD domain 
deletion but the GABARAPs have not been looked at. Therefore a more complete analysis of the 
Atg8 members in non-canonical autophagy needs to be done as it is beginning to emerge that the 
GABARAP proteins may be more significant in the role of lysosome fusion than LC3 [64]. 
Therefore, further downstream analysis from the Atg8 lipidation step needs to be done.  
 
The in vivo models generated as part of this project are a major step in the study of non-canonical 
autophagy. By targeting a bona fide autophagy protein we are able to inhibit non-canonical 
autophagy while leaving canonical autophagy unaffected. This is unlike the previously reported 
Rubicon knockout mouse, which also shows defects in LAP [96]. However, Rubicon is not a 
specific autophagy protein and has major roles in the endocytic system. It is likely that loss of 
Rubicon alters the PI3P and ROS production at phagosomes, irrelevant as to whether LC3 would 
be recruited or not. Indeed, LC3 lipidation to phagosomes from Rubicon knockout macrophage 
can be induced by stimulation with monensin (data not shown). This suggests that Rubicon plays 
a role in generating the signal to activate non-canonical autophagy specifically during 
phagocytosis, and may not play a role in other examples of the pathway, such as 
macropinocytosis and entosis. Also, Rubicon is a negative regulator of autophagy, so its loss can 
lead to increased levels of canonical autophagy which may impact the interpretation of results.  
 
Thus, we believe our Atg16L1 model can be used to explore the functions of non-canonical 
autophagy. Future work includes experiments that challenge the mice with Influenza infection, in 
vitro and in vivo antigen presentation assays, clearance and immune consequences of fungal 
infection or addition of apoptotic corpses.   
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5 Results: Proteomic analysis of Atg16L1 complexes during non-
canonical autophagy. 
 
5.1  Introduction 
 
The work in Chapter 3 implicates the WD domain of Atg16L1, and specific residues within this 
domain, in recruitment to, and subsequent LC3 lipidation at, membranes of the endolysosomal 
system. WD domains are relatively common and found in many proteins. They do not have 
catalytic activity, but instead are classified as a scaffolding domain [231], implicated in protein-
protein interactions. They are considered to be promiscuous domains because they can interact 
with a range of proteins, and interactome studies suggest there is not a clear pattern to the types 
of proteins that they generally bind [231]. Nevertheless, individual WD40 domains do interact 
with specific partners, in a manner that is often controlled by key ‘hot-spot’ residues [195]. This 
concept was already utilised in Chapter 3 by using a published algorithm to predict Atg16L1 WD 
domain residues, on the top face of the beta barrel structure, that could be important in its 
protein-protein interactions [195]. Building on this, the WD domain of Atg16L1 became the focus 
of the project to search for protein interactors. 
Proteomic analysis of Atg16L1 has previously been carried out in the context of canonical 
autophagy. Through various methods, direct interactors of Atg16L1 have been characterised such 
as FIP200, WIPI2b [32, 33, 189]. Furthermore, the WD domain of Atg16L1 has been implicated in 
the binding of various proteins during unconventional autophagy processes, such as its 
interaction with TMEM59 [202] and TRIM 20 [201]. There is some evidence that there may be 
some common features among Atg16L1 WD domain protein interactors, as a specific motif [YW]-
X3-[ED]-X4-[YWF]-X2-L was found on multiple proteins that interact with the WD domain of 
Atg16L1 [202].  
This chapter aimed to identify Atg16L1 interactors via proteomics in the context of non-canonical 
autophagy. The cellular system produced in Chapter 3 uses different mutants of Atg16L1, re-
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expressed in an Atg16L1 null background, to separate canonical and non-canonical autophagy, 
providing an ideal system to study this.  
In order to carry out proteomic analysis of Atg16L1 interactors in the context of non-canonical 
autophagy, endolysosomal LC3 lipidation was stimulated using the ionophore monensin, which 
exchanges hydrogen ions for sodium ions in the lysosome, raising the lysosomal pH but also 
changing the osmotic balance of endolysosomal compartments[220, 221]. This alteration of the 
osmotic properties of the endolysosomal compartment has been shown to induce LC3 lipidation 
to these single membranes, whilst also inhibiting autophagy flux and therefore increasing LC3 
lipidation from accumulated autophagosomes (in WT cells) [98]. After cellular stimulation, the 
cells were lysed and the various Atg16L1 mutants were immunoprecipitated (IP) to look for 
proteins that had been pulled out of the lysate with Atg16L1.  
Two proteomic methods are outlined in the following sections and summarised in FIGURE 5.1 and 
5.5. Various biochemical techniques were used to optimize methods and validate experiments 
before ultimately using mass spectrometry to compare samples from cells expressing the FL 
Atg16L1, competent for both canonical and non-canonical autophagy, in comparison with the C-
terminal WD deletion or point mutant K490A Atg16L1, where cells are deficient for non-canonical 
autophagy. Our hypothesis was that the WD domain may be required to bind key partners in non-
canonical autophagy, which may be revealed by comparative proteomics. 
Samples sent as part of this project used a semi-quantitative mass spectrometry approach where 
all the samples could be run at the same time and compared to one another. The Mass 
Spectrometry Facility at The Babraham Institute, took the IP samples and ran them ~5 mm into an 
SDS-PAGE gel, the proteins were stained and excised from the gel. They were then de-stained and 
trypsin digested before being TMT labelled, a robust way to allow relative abundance of peptides 
to be compared.  The samples were then analysed by mass spectrometry, to identify the 
molecules based on their mass to charge ratio. 
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5.2 IP using Flag-S tagged Atg16L1 constructs. 
 
5.2.1 Introduction to IP methodology using Flag-S tagged Atg16L1 
 
The first method used to look at Atg16L1 binding partners in the context of non-canonical 
autophagy utilised the Flag-S tag on the Atg16L1 constructs. . FIGURE 5.1 shows a schematic of 
the IP strategy and subtractive nature of the experiment. 
 
Figure 5.1: Immunoprecipitation using the S-tag Atg16L1 constructs. 
1. The cell lysate is pre-cleared where uncoated agarose beads are rotated with the lysate and this 
removes proteins that just stick randomly to the beads. 
2. The pre-cleared lysate is then rotated with agarose beads that are conjugated to an antibody 
that recognises the S-tag present on the Atg16L1 constructs. The unbound proteins are removed 
and the beads are washed.  
3. The beads with the bound Atg16L1 and its binding partners were then boiled to elute the 
proteins from the beads.  
4. The IP sample was then run ~5 mm into an SDS-PAGE gel, the proteins were stained and excised 
from the gel. Where they were then de-stained and trypsin digested before being TMT labelled 
for mass spectrometry analysis. A subtractive analysis was used where anything bound to the 
Atg16L1 with the WD deletion was not important but proteins found in the FL Atg16L1 sample 
but not the ΔWD were the interesting hits, visualised by the shapes with asterisks.  
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5.2.2 IP of Atg16L1 and known binding partners  
 
Atg16L1-/- MEF GFP-LC3 cells were re-complemented with Flag-S tagged FL Atg16L1 and the 
ΔWD, as shown previously in FIGURE 3.3C. MEF cells were treated with monensin, to stimulate 
non-canonical autophagy, and then cells were harvested with lysis buffer containing 1% triton. 
After pre-clearing, magnetic Flag beads were initially used to IP tagged Atg16L1 FL or ΔWD.  
Western blots were carried out and Atg16L1 was successfully immunoprecipitated. However, 
known complex partners, such as Atg5 and Atg12, were never detected with this method (data 
not shown). Furthermore, by silver stain, the magnetic Flag beads showed high background levels 
of protein binding in control samples, which has commonly been reported with this reagent (data 
not shown).  
As an alternative, beads that would bind the S-tag on Atg16L1 were used instead to IP Atg16L1. 
FIGURE 3.10 showed there was successful IP of Atg16L1, and co-IP of Atg5-12 as internal controls. 
The pull down of these proteins was specific to the cells expressing the tagged Atg16L1, WT MEF 
cells were used as a negative control (FIGURE 3.10). Furthermore, a silver stain was done to 
crudely look at the total proteins in the IP samples and to get an idea of the background proteins 
in the negative control (FIGURE 5.2). There are extra bands in the IP sample of tagged Atg16L1 
compared with the negative control, indicating specific interacting partners have been recovered 
(FIGURE 5.2).  
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Figure 5.2: Silver stain to assess the total proteins in IP samples from the negative control 
compared to the Atg16L1 FL sample. 
IP samples were prepared by using beads specific to the s-tag to pull out Atg16L1 from cell lysates. A 
negative control was WT MEF cells that do not have tagged Atg16L1. IP samples were run on a pre-cast 
gradient gel to separate proteins by size. The proteins were then silver stained and the arrows indicate 
obvious bands present in the Atg16L1 FL IP sample compared to the negative control which shows 
background levels of protein in the IP sample. 
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5.2.3 Mass spectrometry analysis of IP samples 
 
Now that the method had been optimised to immunoprecipitate Atg16L1, and known interactors 
Atg5-12 and the background had been checked, samples were prepared for mass spectrometry 
analysis. WT MEF cells were used as a negative control, as there is no tagged protein, then MEF 
cells reconstituted with FL Atg16L1 or with the C-terminal WD deletion of Atg16L1 were all 
treated with monensin to activate LC3 lipidation to endolysosomal membranes. It is to be noted 
that this treatment would also have led to the accumulation of autophagosomes. However, 
binding partners specific to Atg16L1 in non-canonical autophagy were to be assessed by using 
subtractive analysis. For instance, proteins identified in the IP sample of the negative control 
would be the background proteins. Proteins identified in the Atg16L1 FL IP sample that were not 
in the Atg16L1 ΔWD IP sample were the proteins of interest as these would technically be the 
interactors to the WD domain of Atg16L1. FIGURE 5.1 visualises the subtractive nature of this 
experiment.  
Therefore, these samples were prepared for mass spectrometry analysis, where Dr David Oxley at 
the mass spectrometry facility at The Babraham Institute, ran the samples into an SDS-PAGE gel 
for trypsin digestion and TMT labelling. The labelled samples were then run to get a semi-
quantitative list of proteins for each sample. The results came back with background proteins in 
the negative control but reassuringly in the IP samples from the cells expressing the tagged 
Atg16L1 known Atg16L1 interactors: Atg16L1, Atg5 and Atg12 were present in the initial list.  
Unfortunately, there were no proteins present in the IP sample from the cells expressing FL 
Atg16L1 that were not in the sample from the ΔWD Atg16L1. Therefore, no candidates were 
identified that specifically bind the WD domain of Atg16L1 to mediate non-canonical autophagy. 
There was also not many membrane bound proteins or lysosome associated proteins as would be 
expected, suggesting the method of lysis could be too harsh to preserve membrane protein 
interactors. 
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5.2.4 Optimisation of cell lysis for IP 
 
The next round of experiments were done with an alternative lysis buffer containing 0.3% CHAPs, 
a gentler detergent, to keep protein complexes intact, more commonly used when looking for 
membrane proteins. The same experiment was performed but with the different buffer. 
Successful IP of Atg16L1 and co-IP ATG5-12 was achieved whether using 1% triton or 0.3% CHAPs 
buffer to lyse the cells (FIGURE 5.3). 
5.2.5 Optimised IP samples for mass spectrometry analysis  
 
The same samples as 5.2.3 were prepared for mass spectrometry analysis. The data came back 
with much less background and again identified known interactors Atg16L1, Atg5 and Atg12 and 
Atg16L2. Nevertheless, again, the subtractive approach of looking for specific binding partners to 
the WD domain of Atg16L1 was not successful; there were no proteins that were present in the FL 
Atg16L1 sample but not the ΔWD Atg16L1 sample. 
Two proteins that bound both full length and WD Atg16L1 looked interesting as novel general 
Atg16L1 interactors: β-integrin and PlekHF1. Therefore, IP experiments were repeated and 
western blots were performed to see if indeed these proteins were interacting with Atg16L1, this 
would be a way to validate mass spectrometry hits. FIGURE 5.4 shows that by western blot, β-
integrin and PlekHF1 could not be detected in the IP sample of cells expressing Atg16L1 FL or Δ
WD. Therefore, these proteins were not followed up any further.  
We next moved to using the BioID technology in the hope of picking up transient or weaker 
interactors of Atg16L1 in the context of non-canonical autophagy. In addition, at this stage of the 
project the Atg16L1 K490A mutant had been identified which could be used as a more refined 
comparison for proteomic analysis.  
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Figure 5.3: Comparison of IP of Atg16L1 and Atg5-12 when cells were lysed in a triton or 
CHAPs buffer. 
Cells were lysed with either 1% triton or 0.3% CHAPs and IP samples were prepared by using beads 
specific to the s-tag to pull out Atg16L1 from cell lysates. A negative control (-) was WT MEF cells that do 
not have tagged Atg16L1. IP samples were run on acrylamide gels to separate proteins by size. A western 
blot was performed to detect Atg16L1 levels or Atg5-12 levels as the Atg5 antibody recognises this 
complex. LE=Low exposure and HE= High exposure.   
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Figure 5.4: β1-integrin and PLEKH1 do not co-IP with Atg16L1. 
Cells were treated for 1 h with monensin and lysed with 0.3% CHAPs buffer. IP samples were prepared by 
using beads specific to the s-tag to pull out Atg16L1 from cell lysates. A negative control (-) was WT MEF 
cells that do not have tagged Atg16L1. IP samples were run on acrylamide gels to separate proteins by 
size. A western blot was performed to detect β1-integrin and PLEKH1 in the total lysate and in the IP 
sample.  
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5.3 Using the BioID system to look for Atg16L1 binding partners. 
 
5.3.1 Introduction into the BioID methodology  
 
The BioID system involves a 321 amino acid,~35 kDa, bacterial biotin ligase (Bir-A) from E.coli 
being fused to a bait protein of interest, in this case Atg16L1. The BirA used in this project has 
been engineered to have the point mutation R118G, and this allows the biotin ligase to have a 
promiscuous activity [219]. The promiscuous BirA can biotinylate proteins in close proximity (~10 
nm range) of the bait protein, upon the addition of exogenous biotin, providing a means of 
identifying proximal proteins.  
BirA works by catalysing the synthesis of activated biotin, 5’-AMP biotin, in its reactive centre. In 
the promiscuous version of BirA, this intermediate, active biotin, is turned over quickly, resulting 
in a “cloud” of active biotin. This active biotin can form amide bonds with amino groups of lysine 
residues on proximal proteins, allowing biotin to label proteins in a living cell [232]. This method 
was developed as a way to identify more transient and dynamic interactors and identify protein 
complexes. It is superior to previous proteomic methods due to the labelling of protein 
complexes in vivo, there are less concerns about lysis buffers and washes destroying the protein-
protein complexes. One limitation is that biotinylation can also occur endogenously [233]. For 
instance, biotin exists endogenously within the cell and is used as a co factor by a variety of 
carboxylases, for instance for the biotinylation of histones [234]. But this is reported as a rare 
modification and the background biotinylation in theory can be easily corrected for [233].  
FIGURE 5.5 summarises the methodology used for this proteomic approach. In order to assess 
Atg16L1 interactors in the context of non-canonical autophagy a subtractive approach was used.  
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Figure 5.5: Summary of BioID method to immunoprecipitate Atg16L1 and proximal 
interactors.  
1. Cells in culture where Atg16L1 is expressing a promiscuous biotin ligase (BirA). Then biotin was 
added to the cells alongside monensin to stimulate non-canonical autophagy. This will lead to 
any proximal proteins to Atg16L1 becoming biotinylated. The cells were lysed.  
2. The cell lysate was then rotated with streptavidin beads that bound anything that was 
biotinylated. The unbound proteins were removed and the beads were washed.  
3. The beads with the bound biotinylated proteins were then boiled to elute the proteins from the 
beads.  
4. The IP sample was then run ~5 mm into an SDS-PAGE gel, the proteins were stained and excised 
from the gel. Where they were then de-stained and trypsin digested before being TMT labelled 
for mass spectrometry analysis. A subtractive analysis was used where proteins found in the FL 
Atg16L1 sample but not the Atg16L1 K490A sample were the interesting hits, visualised by the 
shapes with asterisks. . 
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5.3.2 Creating BirA Atg16L1 constructs and cell lines 
 
The use of the BioID system first of all required some cloning. The BirA C-terminally tagged Atg16L1 
construct was kindly donated by Dr Noor Gammoh. Their lab had validated that the C-terminal BirA 
tag did not affect Atg16L1’s function in canonical autophagy in MEF cells re-expressing this tagged 
version. From this plasmid, the Atg16L1 ΔWD and Atg16L1 K490A mutants were cloned into the 
BirA vector and confirmed by Sanger sequencing. 
FIGURE 5.6A shows the re-expression of the Bir-A Atg16L1 constructs in Atg16-/- MEFs. Proteomic 
studies from this point onwards used comparisons of BirA-Atg16L1 FL to BirA-Atg16L1 K490A. This 
was because expression of the BirA-Atg16L1 ΔWD was not detected by western blot, although 
functional assays suggest that the cells expressing the BirA-Atg16L1 ΔWD still function to lipidate 
LC3 suggestive of protein expression (data not shown). Furthermore, the Atg16L1 K490A mutant 
offered a better comparison, as the BirA was in the same place on Atg16L1, and therefore this 
controlled for functional difference that may have come about due to positioning of the enzyme.   
The re-complemented cells were then tested to check that the C-terminal BirA tag had not affected 
the function of Atg16L1 to lipidate LC3 in non-canonical autophagy. This is shown in FIGURE 5.6B, 
using western blotting to detect LC3 lipidation following monensin and/or wortmannin treatment, 
to distinguish LC3 lipidation from canonical or non-canonical autophagy, as previously used in 
FIGURE 3.5B. Wortmannin, a PI3K inhibitor, inhibits canonical autophagy, but not monensin 
induced non-canonical LC3 lipidation As previously shown, cells expressing FL Atg16L1 have 
wortmannin insensitive LC3 lipidation, which can be attributed to LC3 lipidation to single 
membranes in non-canonical autophagy (FIGURE 3.5B) and this function is not affected upon the 
addition of the C-terminal BirA tag (FIGUIRE 5.6B). However, as expected, wortmannin significantly 
inhibited monensin driven LC3 lipidation in cells expressing the K490A mutation in the WD domain 
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of Atg16L1 (FIGURE 3.17B) and this is still observed upon the addition of the C-terminal BirA tag 
(FIGUIRE 5.6B).  
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Figure 5.6: Expression of Atg16L1 BirA constructs and functional validation. 
A. WT MEF cells or Atg16L1 -/- cells re-complimented with Atg16L1 FL, ΔWD,F467A or K490A all tagged 
with BirA. Cells were lysed and a western blot was performed to detect Atg16L1 expression where GPADH 
was used as a loading control.  
B. Western blot to detect un-lipidated (LC3I) and lipidated LC3 (LC3II) in lysates from MEF Atg16L1 -/- 
cells re-complimented with Atg16L1 FL or K490A tagged with BirA, that were untreated, treated with 67 
µM wortmannin (WM) or 100 µM monensin or both. GAPDH was used as a loading control.  
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5.3.3 Biotin addition and BirA dependent biotinylation of proteins.  
 
The next step was to assess whether, upon the addition of biotin, there was successful 
biotinylation of proteins. Further to this, it was assessed whether the BirA on the Atg16L1 
mutants was causing additional biotinylation above the background levels. This was done by 
adding biotin to the re-complemented MEF cells in culture, where WT MEFs were used as a 
negative control. The cells were lysed, the total lysate was run on an SDS-PAGE gel and a western 
blot was performed using a streptavidin HRP antibody to detect total biotinylated proteins. 
FIGURE 5.7A shows that in cells where no biotin has been added we can detect endogenous 
biotinylated proteins. Addition of biotin increases the intensity of these background biotinylated 
proteins. Moreover, it was apparent that in cells expressing the BirA- FL Atg16L1, biotin addition 
has led to the biotinylation of proteins beyond the background (FIGURE 5.7A). Biotinylation of 
proteins is occurring upon the addition of biotin and the expression of the BirA tagged Atg16L1 is 
increasing biotin dependent biotinylation in the total lysate.  
Next, a similar treatment was done using the addition of biotin and then lysing the cells. These 
lysates were then processed with streptavidin beads to pull out the biotinylated proteins from the 
lysate, leaving an IP sample that should only contain the biotinylated proteins. Total lysates and IP 
samples were analysed via western blot using a streptavidin HRP antibody to detect biotinylated 
proteins (FIGURE 5.7B). These data show that the IP using the streptavidin beads has enriched for 
biotinylated proteins and indeed there are extra biotinylated proteins in the IP sample from cells 
expressing BirA-FL Atg16L1 compared to those in the negative control (FIGURE 5.7B).  
Experiments were optimised at this stage for timings of the addition of biotin, and the timing for 
the rotation of samples with the streptavidin beads. Suboptimal levels of biotinylated proteins 
were produced after two hours of biotin addition and therefore 6 h were tested and chosen to be 
the time point used. This fits in with published data where optimal biotinylation had been shown 
around 6 h [219] (data not shown).  
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5.3.4 Biotinylation and IP of known Atg16L1 binding partners.  
 
The system had been shown to function as expected in terms of biotinylation and enrichment of 
biotinylated proteins using streptavidin beads. The system was further validated for known 
Atg16L1 protein interactors using the drug PP242, an m-TOR inhibitor, which activates canonical 
autophagy. This allowed for a proof of principle to show that expected binding partners of Atg16L1, 
in the context of canonical autophagy, were detected only upon the addition of biotin and 
expression of BirA. The WT MEFs were used as a negative control and the Atg16L1 KO MEFs, 
reconstituted for BirA-Atg16L1 FL, were treated with and without biotin and PP242 for 6 h. The 
cells were lysed and the total lysate was kept as an input sample and quantified so equal protein 
amounts were loaded onto the streptavidin beads for the IP of biotinylated proteins. FIGURE 5.8A 
shows a biotin and BirA specific biotinylation and IP of known binding partners, such as FIP200 and 
WIPI2b, as well as Atg16L1 and Atg5-12, further validating the system. Notably, there also looked 
to be a potential drug dependent increase in Atg16L1 binding to FIP200. This was not completely 
reproducible, seen in 2 out of 3 repeats, so would need to be tested more thoroughly for 
clarification.  
Finally, the conditions for samples to be sent for mass spectrometry analysis were also validated 
by western blot. The control samples were: i) WT MEFs, treated with biotin, to assay for 
endogenously biotinylated proteins and ii) MEF cells re-complemented with the BirA- FL Atg16L1, 
where no biotin had been added, again to assess background biotinylation caused by the 
expression of the BirA. The samples to be analysed were MEF cells, re-complemented with the BirA- 
FL Atg16L1 or the BirA –K490A Atg16L1, treated with biotin alone, biotin and PP242 or biotin with 
monensin for 6 h. Streptavidin blots were performed and specific interactors were also blotted for 
(FIGURE 5.8B). Again, there was a biotin and BirA specific IP of expected proteins, Atg16L1 and 
Atg5-12, in the case of FIGURE 5.8B. Furthermore, the streptavidin blot identified proteins 
additional to background biotinylation (FIGURE 5.8B).  
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Figure 5.7: Specific biotinylation of proteins from biotin addition and expression of BirA.  
A. Cells were treated for 6 h with -/+ 50 µM biotin and lysed with RIPA buffer giving the total 
lysate, INPUT sample. 15 µg of protein was loaded onto an SDS-PAGE gel to separate proteins by 
size. A western blot was performed to visualise biotinylated proteins using a streptavidin HRP 
antibody. The numbers indicate the protein size in kDa. Where the – sample is the negative 
control, WT MEFs with no BirA expression.   
B. Cells were treated for 6 h with -/+ 50 µM biotin and lysed with RIPA buffer giving the total 
lysate, INPUT sample. Equal protein amount was loaded onto magnetic streptavidin beads to 
pull out biotinylated proteins and this is the IP sample. A negative control (-) was WT MEF cells 
that do not have BirA tagged Atg16L1. INPUT and IP samples were run on acrylamide gels to 
separate proteins by size. A western blot was performed to detect biotinylated proteins using a 
streptavidin HRP antibody. The numbers indicate the protein size in kDa. 
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Figure 5.8: Western blots to show specific biotinylation and IP of known Atg16L1 interactors.  
A. Cells were treated for 6 h with 1 µM PP242 and -/+ 50 µM biotin and lysed with RIPA buffer giving the 
INPUT sample. Equal protein concentration was loaded onto magnetic streptavidin beads to pull out 
biotinylated proteins and this is the IP sample. A negative control (-) was WT MEF cells that do not have 
BirA tagged Atg16L1. INPUT and IP samples were run on acrylamide gels to separate proteins by size. A 
western blot was performed to detect Atg16L1, FIP200, Atg5 and WIPI2b in the total lysate and in the IP 
sample. 
B. Cells were treated for 6 h -/+ 50 µM biotin, with -/+ 1 µM PP242 and with -/+ 100 µM monensin and 
lysed with RIPA buffer giving the INPUT sample. Equal protein concentration was loaded onto magnetic 
streptavidin beads to pull out biotinylated proteins and this is the IP sample. A negative control (-) was 
WT MEF cells that do not have BirA tagged Atg16L1. INPUT and IP samples were run on acrylamide gels 
to separate proteins by size. A western blot was performed to detect Atg16L1, Atg5 and streptavidin HRP 
antibody detected biotinylated proteins in the total lysate and in the IP sample. 
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5.3.5 Mass spectrometry analysis of BioID samples  
 
Given that the protocol had been thoroughly validated, the same samples as verified in 5.3.4 
were prepared for mass spectrometry. The control samples were: i) WT MEFs, treated with biotin, 
to assay for endogenously biotinylated proteins and ii) MEF cells re-complemented with the BirA- 
FL Atg16L1, where no biotin had been added, again to assess background biotinylation caused by 
BirA. The experimental samples to be analysed were MEF cells, re-complemented with the BirA- 
FL Atg16L1 or the BirA –K490A Atg16L1, treated with biotin alone, biotin and PP242 or biotin with 
monensin for 6 h. The entire IP sample was submitted to the Mass Spectrometry Facility at The 
Babraham Institute, to maximise the amount of each candidate binding protein for detection. 
They ran the samples into an SDS-PAGE gel, digested the proteins and tagged the peptides with 
TMT, then analysed by mass spectrometry.  
A list of ~3500 proteins came back, disappointingly, the results of this analysis showed no significant 
difference between the peptides in the experimental samples compared with any of the control 
samples. Atg16L1, which would certainly be expected to biotinylate itself, was not a prominent hit. 
Similarly, known Atg16L1 binders, which had been detected by western blot using the BioID system, 
were also absent. Even proteins that are known to undergo endogenous biotinylation, such as the 
carboxylases, were not detected in the control samples. These important omissions suggest that 
there was a major problem in sample preparation, handling or analysis, which confounded our 
ability to identify novel binding proteins. 
Unfortunately, as the whole IP had been digested and TMT labelled, to maximise the amount sent 
for analysis, no sample was available with which to go back and assess whether the experiment had 
worked as before. Therefore, it cannot be known whether the problem lies in the preparation of 
this particular batch of samples, or somewhere during the mass spectrometry procedure. This will 
be discussed further below.  
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Due to time constraints, the mass spectrometry analysis could not be repeated in full for this thesis. 
However, the samples were re-prepared, this time withholding a small proportion of these samples, 
which were validated by western blot; similar results to FIGURE 5.9B were obtained and ensured 
the system was working as expected in the exact samples sent for mass spectrometry analysis. 
These have been stored for future mass spectrometry analysis. 
5.4 Discussion 
 
Atg16L1 binding partners in the context of canonical autophagy have been previously studied, 
with most interactors found using cross linking to stabilize weak interactions, using GST-tagged 
proteins as bait. This suggests that Atg16L1 is not an easy protein to work with when uncovering 
binding partners. For instance, chemical cross-linking was required to identify the interaction 
between Atg16L1 and WIPI2b, suggesting stabilisation of this complex was required due to the 
potential transient nature of this interaction [33]. Chemical crosslinking was also required in the 
case when the FIP200 and Atg16L1 interaction was discovered [189]. Similarly, an alternative 
method, using a system that stabilised Atg16L1 at membranes, in an Atg3 -/- background, was 
needed to observe the same interaction of Atg16L1 with FIP200 [32]. In this case, the IP was done 
from a membrane fraction to further enrich for context specific binding partners. Therefore, this 
may explain the lack of success we had using traditional IP methods, with the S-tagged Atg16L1 
constructs, without any enrichment or cross-linking strategies to stabilise Atg16L1’s interactions. 
As such, future work with this method could be to try cross-linking or membrane fractionation 
prior to the IP, both with the aim to stabilise or enrich interactors of Atg16L1.  
Encouragingly, the BioID proteomics approach was sensitive enough to detect interactors such as 
FIP200 and WIPI2b, that had previously required cross-linking, through proximity to Atg16L1. 
Therefore, this suggests BioID as a method that has the potential to pick up a more global view of 
Atg16L1 proximal interactors and is more sensitive than previous methods used to look at 
Atg16L1 interactors.  
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Further tentative evidence for BioID being a more sensitive approach, comes from the suggestion 
that FIP200 may interact more with Atg16L1 in autophagy induced conditions when using BioID 
proteomics.  Previously it was shown that the interaction between FIP200 and Atg16L1 was 
independent of starvation [32, 189], which is perhaps surprising as it might be expected to be a 
regulated interaction. It is possible that this inducible binding was missed due to a limitation in 
the traditional IP methods. However, further work would be needed to confirm that ours is a true 
result, as starvation induced FIP200 binding was only seen on two of three occasions.  
In spite of its advantages, BioID does have some drawbacks because of its sensitivity. It can label 
many proximal proteins, some that may just be in the vicinity due to random chance, therefore 
repeats of the BioID preparation and mass spectrometry would be essential. Unfortunately, due 
to time constraints, sample preparation and mass spectrometry analysis for a specific set of 
conditions was not repeated. 
As part of this project a BioID method has been successfully optimised and validated by western 
blot to be a useful tool for proteomic analysis of Atg16L1. Unfortunately, mass spectrometry 
results from the BioID proteomics were so far unsuccessful, because no known protein 
interactors were pulled out from any samples, and our controls suggested a general problem with 
that batch of samples. The reason for this is hard to determine, as the specific samples prepared 
were not validated before being sent to mass spectrometry, it was assumed that the system was 
working as optimised. In future work, it will be important to validate a small fraction of the exact 
samples to be sent, prior to mass spectrometry as a quality control step. 
There could be some possible explanations for the failure of this experiment. The results may 
suggest that either the biotin addition or biotinylation did not occur at an optimal level, or a 
combination of both, which could explain why no endogenously biotinylated proteins were 
enriched for in the control sample and why no known interactors were present. Alternatively, it 
could be the case that the IP failed, and the proteins were being biotinylated however, the 
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streptavidin IP did not work or the biotinylated proteins were not eluted from the beads properly 
before handing over the samples for mass spectrometry. This would explain why even the 
endogenously biotinylated proteins were not detected by mass spectrometry and would further 
explain why known interactors were not identified. Seeking advice from the mass spectrometry 
facility, they suggest it is unlikely that the gel running, TMT labelling or mass spectrometry could 
have contributed to the failure of this experiment, as previous samples have been TMT labelled in 
the same way and there was detection of known interactors. Furthermore, when repeating this 
experiment to re-send validated samples for mass spectrometry analysis, the first attempt 
showed that biotinylated proteins were not enriched for by IP, suggesting that something within 
the IP method is temperamental, indeed adding a confirmation that the problem came before the 
mass spectrometry analysis. It is evident that validation of IP samples should always be done 
before sending and waiting for mass spectrometry analysis. Therefore, new samples have now 
been prepared and validated to be re-submitted for mass spectrometry analysis, experiments 
have shown successful biotinylation within the system and enrichment of these biotinylated 
proteins after IP and Atg16L1 and Atg5-12 have been specifically detected in relevant samples 
and not in the controls. This will form the basis of future work within the lab.  
Depending on the results from this experiment, which will be beyond the scope of this thesis, 
maybe an additional control sample in the future could be added. Looking at cells that express 
BirA alone, with biotin addition, to then subtract the background biotinylation. This seems a 
common method [235] and was something that was not used in this project when submitting 
samples for mass spectrometry analysis. Although other ways to correct for background 
biotinylation were used such as cells with no BirA tagged protein and cells with the tagged BirA 
Atg16L1 but with no biotin addition. More stringent washes could be used to optimise the 
protocol in future, such as higher concentrations of SDS, due to the strong nature of the biotin 
and streptavidin interaction [219, 236]. The washes used as part of this project were more 
reminiscent of normal IP washes where much more care needed to be taken.  
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If the subtractive approach to identify Atg16L1 interactors specific to non-canonical autophagy 
does not work, the BirA FL Atg16L1 construct could be expressed in the Atg13 -/- Atg16L1-/- HEKs 
developed in chapter 3. This cell line would be deficient for canonical autophagy and therefore all 
interactors identified are candidates for binding partners involved in non-canonical autophagy.  
Furthermore, future work could involve even more refined proteomic approaches that are now 
available including an alternative system such as the APEX system. This is based on an engineered 
form of ascorbate peroxidase that in the presence of biotin-phenol and the addition of hydrogen 
peroxidase rapidly biotinylates proximal proteins in a matter of minutes rather than hours [237]. 
This cuts out having to add biotin for long periods of time and doing unnecessary long drug 
treatments, where the downstream methodology is the same using streptavidin beads. The 
shorter addition of biotin may reduce background biotinylation. However, literature detailing the 
APEX system has largely been done in targeted cellular compartments such as the inner 
mitochondrial space [237] although it has been done in non-membrane enclosed organelles 
[238].  
The other method that can be used as an advancement of the BioID method in this project is 
BioID2 [236]. It is based on the BioID method outlined but involves a much smaller promiscuous 
biotin ligase that allows for a better identification of proximal interactors due to it being smaller 
and less disruptive to its fusion bait protein. A flexible linker can also be added to improve the 
range of the enzyme. It also requires significantly less biotin addition to cells and this may affect 
the background biotinylation levels. With the mouse models developed in Chapter 4, the BioID 
technology has the potential to be used in vivo to identify protein interactions directly in a living 
system. 
Finally, this work has focused on proteomic approaches to investigate the role of the WD domain 
of Atg16L1 in non-canonical autophagy, the other possibility is that lipid interactions may regulate 
the recruitment of Atg16L1. Lipidomic strategies will also be considered as part of future work.  
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6 General discussion and Impact of thesis 
 
Autophagy is a fundamental and widely studied pathway, that has roles in both physiological and 
pathophysiological processes. The importance of autophagy is evidenced by the award of the 
Nobel Prize in Physiology or Medicine in 2016 to Yoshinori Oshumi for his contributions to the 
field. Therefore, autophagy is an exciting and rapidly developing field to be working in. Since the 
recent discoveries that LC3 can be recruited and lipidated to membranes distinct from 
autophagosomes, it was exciting to contribute to the novel non-canonical autophagy field. 
Non-canonical autophagy refers to the unconventional lipidation of LC3 to single endolysosomal 
membranes, which often follows cell engulfment events such as LAP, macropinocytosis or entotic 
cell cannibalism. The term ‘non-canonical autophagy’ can be thought of as misleading by some, 
because ‘auto’ implies self-eating, and this pathway targets material ingested from the outside. 
However, as the field continues to grow this term has begun to be used by many groups, in high 
profile publications [41, 93-96], and as such, it was used for this project. We do not feel that LAP 
can be substituted, as it does not encompass the whole pathway, but in the future, a better name 
may emerge. One suggestion could be LC3 Lipidation to Endolysosomal Membranes (LLEM); this 
offers a broader name and detaches the pathway from autophagy. 
This project set out to uncover the role of Atg16L1 in the context of non-canonical autophagy. 
Firstly, Atg16L1 was shown to localise to single membranes of the endolysosome and function 
with Atg5-12 to lipidate LC3 to these membranes. Previous work suggested that LC3 lipidation to 
single membrane endolysosomes was independent of some canonical autophagy proteins such as 
the ULK1 complex [91]. This project further validated this and showed that Atg16L1 lacking the 
FIP200 binding domain still supported LC3 lipidation in non-canonical autophagy. This project also 
confirmed that the WD domain of Atg16L1 was indeed dispensable for LC3 lipidation to 
autophagosomes [197].  
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Using a structure function approach, this project then went on to demonstrate that the C-
terminal WD domain of Atg16L1 is essential for LC3 lipidation in non-canonical autophagy, under 
both drug induced and physiological settings such as LC3-associated phagocytosis (LAP). A more 
refined model was also determined through site directed mutagenesis; single amino acid residues 
were identified within the WD domain of Atg16L1 that are essential to the role of Atg16L1 in non-
canonical autophagy. Specifically, the WD domain of Atg16L1, and key residues, were shown to 
be essential for the recruitment of Atg16L1 to single membrane endolysosomes upon non-
canonical autophagy stimulation.  
This novel observation provided a genetic means to specifically dissect canonical and non-
canonical autophagy pathways, allowing the impact of inhibiting non-canonical autophagy to be 
assessed without affecting autophagy. The use of truncated or mutated Atg16L1 offers some 
advantages to existing models. For instance, knock out of the Atg8-conjugation machinery, such 
as Atg5, will affect both pathways so lacks specificity. Knockout of rubicon, a component of the 
class 3 PI3 kinase Vps34, has been used to model inhibition of LAP[96], but rubicon has other 
functions that will impact phagocytosis separately from any role it has in non-canonical 
autophagy. As such it is unclear whether results from using rubicon knockout cells, stems from 
inhibition of LC3 recruitment or some other defect in phagocytosis. Furthermore, not all non-
canonical autophagy associated processes may depend on rubicon. Thus, we feel that our model, 
that targets a bona fide autophagy protein, will more specifically inhibit LC3 lipidation associated 
with all non-canonical autophagy processes. Nevertheless, it has to be acknowledged that 
Atg16L1 may have functions outside of its role in lipidating LC3. Indeed, there is evidence that 
Atg16L1 may function in regulating inflammatory responses to pathogens independently of its 
conjugation function [239] or IFNγ responses to murine norovirus [240]. Whether these processes 
depend on the WD domain is not known and so some caution should still be considered in what 
effect deletion of this domain will have. 
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This study has focused on Atg16L1 recruitment and LC3 lipidation, however, the function of LC3 at 
these single membrane endolysosomes, particularly in entosis and macropinocytosis, remains 
elusive. LC3 lipidation in LAP is reported to speed up the clearance of apoptotic debris or 
pathogens [109, 111], however, this is not a universal view [185] and these functional outcomes 
of LC3 lipidation were not studied as part of this project. However, existing mice models that have 
inferred the role of non-canonical autophagy, from the comparison of various autophagy related 
protein knockouts, have interesting phenotypes. For instance non-canonical autophagy has been 
implicated in the visual cycle of mice [94], controlling autoimmune signalling in B cell activation 
[181] and controlling autoimmune pathologies such as SLE [96]. Further work will need to be 
done to look at the functional implications of LC3 lipidation using the in vivo mouse models 
developed as part of this project. They are one of the first mammalian systems that will lack non-
canonical autophagy without affecting canonical autophagy. A model of both Atg16L1 ΔWD and 
Atg16L1 K490A were made using CRISPR Cas9 technology. While there appears to be no obvious 
problems or phenotype with the mice, as they are maintained in a clean mouse facility, it is 
predicted that phenotypes may emerge as they are challenged with pathogens, as there is 
consensus that non-canonical autophagy plays important roles in the immune system. 
This project has already utilised an Atg16L1 E230 mouse model from Dr Tom Wileman’s lab, a C-
terminal Atg16L1 deletion, which also appears to inhibit specifically non-canonical autophagy. 
Using this model we uncovered an involvement for LC3 lipidation to endolysosomal membranes 
in MHC II antigen presentation. This is something that will be interesting to study in more detail 
and repeat with the mice produced through this project. Understanding at what point in the 
antigen presentation process non-canonical autophagy impacts will provide molecular insight into 
the pathway. It was also shown as part of this project, in collaboration with Dr Rupert Beale, that 
Influenza A infection, through the action of the viral protein M2, activates non-canonical 
autophagy. The possible functions of this lipidation are currently being investigated. The hope is 
that non-canonical autophagy may be a pathway to target therapeutically. Activating the pathway 
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could possibly increase the efficiency of antigen presentation and vaccination. Dampening the 
pathway could help protect from autoimmune responses. The data generated in this project on 
the critical residues of Atg16L1 could help guide new drugs to modulate non-canonical 
autophagy. 
The Atg8 protein LC3 has been a major focus in this project.  For western blot analysis, LC3 A/B 
have been detected, and cells have been expressing GFP-LC3A or GFP-LC3B. However, a recent 
publication discusses the role of LC3 and GABARAPs in autophagy, where GABARAPs seem to be 
more important than LC3 family members in the efficient formation and fusion of 
autophagosomes [64]. Therefore, to build on this project, it would be worthwhile to look at the 
GABARAPs in non-canonical autophagy. Furthermore, published work shows that GABARAPs, as 
well as LC3, go to non-canonical autophagy membranes [41, 120, 171] and are lipidated in the 
same way as LC3, by Atg16L1 in complex with Atg5. Therefore, the conclusions of this project 
could be relevant to Atg8 proteins more broadly.  
To begin to understand the molecular details of how the WD domain of Atg16L1 targets it to 
single-membrane compartments, proteomic analysis was used to identify binding partners of 
Atg16L1 during non-canonical autophagy. Optimised conditions were achieved using the BioID 
system to biotinylate proteins in proximity to Atg16L1 during non-canonical autophagy activation. 
Pilot studies were performed, conditions were optimised, building important preliminary data for 
a successful BBSRC grant application in our lab. However, the comprehensive analysis of WD-
domain interactors, induced upon activation of non-canonical autophagy, was not fully concluded 
in the period of this project. Optimised samples have been prepared for analysis, but the 
identification and follow up on candidate interacting proteins will now form the basis of future 
work in the lab.  The critical residues identified on the top face of the WD domain were proposed 
to be important in protein-protein interaction, which is a common feature of WD domain 
containing proteins [231]. Nevertheless, it is possible that the WD domain could interact with a 
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lipid. So future work could also analyse lipid interactions and their possible role in recruiting 
Atg16L1 to membranes.  
Currently, these data show that the sites identified in Atg16L1 are important in all tested 
examples of non-canonical autophagy: LAP, macropinocytosis, Influenza induced non-canonical 
autophagy and entosis. This is suggestive of a common mechanism with the WD domain of 
Atg16L1 acting as a molecular hub for non-canonical autophagy processes. It will be intriguing to 
uncover if there is one mechanism of recruitment of Atg16L1 through the WD domain or whether 
there are process-specific mechanisms. For instance, could it be that the mechanism for Atg16L1 
recruitment to phagosomes is distinct to its recruitment to entotic vacuoles, possibly involving 
different WD domain binding proteins. 
In conclusion, this project offers an important new way to separate two related pathways, 
autophagy where LC3 gets lipidated to autophagosomes and non-canonical autophagy where LC3 
can become lipidated to single membranes of the endolysosome. This provides an important 
strategy to study non-canonical autophagy and further understand the physiological relevance of 
the signalling pathway. Future work will build directly on these findings, identifying binding 
partners to reveal molecular mechanisms, and exploring mouse model phenotypes, to uncover 
the physiological roles of non-canonical autophagy.  
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Figure 6.1 Summary Diagram 
Atg16L1 complexes with Atg5 and Atg12 to form the lipidation complex that localises to both 
autophagosomes and single membranes during non-canonical autophagy. These single endolysosomal 
membranes are formed after phagocytosis, macropinocytosis, and entosis and can be targeted in a 
manner distinct from canonical autophagy for LC3 recruitment and lipidation. Endolysosomal membranes 
in influenza infection and after the use of lysosomotropic drugs show activation of this non-canonical LC3 
lipidation. Atg16L1 recruitment in non-canonical autophagy is due to the C-terminal WD40 domain and 
specific residues within this domain that are dispensable for canonical autophagy. This offers a novel 
strategy to distinguish between canonical and non-canonical autophagy processes and utilising this 
approach, in vivo mouse models have been generated. Initial studies implicate the C-terminal of Atg16L1 
in MHC class II antigen presentation in dendritic cells. There is still a question mark about what signals 
are involved in the recruitment of Atg16L1 to these single membrane compartments.  
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